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Abstract 

Background 
 
Cholera is an acute diarrhoeal disease that generally presents as abrupt watery diarrhoea and 
vomiting. For the years 2008 to 2009, South Africa experienced two major outbreaks of cholera. 
The first outbreak was reported from May to July 2008 (Chapter Three) and the second outbreak 
from November 2008 to April 2009 (Chapter Four). Within both events, Vibrio cholerae (V. 
cholerae) O1 identified at peripheral laboratories displayed resistance to three or more routinely 
tested antimicrobial agents. The molecular epidemiology and mechanism of antimicrobial 
resistance of V. cholerae O1 isolates was investigated. This was achieved by using various 
molecular techniques, which included pulsed-field gel electrophoresis (PFGE) analysis, 
polymerase chain reaction (PCR), nucleotide sequencing, identification of plasmid DNA and 
Southern blot hybridization analysis. 
 
Methods 
 
As part of routine characterization of V. cholerae isolates at the Centre for Enteric Diseases 
(CED), isolates underwent serological and biochemical confirmatory identification as well as 
antimicrobial susceptibility testing using the Etest method. PFGE analysis was performed on V. 
cholerae O1 isolates digested with NotI restriction enzyme. One-hundred V. cholerae O1 
isolates, ten isolates characterized in Chapter Three and 90 isolates characterized in Chapter Four 
were selected for further analysis to ensure that all PFGE banding patterns were represented. 
Three probable mechanisms of antimicrobial resistance were investigated. Firstly, PCR was used 
to detect for the presence of class 1 integrons (3’-CS and 5’-CS), class 2 integrons (intI2), 
plasmid-mediated quinolone resistance (PMQR) genes (qnrA, qnrB, qnrS, qnrC and qepA), 
quinolone resistance determinant (qnrVC3), ESBL producing genes (blaTEM, blaSHV and blaCTX-
M), genes coding for the quinolone resistance-determining region (QRDR) of DNA gyrase 
(gyrA/gyrB) and topoisomerase IV (parC/parE), SXT element-integrase gene (SXTint) and 
associated SXT resistance genes (floR, sul2, dfrA1, dfr18, strA and strB) and the class A 
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tetracycline resistance determinant (tetA). The presence of resistance plasmids was investigated 
by isolation of intact bacterial plasmid DNA. Southern blotting and DNA probing was used to 
investigate the location of resistance genes on the plasmids. Secondly, nucleotide sequencing 
was used to detect amino acid mutations in the QRDR of DNA gyrase and topoisomerase IV 
respectively. Thirdly, to determine the role of an active efflux pump in quinolone resistance, 
susceptibility testing to nalidixic acid was investigated in ten V. cholerae O1 isolates 
characterised in Chapter Three using agar dilution in the presence and absence of two efflux 
pump inhibitors, reserpine and phenylalanyl arginine-β-naphthylamide. PCR analysis was used 
to detect for virulence determinants, which included the enzymatic A subunit of the cholera toxin 
(CT), ctxA and the gene encoding for the toxin co-regulated pilus (TCP), tcpA respectively. In 
addition, the complete coding region of the ctxAB gene was amplified and sequenced from four 
V. cholerae O1 isolates, two isolates characterized in Chapter Three and two isolates 
characterized in Chapter Four as several V. cholerae O1 atypical El Tor isolates have been 
described in Africa. Minimum inhibitory concentration (MIC) values for azithromycin were 
determined for all 100 V. cholerae O1 isolates using both the Etest and agar dilution methods 
(Chapter Five). PCR-analysis was used to determine the presence of seven macrolide resistance 
determinants (mefA, ereA, ereB, ermB, mphA, mphB and mphD) in all 100 V. cholerae O1 
isolates.  
 
Results 
 
For both cholera outbreaks, a total of 751 isolates were received and available for analysis. All 
31 isolates recovered from the first outbreak (Chapter Three) were characterized as V. cholerae 
O1 serotype Ogawa. For the second outbreak (Chapter Four) 708 isolates were characterized as 
serotype Ogawa, while the remaining 12 isolates were characterized as serotype Inaba. All 
isolates analyzed from both outbreaks were susceptible to ciprofloxacin and imipenem, but 
resistant to six or more antimicrobial agents tested for surveillance purposes. All V. cholerae O1 
isolates were shown to be resistant to nalidixic acid, co-trimoxazole, trimethoprim, 
sulfamethoxazoleand streptomycin. Extended-spectrum β-lactamase (ESBL) activity was 
observed in V. cholerae O1 isolates (MIC 64 µg/ml) from both outbreaks. In the second outbreak 
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reduced susceptibility to ampicillin, tetracycline, kanamycin, chloramphenicol, erythromycin and 
furazolidone were observed. Dendrogram analysis produced two main PFGE clusters. PFGE 
fingerprint patterns from V. cholerae O1 isolates recovered from the first outbreak clustered 
away from V. cholerae O1 isolates recovered from the second outbreak (data not shown in this 
study). Class 1 integrons, class 2 integrons and PMQR genes were not detected by PCR.All 100 
V. cholerae O1 isolates were PCR-positive for the SXTint gene and five of the six associated 
SXT resistance genes encoding for chloramphenicol (floR), sulfamethoxazole (sul2), 
trimethoprim (dfrA1) and streptomycin (strA and strB). Seventeen V. cholerae O1 isolates (ten 
isolates characterized in Chapter Three and seven isolates characterized in Chapter Four) were 
PCR-positive for the tetA resistance determinant. Nucleotide sequencing of the QRDR, showed 
that all nalidixic acid-resistant isolates harboured the same mutations in GyrA (S83-I) and ParC 
(S85-L) but none were observed in GyrB and ParE.There was no involvement of an active efflux 
pump in quinolone resistance in ten isolates characterised in Chapter Three. Sixteen V. cholerae 
O1 isolates (ten isolates characterized in Chapter Three and six isolates characterized in Chapter 
Four) harboured a single plasmid of approximately 140 kilobase pairs in size and showed to 
harbour the blaTEM gene, which produced the TEM-63 β-lactamase.PCR analysis showed that all 
100 V. cholerae O1 isolates were positive for the CT, and all were PCR-positive for the El Tor 
variant of the TCP. Nucleotide sequencing of the ctxAB gene of the four selected isolates showed 
that all four isolates expressed the encoded ctxB allele for the CT of the classical biotype and 
were defined as “altered El Tor”. A mobilome is characterized by related genome sequences that 
differ by combinations of genomic islands, prophages and integrative conjugative elements. All 
four isolates contained an identical mobilome profile pattern, profile B. Comparative analysis 
using both the Etest and agar dilution methods (Chapter Five) showed that all V. cholerae O1 
isolates were susceptible to azithromycin provided that the tentative breakpoint of ≤ 16µg/ml is 
applied. All 100 isolates were PCR-negative for all seven macrolide resistance determinants, 
which are commonly associated in the family Enterobacteriaceae respectively. 
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Conclusion 
 
This is the first incidence of TEM-63 β-lactamase-producing, antimicrobial-resistant, toxigenic 
V. cholerae O1 altered El Tor isolates in South Africa. This study highlights the need to further 
analyze antimicrobial resistance and track emerging epidemic isolates of V. cholerae O1. The 
MIC values and PCR results reported in this study for azithromycin provides a foundation for the 
surveillance of azithromycin susceptibility and to determine MIC breakpoints in V. cholerae O1 
isolates circulating in South Africa.  
 



Acknowledgements 
 
It would not have been possible to write this thesis without the help and support of the kind 
people around me to whom I offer my kind regards and blessing, but to only some of whom it is 
possible to give particular mention here.I am heartily thankful to both my principal supervisors, 
Doctor (Dr.) Anthony Smith, whose encouragement, guidance, advice and support, not to 
mention his knowledge of molecular bacteriology, enabled me to develop an understanding of 
the subject. The good advice and support of my second supervisor, Dr. Karen Keddy, has been 
invaluable on both an academic and a professional level, for which I am extremely grateful. I 
would like to acknowledge the financial, academic and technical support of the National Health 
Laboratory Service (NHLS) and its staff, particularly the NHLS Research Trust (NHLSRT), the 
Group for Enteric Respiratory and Meningeal Surveillance-South Africa (GERMS-SA) and the 
Centre for Enteric Diseases (CED) that provided the necessary financial support for this research. 
The library facilities and computer facilities of the National Institute for Communicable Diseases 
(NICD), as well as the University of the Witwatersrand, have been indispensable. 
 
I would like to thank the staff from the Division of Public Health Surveillance and Response, 
NICD, NHLS, for their assistance in the outbreak investigations. I am very grateful to Dr. 
George A. Jacoby of the Lahey Clinic, Burlington, United States of America, for providing 
control strains positive for PMQR genes. My gratitude to Dr. Maria Colombo of the Dip. 
Biologia Cellulare e dello Sviluppo, Rome, Italy and Dr. Carlo Pazzani of the Dip. Di Genetica e 
Microbiologia, Bari, Italy for providing control strains positive for class 1 integrons and the SXT 
element. Thank you to Dr. Monica Birkhead from the Centre of Emerging and Zoonotic 
Diseases, NICD, NHLS for providing negatively-stained whole mounts of V. cholerae. Thank 
you to the team from the Centre for Opportunistic, Tropical and Hospital Infections, NICD, 
NHLS, for providing control strains positive for ESBL genes. Thank you to Dr. Nicole Wolter 
from the Centre for Respiratory Diseases and Meningitis for providing control strains positive 
for macrolide resistance determinants.  I would like to extend a special thank you to the team that 
is the CED. To those colleagues both past and present, thank you for promoting a stimulating and 
welcoming academic, professional and social environment.  
 



Ethics clearance certificates 
 



 
 



List of Figures  
 
Figure 1 A negatively-stained whole mount of V. cholerae illustrating curved-shaped bacilli 
containing single polar, sheathed flagella. 
 
Figure 2a Classification of V. cholerae according to serogroup and serotype. 
 
Figure 2b Classification of V. cholerae serogroup O1 according to biotype. 
 
Figure 3 A flow diagram illustrating pathogenesis of V. cholerae O1. 
 
Figure 4 Schematic representation of the V. cholerae O1 El Tor biotype strain N16961 genome. 
 
Figure 5 The CTX genetic element of the filamentous bacteriophage CTXΦ composed of two 
functional domains including the core, which is flanked by 1 or more repetitive sequence (RS). 
The Illustration was taken from Waldor and Mekalanos, 1996 [35]. 
 
Figure 6 Regulation of the cholera toxin and toxin co-regulated pilus. 
 
Figure 7 Preparation of agarose plugs for pulsed-field gel electrophoresis (PFGE) analysis. 
 
Figure 8 Restriction enzyme digestion of total bacterial DNA contained in agarose plugs. 
 
Figure 9 Pulsed-field gel electrophoresis (PFGE) image of ten V. cholerae O1 isolates digested 
with NotI restriction enzyme using the PulseNet standardized protocol for V. cholerae. Lane S 
Salmonella Braenderup strain CDC-H9812 digested with XbaI restriction enzyme. 
 
Figure 10 An “In-house” Southern blot apparatus.  
 
Figure 11 Agar dilution susceptibility testing. 
 



Figure 12 (A) Plasmid DNA isolation from the ten selected V. cholerae O1 isolates. (B) 
Southern blot hybridization of plasmid DNA probed with DIG-blaTEM from ten selected V. 
cholerae O1 isolates. 
 
Figure 13 Alignment report showing the amino acid sequences of DNA gyrase subunit A 
(GyrA) for V. cholerae O1, biotype El Tor, strain N16961 accession number NC_002505 and 
isolate, TCD273377. 
 
Figure 14 Alignment report showing the amino acid sequences of DNA topoisomerase IV 
subunit A (ParC) for V. cholerae O1, biotype El Tor, strain N16961 accession number 
NC_002505 and isolate, TCD273377. 
 
Figure 15 Dendrogram of PFGE fingerprint patterns of V. cholerae O1 isolates (NotI-digestion) 
associated with the cholera outbreak in South Africa, November 2008 to April 2009. “*” 
indicates the most commonly identified pattern. 
 
Figure 16 Alignment report showing the amino acid sequence of ctxB of four selected V. 
cholerae O1, serotype Ogawa, biotype El Tor isolates, TCD306373, TCD325765, TCD273214 
and TCD273377; V. cholerae O1, biotype El Tor, strain N16961 accession number NC_002505 
and V. cholerae O1, biotype classical, strain 569B accession number VCU25679. Amino acid 
residues that match the consensus sequence displayed on top are hidden. Amino acid residues 
that do not match the consensus sequence displayed on top are shown.  
 
Figure 17 PCR amplification and detection of particular genetic markers in multiplex PCR 1 and 
multiplex PCR 2 for three V. cholerae O1 isolates. PCR-amplified products were separated on a 
1.5 % (w/v) agarose gel.  
 
Figure 18 Chemical structures of azithromycin and erythromycin A. Picture adapted from 
Retsema et al, 1987. 
 
 



Figure 19 Schematic overview of creating internal positive control DNA for the detection of the 
macrolide resistance determinant, mphA. 
 
Figure 20 PCR amplification and detection of the eae (~ 482 bp) gene in lane 1 and the internal 
positive control, mphA-eae (~ 522 bp) in lane 2. PCR-amplified products were separated on a 1.5 
% (w/v) agarose gel. Lane M, HyperLadder™ IV (100 bp molecular weight marker). 
 
List of Tables 
 
Table 1 Phenotypic differences between V. cholerae O1 biotype El Tor and classical isolates. 
 
Table 2 Proposed WHO clinical case definitions for cholera. 
 
Table 3 Antimicrobial concentration range and minimum inhibitory concentration (MIC) 
breakpoints for antimicrobial resistance using ETest® strips tested for surveillance purposes at 
the Centre for Enteric Diseases. 
 
 
 
 
 
 
 
 
  
 



Nomenclature 
 
ACF  Accessory colonization factor 
ADP  Adenosine diphosphate 
ATP  Adenosine tri-phosphate 
ABC  ATP-binding cassette 
A  Alanine 
AP  Alkaline phosphatase  
AFLP  Amplified fragment length polymorphism 
ATCC  American Type Culture Collection  
et al.   And others 
D  Aspartic acid 
~   Approximately  
R  Arginine  
N  Asparagine 
att  Attachment  
bp   Base pair 
β   Beta 
BCIP  5-Bromo-4-chloro-3-indolyl phosphate 
CED  Centre for Enteric Diseases 
CFR  Case-fatality-rate 
cm  Centimetre  
cm2  Centimetre squared 
CT  Cholera toxin 
ChrI  Chromosome 1 
ChrII  Chromosome 2 
CLSI   Clinical and Laboratory Standards Institute 
CFU/ml Colony forming units per milliliter 
CHEF   Contour-clamped homogenous electric field 
CTXclassΦ CTX classical 
 



CTXETΦ CTX El Tor 
C  Cysteine 
DMP   Diagnostic Media Products 
º   Degree 
ºC   Degree Celsius 
DNA   Deoxyribonucleic acid 
dNTP   Deoxynucleoside triphosphates 
DIG  Digoxigenin 
DGREA Direct genomic restriction enzyme analysis 
Dr.  Doctor 
EDTA  Disodium ethylenediaminetetra-acetic acid 
EPI  Efflux pump inhibitor 
ERIC-PCR Enterobacterial repetitive intergenic consensus-based PCR 
=   Equal to 
erm  Erythromycin ribosome methylase 
ESBL  Extended spectrum β-lactamase 
Etest  Episolimeter test 
EtBr  Ethidium bromide 
EUCAST European Committee on Antimicrobial Susceptibility Testing 
GI  Genomic island 
E  Glutamic acid 
Q  Glutamine 
G  Glycine 
g   gram 
>  Greater than 
≥   Greater than or equal to 
G  Guanine 
GERMS-SA Group for Enteric Respiratory and Meningeal Surveillance-South Africa 
H  Histidine 
HIV  Human immunodeficiency virus 
 



HCl  Hydrochloric acid 
Inc  Incompatible  
∞  Infinity 
ICE  Integrating conjugative element 
IV  Intravenous 
I  Isoleucine 
kb   Kilo base pair 
kDa  Kilodalton 
kg/cm2  kilogram per centimeter squared  
LGT  Lateral gene transfer 
<  Less than 
≤   Less than or equals to 
L  Leucine 
LPS  Lipopolysaccharide 
l   Litre 
K  Lysine 
LB  Luria-Bertani 
MLS  Macrolide, lincosamide and streptogramin 
MgCl2   Magnesium chloride 
MFS  Major facilitator superfamily 
MDGs  Millennium Development Goals 
mRNA  Messenger ribonucleic acid 
M  Methionine 
µg   Microgram 
µl   Microlitre 
µl/ml  Microliter per millilitre 
µg/ml   Microgram per millilitre 
µm  Micrometer 
µM   Micromolar 
mg   Milligram 
 



ml  Millilitre 
mg/kg  Milligram per kilogram 
mg/ml  Milligram per millilitre 
mm   Millimetre 
mM  millimolar 
MIC   Minimum Inhibitory Concentration 
-   Minus 
M   Molar 
>  More than 
≥  More than or equal to 
MATE  Multidrug and toxic compound extrusion 
MLST  Multi locus sequence typing 
MLVA Multiple-locus variable-number of tandem repeat analysis 
ng  Nanogram  
ng/µl  Nanogram per microliter 
NPET  Nascent peptide exit tunnel 
NCBI  National Center for Biotechnology Information 
NHLS  National Health Laboratory Service 
NHLSRT National Health Laboratory Service Research Trust 
NICD   National Institute for Communicable Diseases 
NDM-1 New Delhi metallo-β-lactamase 
NBT   Nitro blue tetrazolium chloride  
NTC  No template control 
#  Number 
( )  Open bracket close bracket / parenthesis 
ORF  Open reading frame 
[ ]  Open square bracket close square bracket 
OCV  Oral cholera vaccine 
ORS  Oral rehydration solution 
PTC  Peptidyl transferase center 
 



/  Per 
%   Percent 
pH   Percentage Hydrogen 
F  Phenylalanine 
+  Plus 
PCR   Polymerase chain reaction 
PMF  Proton-motive force 
PFGE   Pulsed-field gel electrophoresis 
PMQR  Plasmid-mediated quinolone resistance 
QRDR  Quinolone resistance determining region 
RAPD  Randomly amplified polymorphic DNA 
REP-PCR Repetitive extragenic palindromic PCR 
RS  Repetitive sequence 
RND  Resistance-nodulation-cell division 
rpm   Revolutions per minute 
RNA  Ribonucleic acid 
rRNA  Ribosomal ribonucleic acid 
S  Serine 
STI  sexually transmitted infection 
SMR  Small multidrug resistance 
NaCl   Sodium chloride 
SSC  Sodium chloride, Sodium citrate buffer 
SDS  Sodium dodecyl sulphate 
NaOH  Sodium hydroxide 
TD  Traveller’s diarrhoea 
TCBS  Thiosulphate citrate bile salts sucrose agar 
T  Threonine 
X  Times 
TCP  Toxin co-regulated pilus 
tRNA  transfer ribonucleic acid 
 



TD  Traveller’s diarrhoea  
TAE   Tris-acetate-EDTA 
TBE   Tris-borate-EDTA 
TE   Tris-EDTA 
W  Tryptophan 
Y  Tyrosine 
U   Unit 
UPGMA  Unweighted pair group method with arithmetic averages 
V  Valine 
VNTR  Variable number of tandem repeats 
V.  Vibrio 
VPI  Vibrio pathogenicity island 
V  Volt 
V/cm  Volt per centimetre 
w/v   Weight to volume 
WHO  World Health Organization 
  
 



Table of contents 
Molecular characterization of cholera outbreak isolates in South Africa, 2008-2009 .................... I 
Advisory committee .................................................................................................................... II 
Declaration ................................................................................. Error! Bookmark not defined. 
Publications ............................................................................................................................... IV 
Presentations .............................................................................................................................. IV 
Oral ........................................................................................................................................ IV 
Poster ...................................................................................................................................... V 
Conference attendance .............................................................................................................. VI 
Abstract .................................................................................................................................... VII 
Acknowledgements ................................................................................................................... XI 
Ethics clearance certificates ..................................................................................................... XII 
List of Figures ........................................................................................................................ XIV 
List of Tables .......................................................................................................................... XVI 
Nomenclature ........................................................................................................................ XVII 
Chapter One ................................................................................................................................. 1 
Introduction ................................................................................................................................. 1 
1.1 Bacteriology....................................................................................................................... 1 
1.1.1 Microbiology .................................................................................................................. 1 
1.1.2 Serology .......................................................................................................................... 2 
1.1.3 Biotypes .......................................................................................................................... 3 
1.2 Burden of disease............................................................................................................... 5 
1.2.1 Pandemics of cholera ...................................................................................................... 6 
1.2.2 Cholera in Africa ............................................................................................................ 8 
1.3 Transmission of Vibrio cholerae O1 ................................................................................. 8 
1.4 Clinical features ................................................................................................................. 9 
1.5 Pathogenesis of infection due to Vibrio cholerae O1 ...................................................... 10 
1.6 Prevention and treatment of cholera ................................................................................ 11 
1.6.1 Public health measures ................................................................................................. 12 
1.6.2 Cholera vaccination strategies ...................................................................................... 12 
 



1.6.3 Specific treatment for cholera....................................................................................... 14 
1.7 Molecular aspects of toxigenic Vibrio cholerae O1 ........................................................ 15 
1.7.1 Cholera toxin (CT) and the bacteriophage CTXΦ........................................................ 16 
1.7.2 Vibrio pathogenicity island (VPI) ................................................................................ 18 
1.7.3 Regulation of the Cholera Toxin (CT) and toxin co-regulated pilus (TCP) ................. 18 
1.8 Molecular epidemiology and genetic characterization of toxigenic Vibrio cholerae O1 19 
1.9 Mechanisms of antimicrobial resistance in toxigenic Vibrio cholerae O1 ..................... 21 
1.9.1 Efflux systems .............................................................................................................. 22 
1.9.2 Spontaneous mutations in chromosomal DNA ............................................................ 23 
1.9.3 Horizontal gene transfer through mobile genetic elements .......................................... 23 
1.10 Background and setting of my research project ............................................................ 25 
1.11 Study objectives ............................................................................................................. 25 
1.12 References ..................................................................................................................... 27 
Chapter Two .............................................................................................................................. 35 
Materials and Methods .............................................................................................................. 35 
2.1 Collection, phenotypic identification, serological characterization and storage of 
bacterial isolates of Vibrio cholerae O1 ................................................................................ 35 
2.2 Antimicrobial susceptibility testing ................................................................................. 36 
2.3 Genotypic characterization of Vibrio cholerae O1 by pulsed-field gel electrophoresis 
(PFGE) analysis ..................................................................................................................... 39 
2.4 Crude extraction of genomic DNA .................................................................................. 45 
2.5 Polymerase chain reaction (PCR) amplification ............................................................. 46 
2.5.1 Detection and analysis of the enzymatic A subunit of the cholera toxin (CT) ............. 46 
2.5.2 Detection and analysis of the toxin co-regulated pilus (TCP) ...................................... 47 
2.5.3 Detection and analysis for extended spectrum β-lactamases (ESBLs)......................... 47 
2.5.4 Detection and analysis for class 1 and class 2 integrons .............................................. 48 
2.5.5 Detection and analysis for the tetracycline resistance determinant, SXT element-
integrase and SXT associated resistance genes ..................................................................... 49 
2.5.6 Detection and analysis for plasmid-mediated quinolone resistance (PMQR) genes and 
quinolone resistance determinants ......................................................................................... 50 
 



2.5.7 Detection and analysis of genes encoding for the DNA gyrase and topoisomerase IV of 
the quinolone resistance-determining region (QRDR) .......................................................... 50 
2.6 Detection and size analysis of PCR-positive products using conventional agarose gel 
electrophoresis ....................................................................................................................... 51 
2.7 Nucleotide sequencing of PCR-positive amplicons ........................................................ 52 
2.8 Identification and preparation of plasmid DNA .............................................................. 54 
2.9 Southern hybridization analysis ....................................................................................... 56 
2.10 References ..................................................................................................................... 62 
Chapter Three ............................................................................................................................ 64 
Molecular characterization of Vibrio cholerae O1 associated with an outbreak of cholera in the 
Mpumalanga Province, South Africa, May to July 2008 .......................................................... 64 
3.1 Introduction ..................................................................................................................... 64 
3.2 Materials and Methods .................................................................................................... 64 
3.2.1 Bacterial isolates and phenotypic characterization ....................................................... 64 
3.2.1.1 Involvement of efflux pumps .................................................................................. 655 
3.2.2 Genotypic characterization ........................................................................................... 67 
3.2.2.1 Pulsed-field gel electrophorsis (PFGE) analysis ....................................................... 67 
3.2.2.2 Detection for virulence determinants ........................................................................ 67 
3.2.2.3 Detection for antimicrobial resistance determinants ................................................. 67 
3.2.2.4 Isolation of plasmid DNA and Southern blot hybridization analysis ........................ 68 
3.3 Results ............................................................................................................................. 68 
3.3.1 Bacterial isolates and antimicrobial susceptibility patterns .......................................... 68 
3.3.2 Genes encoding for virulence determinants ................................................................. 68 
3.3.3 PFGE analysis............................................................................................................... 68 
3.3.4 Genes conferring antimicrobial resistance ................................................................... 69 
3.3.5 ESBL activity and identified ESBL genes ................................................................... 69 
3.3.6 Chromosomal mutations in the QRDR of DNA gyrase and topoisomerase IV ........... 69 
3.4 Discussion ........................................................................................................................ 72 
3.5 Conclusion ..................................................................................................................... 766 
3.6 References ....................................................................................................................... 77 
 



Chapter Four .............................................................................................................................. 81 
Molecular characterization of Vibrio cholerae O1 isolates associated with a country wide 
outbreak of cholera in South Africa, 2008 to 2009 ................................................................... 81 
4.1 Introduction ..................................................................................................................... 81 
4.2 Materials and Methods .................................................................................................. 822 
4.2.1 Bacterial isolates and phenotypic characterization ..................................................... 822 
4.2.2 Genotypic characterization ........................................................................................... 82 
4.2.2.1 Pulsed-field gel electrophorsis (PFGE) analysis ....................................................... 82 
4.2.2.2 Detection for virulence determinants ........................................................................ 82 
4.2.2.3 Detection for antimicrobial resistance determinants ............................................... 833 
4.2.2.4 Isolation of plasmid DNA and Southern blot hybridization analysis ........................ 83 
4.2.2.5 Molecular characterization of Vibrio cholerae seventh pandemic variants .............. 83 
4.2.2.5.1 Cholera toxin .......................................................................................................... 84 
4.2.2.5.2 Toxin co-regulated pilus ......................................................................................... 84 
4.2.2.5.3 Mobilome................................................................................................................ 84 
4.3 Results ............................................................................................................................. 85 
4.3.1 Bacterial isolates ........................................................................................................... 85 
4.3.2 Antimicrobial susceptibility patterns ............................................................................ 85 
4.3.3 PFGE analysis............................................................................................................... 86 
4.3.4 Genes conferring antimicrobial resistance ................................................................... 86 
4.3.5 ESBL activity and identified ESBL genes ................................................................... 86 
4.3.6 Chromosomal mutations in the QRDR of DNA gyrase and topoisomerase IV ........... 88 
4.3.7 Molecular characterization of Vibrio cholerae seventh pandemic variants ................. 88 
4.4 Discussion ........................................................................................................................ 91 
4.5 Conclusion ....................................................................................................................... 93 
4.6 References ....................................................................................................................... 94 
Chapter Five .............................................................................................................................. 97 
Azithromycin susceptibility in recent antimicrobial-resistant Vibrio cholerae O1 altered El Tor 
variant isolates in South Africa. ................................................................................................ 97 
5.1 Introduction ..................................................................................................................... 97 
 



5.2 Materials and Methods .................................................................................................. 102 
5.2.1 Bacterial isolates ......................................................................................................... 102 
5.2.2 Antimicrobial susceptibility testing ............................................................................ 102 
5.2.2.1 Episolimeter test (Etest) method.............................................................................. 102 
5.2.2.2 Doubling agar dilution method ................................................................................ 102 
5.2.3 Genotypic characterisation ......................................................................................... 103 
5.2.3.1 Detection for macrolide resistance determinants ..................................................... 103 
5.2.3.2 Internal control DNA constructs .............................................................................. 104 
5.2.4 Statistical analysis....................................................................................................... 106 
5.3 Results ........................................................................................................................... 107 
5.3.1 Azithromycin susceptibility testing ............................................................................ 107 
5.3.2 Detection for macrolide resistance determinants ........................................................ 107 
5.3.3 Statistical analysis....................................................................................................... 107 
5.4 Discussion ...................................................................................................................... 107 
5.5 Conclusion ..................................................................................................................... 112 
5.6 References ..................................................................................................................... 113 
Chapter Six .............................................................................................................................. 119 
Limitations .............................................................................................................................. 119 
6.1 References ..................................................................................................................... 122 
Chapter Seven ......................................................................................................................... 125 
General Discussion and Conclusion ........................................................................................ 125 
7.1 References ..................................................................................................................... 131 
Appendices ............................................................................................................................ 1344 
Appendix A: Pulsed-field gel electrophoresis (PFGE)...................................................... 1344 
Appendix B: Polymerase Chain Reaction (PCR) .............................................................. 1399 
Appendix C:  Detection of PCR products using conventional agarose gel electrophoresis 153 
Appendix D: Nucleotide sequencing using the ABI Prism®BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems) ................................................................................ 154 
Appendix E: Isolation and preparation of plasmid DNA .................................................... 155 
Appendix F: PCR DIG-labelling and Southern blot hybridization ..................................... 157 
 



Appendix G: Involvement of efflux pumps ......................................................................... 161 
Appendix H: Tracking seventh pandemic variants.............................................................. 162 
Appendix I: Azithromycin susceptibility testing ................................................................. 168 
Appendix J: Plagiarism declaration with Turnitin report .................................................... 171 
 
 



Chapter One 
Introduction 
 
Diarrhoeal illness is one of the contributing factors of mortality among children less than five 
years of age worldwide [1,2].  In South Africa, diarrhoeal illness contributes ~ 3 % of the total 
deaths and is the eighth largest cause of death nationally [3]. Unsafe drinking water together with 
the lack of sanitation and poor hygiene behaviours facilitate the transmission of enteric 
pathogens [3]. Cholera is a severe watery diarrhoeal disease caused by the toxin-producing 
bacterium, Vibrio cholerae (V. cholerae) [4]. Between 1849 and 1854, John Snow, a physician in 
London proposed that cholera was a communicable disease and that stool contained the 
infectious material [4]. V. cholerae was first described by Filippo Pacini in 1854 in Italy who 
observed a large number of curved bacteria in the gastrointestinal tract of patients [4]. This 
discovery was better described in cholera studies done by Robert Koch in 1883 in Egypt and 
continued in 1884 in Calcutta, India [4]. V. cholerae has since been well described based on 
biochemical testing and deoxyribonucleic acid (DNA) homology studies [4]. 
 
1.1 Bacteriology 
 
1.1.1 Microbiology 
 
V. cholerae is a non-invasive bacterium, which belongs to the family Vibrionaceae [4-6]. This 
organism is facultative anaerobic, non-spore forming, gram-negative, rod-shaped and highly 
motile with a single polar, sheathed flagellum [5-7]. Vibrio species are ~ 0.5 micrometre (µm) to 
0.8 µm in diameter by 1.5 µm to 3.0 µm in length [5,7]. V. cholerae ferments glucose, sucrose, 
mannitol and produces lysine and ornithine decarboxylase [7]. The growth of the organism is 
stimulated by the addition of 1 % sodium chloride [7]. An important biochemical test for 
distinguishing V. cholerae from members of the family Enterobacteriaceae is the oxidase test 
[5,7]. V. cholerae is positive for oxidase [5-7].  
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The optimal growth temperature and percentage Hydrogen (pH) for V. cholerae is between plus 
(+) 30 Degree Celsius (°C) and + 40 °C and a pH 8.0 [7,8]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 A negatively-stained whole mount of V. cholerae illustrating curved-shaped bacilli 
containing single polar, sheathed flagella. 
 
1.1.2 Serology 
 
V. cholerae is classified into serogroups based on antibody-antigen differences of the somatic 
“O”-antigen of the lipopolysaccharide (LPS) [4,6]. Based on these antigenic differences, 
210“O”-antigen serogroups have been described [4,6]. Toxin-producing V. cholerae belonging to 
serogroups O1 and O139 Bengal are known to be associated with endemic and epidemic cholera 
[4,6]. Serogroups other than serogroups O1 and O139 are referred to as non-O1 and non-O139 
however, they have been known to cause moderate to severe human gastroenteritis [9]. V. 
cholerae O1 is further characterized into three serotypes namely Inaba, Ogawa and Hikojima 
(Figure 2a) [4,6,9]. All three serotypes are clustered according to the structure of the “O” antigen 
on the LPS and have a common “A” antigenic determinant [9,10]. V. cholerae O1 serotype 
Ogawa isolates express the “B” antigenic determinant, while V. cholerae O1 serotype Inaba 
isolates express the “C” antigenic determinant [9,10]. V. cholerae O1 serotype Hikojima isolates 
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are rare and express both the “B” and “C” antigenic determinants [9,10]. To date, there have not 
been recent publications on the prevalence of V. cholerae O1 serotype Hikojima. Serotype 
switching has been described in V. cholerae isolates [10,11]. No serotype(s) exist for V. cholerae 
O139 Bengal [6].  
 
 
Figure 2a Classification of V. cholerae according to serogroup and serotype. 
 
1.1.3 Biotypes 
 
Cholera biotypes are discrete phenotypes that differ with respect to severity of infection, ability 
to survive outside of the human host and seasonality patterns [10]. V. cholerae O1 is 
characterized into two well established biotypes namely, El Tor and classical (Figure 2b) [6]. 
These biotypes are differentiated based on various phenotypic characteristics, which include 
susceptibility to polymyxin B, chicken cell agglutination, haemolysis of sheep erythrocytes, 
production of acetylmethylcarbinol by the Voges-Proskauer test and susceptibility to 
bacteriophages [12]. These differences are listed in Table 1 [12]. The majority of V. cholerae O1 
Vibrio cholerae 
Serogroup O1
Serotype Inaba
Serotype Ogawa
Serotype HikojimaSerogroup O139
Serogroups non-O1 
and non-O139
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biotype El Torisolates has become non-haemolytic worldwide [12]. However, this is an 
exception for V. cholerae O1 biotype El Torisolates from Australia and the United States Gulf 
Coast [12]. Differentiation between the two biotypes is now based on a Polymerase Chain 
Reaction (PCR) test, which exploits sequence differences in the toxin co-regulated pilus (TCP) 
gene [13]. 
 
 
 
Figure 2b Classification of V. cholerae serogroup O1 according to biotype. 
 
Table 1 Phenotypic differences between V. cholerae O1 biotype El Tor and classical isolates 
[12]. 
 
Phenotypic property Result for V. cholerae O1 biotype 
Classical El Tor 
Inhibition by polymyxin B Positive Negative 
Voges-Proskauer test Negative Positive 
Haemolysis of sheep erythrocytes Negative Positive or Negative 
Agglutination of chicken cells  Negative Positive 
Bacterial cell lysis by classical IV 
bacteriophage 
Positive Negative 
Bacterial cell lysis by El Tor V bacteriophage Negative Positive 
 
Vibrio cholerae 
serogroup O1
Biotype El Tor
Prototype 
Variant
Matlab variant
Mozambique 
variant
Altered variant
Biotype 
Classical
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1.2 Burden of disease 
 
Cholera continues to be a global concern particularly in many developing countries [4].  Cholera 
is a notifiable diarrhoeal disease in many countries including South Africa (accessed from 
http://www.kznhealth.gov.za/pharmacy/edladult_2012.pdf; September 2014) with approximately 
one percent of cases being reported to the World Health Organization (WHO) [14]. Cases of 
cholera generally remain undetected for various reasons. For example, stool specimens are not 
always routinely cultured for isolation and identification of V. cholerae or health care advice is 
not sought after when mild symptoms are presented or limitations may exist in current 
surveillance and reporting systems [6,14,15]. 
 
Cholera in recent years has shown a 130 % increase in the number of cases from 2000 to 2010 
and an overall increase of 43 % from 2009 to 2010 [6]. The WHO estimates more than 120 000 
individuals die from cholera each yearand three to five million cholera cases occur worldwide 
(accessed from http://www.who.int/mediacentre/factsheets/fs107/en/; July 2015). Cholera is 
endemic (refer to Table 2 for proposed WHO clinical case definition [4,16]) in many regions of 
Asia, Africa, South and Central America [4,14]. It has been shown that V. cholerae O1 serotypes 
are likely to vary in dominance in geographical regions where cholera is endemic [10]. The 
reasons for these fluctuations have not been well described [10].  
 
Table 2 Proposed WHO clinical case definitions for cholera. 
 
Description Case definition 
Disease unknown in area Severe dehydration or death from acute watery diarrhoea in a 
patient aged five or more. 
Endemic cholera Acute watery diarrhoea with or without vomiting in a patient aged 
five years and older. 
Epidemic cholera Acute watery diarrhoea with or without vomiting in any patient. 
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1.2.1 Pandemics of cholera 
 
Seven pandemics of cholera have been described [4,7,17]. The first six pandemics of cholera 
were associated with human migration [7]. The first cholera pandemic began in 1817 in the 
Indian subcontinent along trade routes to the West [7,17]. The second pandemic began in 1826 
and reached the British Isles and major European cities in the early 1830s [7,17]. In 1854 
following the second cholera pandemic, John Snow conducted an archetypal investigation 
whereby he showed the association of cholera with contaminated drinking water [7,17]. During 
the 1850s, the United States of America was extensively affected by the third cholera pandemic 
[7,17]. Up to 1925, the fourth, fifth and sixth cholera pandemics, affected Australia, Europe, 
Africa and South America [7,17].  
 
Compared to the first six cholera pandemics, which originated in Bangladesh, the ongoing 
seventh pandemic of cholera began in 1961 in Indonesia and has since, disseminated across 
continents [4,7,17,18]. The causative agent is V. cholerae O1 biotype El Tor and has therefore 
replaced the classical biotype [4,7,17,18]. This biotype was originally isolated in 1905, which 
was associated with Indonesian pilgrims travelling to Mecca through a village of El Tor, Egypt 
[4,7,17,18].  
 
It is uncertain as to why the El Tor biotype became pandemic when it did as well as the 
replacement of the classical biotype worldwide [18]. A theory from evolutionary biology 
suggests that when there is improvement in sanitation, selection pressure acts against V. cholerae 
O1 biotype classical and in favour of the more benign El Tor biotype [18]. V. cholerae O1 
biotype classical isolates are more virulent, as it kills the host in a shorter period of time and 
therefore reduces the opportunity of infection of other potential hosts [18]. V. cholerae O1 
biotype El Tor isolates are less virulent and as a result, are more capable of infecting other 
potential hosts for a longer period of time [18].  
 
Cholera spread across India in 1964 and re-emerged in Africa in 1970 and in South and Central 
America in 1991, which had been free of the disease for more than 100 years [4,14,17]. As a 
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result, cholera has now become endemic in many of these regions [1,10,14]. Both classical and 
El Tor biotypes behave differently from each other [18]. For example, the seventh cholera 
pandemic was more widespread with respect to covering larger geographical areas [18]. As a 
result more countries were affected [18]. This seventh pandemic has illustrated temporal 
differences with respect to how fast the disease has spread and duration of the pandemic [18]. 
The longest previous pandemic was the sixth, which lasted 24 years (1899 to 1923) [18]. As of 
2014, the seventh pandemic lasted over 50 years and continues to show no signs of disappearing. 
 
In 1992, in Bangladesh, a new serogroup V. cholerae O139 Bengal emerged [7,14,17,18]. 
Previously, only V. cholerae O1 was known to cause cholera epidemics [7,14,17,18]. Presently, 
V. cholerae serogroups O1 and O139 co-exist to cause a large number of cholera outbreaks in 
India and Bangladesh [7,14,17,18]. There were concerns that V. cholerae O139 Bengal could 
cause the eighth pandemic of cholera [7,14,17,18]. However, the number of cases caused by this 
serogroup remains a small proportion of the total number of cases of cholera [7,14,17,18].  
 
Over recent years, new variants of V. cholerae O1 have been described namely, the Matlab, 
Mozambique and Altered El Tor (Figure 2b) [4,6,19]. These variants display characteristics of 
both El Tor and classical biotypes [4,6,19]. V. cholerae O1 El Tor variants were initially 
described by Nair et al. in clinical cholera isolates collected in Matlab, Bangladesh, for the 
period, 1991 to 1994 [19]. As a result, related variants have been isolated in other countries in 
Asia and Africa [4,6,19] with the first reports in Africa described in Mozambique [20].  
 
 
 
 
 




 



1.2.2 Cholera in Africa 
 
Before the seventh cholera pandemic reached Africa in 1970, cholera had an exclusively Asian 
focus [6,21]. In 2005, approximately 78 % of cholera cases that were reported to the WHO were 
from sub-Saharan Africa [6,22]. The reported annual incidence for cholera in 2005 was 95 times 
higher (166 cases per million population) than the reported annual incidence in Asia (1.74 cases 
per million population) and 16 600 times higher than Latin America (0.01 cases per million 
population) [6,22]. During the same year, the case-fatality-rate (CFR) was three times higher in 
sub-Saharan Africa (~ 1.8 %) than that in Asia (~ 0.6 %) [6,21]. 
 
In 2009, 45 countries reported a total of 221 226 cases of cholera including 4 946 deaths to the 
WHO [23]. Compared to 2008, the number of cholera cases increased by ~ 16 % with a CFR of 
~ 2.24 % [23]. From the total number of cholera cases reported in 2009, 217 333 (~ 98 % of the 
global total) cases including 4 883 deaths were reported from Africa [23]. Compared to 2008 
(179 323 cases), the number of cholera cases increased by ~ 20 % with a CFR of ~ 2.25 % [23]. 
From the total number of cholera cases reported from Africa (2009), Zimbabwe reported the 
highest number cases (68 153 cases), followed by Ethiopia (31 509 cases) and then the 
Democratic Republic of the Congo (22 899 cases) [23]. In 2009, a total of 10 520 (~ 4.76 %) 
cholera cases including 57 deaths with a CFR of ~ 0.54 % was reported from South Africa [23].  
 
In 2010, Central Africa experienced a devastating wave of cholera. Countries that were affected 
included Cameroon, Chad, Niger, Nigeria and around the Lake Chad Basin [6,24].  
 
1.3 Transmission of Vibrio cholerae O1 
 
The main reservoir for the amplification and spread of V. cholerae O1 via the faecal-oral route is 
the human host [1,4]. A general definition for a host is “a living organism that temporarily 
harbours the pathogen, generally providing nourishment and shelter” [8]. However, 
environmental reservoirs have shown an important function in the persistence of V. cholerae O1 
and its role in cholera [1,8]. An environmental reservoir is defined as “locations out of the human 
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body within the niche favouring bacterial persistence and replication in the environment, and 
pathogen transmission to susceptible hosts” [1]. V. cholerae O1 constitute part of the normal 
aquatic environment in estuarine and brackish waters [1,4,8]. Examples of these environmental 
reservoirs include chironomids and zooplankton [1,4,8]. 
 
The mode of transmission of V. cholerae O1 is the ingestion of contaminated water or food 
[1,4,8], although, human-to-human transmission has been described [1]. Symptomatic patients 
infected with either V. cholerae O1 or O139 usually shed the organism between two days and 
two weeks [1,4,25]. As V. cholerae O1 leaves the human body, the organism has a 
hyperinfectious phenotype [4,26]. This relates to the infectious dose, which is 10 to 100 times 
lower than that for non-human-shed organisms [4,26]. Recently shed V. cholerae O1 has shown 
to persist in water between five to 24 hours [1,4,26]. This suggests that human-to-human 
transmission might be more infectious than those who have adapted to the environment [4].  
 
1.4 Clinical features 
 
Bacterial infection with V. cholerae O1 leads to a clinical spectrum that ranges from 
asymptomatic colonization to cholera gravis (the most severe form of cholera) [1,4,14]. The 
death rate for untreated patients with severe cholera can exceed 70 % [4,27]. The incubation 
period for V. cholerae O1 to colonize the small intestine of the human host ranges between 12 
hours to five days before symptoms appear [1,4,25].  
 
Symptoms usually begin with abdominal cramps and vomiting (common feature) followed by 
diarrhoea, which is generally painless [1,4]. Stools acquire a characteristic rice-water appearance 
and harbour 1x1010 to 1x1012 vibrios per litre [1,4,7,28]. Dehydration and electrolyte imbalance 
are the most important complications of cholera [4,28]. Patients are generally described as being 
lethargic; they might have sunken eyes, a dry mouth, cold clammy skin, decreased skin turgor 
and kussmaul breathing can occur [4,28,29]. Urine output decreases with time [4]. Muscle 
cramps and weakness due to loss of electrolytes and ion shifts are common [4]. Children with 
depleted glycogen can lead to severe hypoglycaemia [4]. Another clinical feature described is 
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cholera sicca, which is an unusual form of the disease [4]. In cholera sicca, fluid accumulates in 
the intestinal lumen, which can result in circulatory collapse or even death before the passage of 
the first loose stool [4]. 
 
The presentation of cholera differs between endemic and epidemic settings [1,4]. In an endemic 
setting, children are more likely to be hospitalized with severe illness [1,4]. When V. cholerae 
O1 is introduced into an immunity naive population, all age groups are equally susceptible to 
symptoms of infection and this is usually associated with high CFRs [1,4].  
 
The infectious dose of V. cholerae O1 required for pathogenesis in a human host varies with 
respect to the bacterial isolate and the host [1]. An infectious dose of 1x105 to 1x1011 of bacterial 
cells is required to cause severe cholera in a healthy individual [1,4]. A lower infectious dose of 
1x103 to 1x108 of bacterial cells is needed to cause cholera in an individual taking an antacid 
(Bicarbonate buffer) to neutralize stomach acid [1,4].  
 
1.5 Pathogenesis of infection due to Vibrio cholerae O1 
 
Pathogenic isolates of V. cholerae O1 harbour two essential virulence factors namely, the 
choleragen or cholera toxin (CT), which is primarily responsible for the excretion of profuse 
diarrhoea and the toxin co-regulated pilus (TCP), which is a colonization factor (Figure 3) 
[1,4,9]. Upon ingestion of contaminated water or food with V. cholerae O1, most of the 
organisms are killed by the gastric acid in the stomach (Figure 3) [1,4,9]. The surviving 
organisms pass through the acid barrier of the stomach and colonize the small intestine by means 
of the TCP (Figure 3) [1,4,9]. Colonization is an essential step in cholera pathogenesis [1]. 
Following adherence, the CT (secreted AB5-subunit toxin) and other proteins for example, Zot, 
Ace and haemolysin are produced [1,4,7]. The B subunit pentamer of the CT binds 
monosialotetrahexosyl-gangliosides on absorptive intestinal epithelial cells [1,4,7]. This initiates 
endocytosis of the enzymatic A subunit of the CT (Figure 3) [1,4,7]. This reaction results in the 
adenosine diphosphate (ADP) ribosylation of a subunit of the G protein (a heterotrimer that 
connects cell surface receptors to effector proteins at the plasma membrane), which regulates 
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adenylyl cyclase activity [1,4,7]. As a result ion transport by intestinal epithelial cells is 
disrupted and subsequent loss of water and electrolytes leads to the severe diarrhoea and 
dehydration [1,4,7].  
 
 
Figure 3 A flow diagram illustrating pathogenesis of V. cholerae O1. 
 
1.6 Prevention and treatment of cholera 
 
Decisions relating to prevention and control of cholera are generally based on surveillance 
reports [14]. Prevention strategies vary between indigenous populations and travellers as the 
majority of travellers do not reside in the same conditions as indigenous populations [14]. 
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1.6.1 Public health measures 
 
Cholera control measures have focused on safe drinking water, improved sanitation and effective 
food hygiene by appropriate preparation of high-risk foods [14,30]. 
 
1.6.2 Cholera vaccination strategies 
 
Another preventative measure is the administration of oral cholera vaccines (OCVs) [14,30]. 
Cholera vaccines have evolved from injectable vaccines with side effects and questionable 
protective efficacy to state-of-the-art killed whole-cell OCVs, which have shown to be safe and 
guarantees a high level of protection for several years [30].  Since the early 1990s, OCVs have 
been licensed and pre-qualified for purchase by the United Nations agencies [30]. However, 
these OCVs have been overlooked for public health interventions and are now marketed for 
travellers from industrialized countries who perceive themselves at risk for cholera [30].  
 
Up to the 1990s, the only cholera vaccines that were available were those made from phenol-
killed whole cells of V. cholerae O1 organisms [30]. They were administered by injection as two 
doses given two weeks apart [30]. These vaccines offered ~ 50 % protection for a short duration 
and was associated with painful local inflammatory reactions [30]. These parenteral cholera 
vaccines are no longer in use and were replaced by orally administered vaccines, specifically 
killed whole-cell vaccines and genetically modified live attenuated vaccines [30]. Currently there 
are two WHO pre-qualified OCVs namely Dukoral and Shanchol [30]. 
 
Dukoral was the first OCV to be internationally licensed [30]. It is produced by Crucell and 
contains whole V. cholerae O1 organisms and the recombinant CT B subunit (WC/rBS) [30]. 
The minimum age for an individual to be vaccinated is two years and older [30]. Individuals 
aged five years or older require two doses while individuals aged less than five years require 
three doses [30]. This vaccine has shown a 60 % efficacy in individuals over two years of age 
[30]. Dukoral has been evaluated in several countries in Africa particularly in Beira, 
Mozambique [30]. The findings from Mozambique were of importance for two reasons [30]. The 
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first reason was the circulating isolates of V. cholerae O1 El Tor variants expressing the classical 
CT and second, the prevalence of human immunodeficiency virus (HIV) infection in Beira, 
which was very high, as shown by the 20 % to 30 % prevalence among women of child-bearing 
age [30]. Dukoral was shown to protect against V. cholerae O1 El Tor variants as well as in 
environments with a high HIV prevalence [30]. The findings from Indonesia and western Sudan 
showed that mass vaccination campaigns with Dukoral can be successful in complex 
emergencies [30].  
 
Compared to Dukoral, which is relatively expensive, Shanchol, the next generation of killed 
whole-cell OVC, is significantly cheaper and much easier to administer [30]. Shanchol is a 
bivalent OCV and is produced by Shanta Biotechnics [30]. It contains whole V. cholerae O1 
organisms together with V. cholerae O139 strain 4260B [30]. Therefore the difference between 
the two licensed OCVs is the presence of the recombinant CT B subunit in Dukoral [30]. The 
minimum age for an individual to be vaccinated is one year and older and only two doses are 
required [30]. This vaccine has shown a 67 % efficacy in individuals over three years of age 
[30]. Another WC/rBS OCV, which might have potential in an African setting, is OraVacs [30]. 
 
OraVacs is produced by Shanghai United Cell Biotechnology and is only licensed in China and 
Philippines [30].  Reports on the safety and efficacy of this OCV are still to be published in peer-
reviewed international journals [30]. Compared to Dukoral, which needs to be reconstituted, 
OraVacs is formulated as an enteric coated capsule [30].  
 
A second type of OCV described, is a genetically modified live attenuated OCV, CVD 103-HgR 
(Orachol or Mutachol) [30]. This OCV was licensed, administered as a single-dose with buffer 
and was shown to be safe in North American volunteers [30]. However it has not been in 
production since 2004 [30]. Studies conducted in Indonesia did not display convincing results 
and as a result the manufacturer ceased production [30]. Currently, PaxVax is preparing to 
reintroduce an improved, new generation version of CVD 103-HgR [30]. Aside from the 
licensed OCVs aforementioned, there are several vaccines, which are in development (current 
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phase 2, V. cholerae Peru 15) and several, which are undergoing clinical assessment (V. cholerae 
638, VA 1.3, and IEM 108) [30]. 
 
1.6.3 Specific treatment for cholera 
 
The mainstay of treatment of cholera is adequate rehydration and electrolyte replacement therapy 
[4,16,31]. Taking into consideration the present standard of care, the mortality rate of severe 
cholera can be reduced to less than 0.2 % even in resource-limited settings [4]. Patients 
presenting with mild dehydration can be treated effectively with oral rehydration solutions 
(ORSs) [4,16]. This ORS formula has been approved by the WHO since 2002 [4,16]. Patients 
presenting with severe dehydration require intravenous (IV) rehydration with a multi-electrolyte 
solution to replace fluid and electrolyte loss [4,16]. In conditions whereby there is limited access 
to rehydration treatment or in severe cases of dehydration, antimicrobial agents can be 
administered [4,16]. Appropriate antimicrobial agents can shorten the duration of diarrhoea and 
shorten the duration of excretion to reduce secondary transmission, mainly in settings where 
affected individuals are residing in close proximity to each other [4,14,16]. Antimicrobial agents 
can be administered once the initial fluid deficit is corrected and vomiting has stopped [4].  
 
For adults, a single 300 milligram (mg) dose of doxycycline or 500 mg of tetracycline four times 
a day for three days should be given [4,16]. The prescribed regimen differs for children, for 
whom it is recommended that tetracycline in a dose of 12.50 milligram per kilogram (mg/kg) be 
administered four times daily for three days [4,16]. However, prophylaxis with tetracycline is not 
recommended due to the high incidence of antimicrobial resistance. Alternative antimicrobial 
regimens for the treatment of cholera include furazolidone, 100 mg four times daily for adults, 
1.25 mg/kg four times daily for three days for children; or erythromycin, 250 mg four times daily 
for adults, 12.5 mg/kg four times daily for three days for children [4,16]. Ciprofloxacin may also 
be utilized as an alternative treatment for adults in a dose of 500mg twice daily for three days 
[4]. Single dose of azithromycin is the preferred therapy both in children (20 mg/kg) and in 
adults (1 g)  and has been shown to be more effective than ciprofloxacin in randomized trials in 
regions where reduced susceptibility to fluoroquinolones are common [4]. In South Africa, 
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cholera vaccinations are not recommended [32]. The recommended treatment of cholera patients 
in South Africa is the equivalent to internationally accepted cornerstone of cholera treatment, 
which is timely and adequate rehydration therapy [32,33]. Antimicrobial resistance has been 
associated with antimicrobial usage and is further discussed in section 1.9.  
 
1.7 Molecular aspects of toxigenic Vibrio cholerae O1 
 
The V. cholerae genome is comprised of two circular chromosomes and belongs to the γ-
subdivision of the family Protobacteriaceae [6,34]. This analysis is based on the complete 
genome sequence of V. cholerae O1 El Tor biotype strain N16961 [34]. The large chromosome 
is assigned as chromosome 1 or ChrI and consists of 2 961 146 base pairs (bp) in length, while 
the smaller chromosome is assigned chromosome 2 or ChrII and consists of 1 072 314 bp (Figure 
4) [34]. Together they encode 3 885 open reading frames (ORFs). ChrI contains genes required 
for essential functions such as growth and virulence [34]. These genes encode for DNA 
replication, transcription, translation and cell-wall synthesis [34]. In addition, genes required for 
bacterial pathogenesis include surface antigens, toxins and adhesions [34]. ChrII is comprised of 
hypothetical genes and genes of unknown function [34]. It contains a gene capture system known 
as an integron island and contains “addiction” genes, which are usually associated on plasmids 
[34]. Both chromosomes contain several identical ORFs with the same function. Acquisition of 
genes may have been a result of horizontal gene transfer [34].  
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Figure 4 Schematic representation of the V. cholerae O1 El Tor biotype strain N16961 genome 
[34].  
 
 
 
1.7.1 Cholera toxin (CT) and the bacteriophage CTXΦ 
 
In V. cholerae O1, pathogenesis requires a number of essential virulence genes, which are 
located in clusters in regions on the chromosome [9,17,34-36]. The existence of these pathogenic 
gene clusters indicate that they have the potential to propagate laterally by means of horizontal 
gene transfer and disseminate to other bacteria [9,17,34-36]. Pathogenic V. cholerae O1 can be 
distinguished from non-pathogenic isolates by the presence of two genetic elements namely, the 
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CTX element, which is the genome of a filamentous bacteriophage, designated CTXΦ that 
encodes genes for the CT (Figure 5) and the vibrio pathogenicity island (VPI), which contains 
genes coding for the TCP [9,17,34-36].  
 
 
 
Figure 5 The CTX genetic element of the filamentous bacteriophage CTXΦ composed of two 
functional domains including the core, which is flanked by 1 or more repetitive sequence (RS). 
The Illustration was taken from Waldor and Mekalanos, 1996 [35].  
 
Waldor and Mekalanos were the first to describe that the ctxAB genes coding for the A and B 
subunits of the CT were located on the filamentous CTXΦ [35]. The CTX genetic element is 
between seven and ten kilobase pairs (kb) in size and is composed of two functional domains 
namely, the core and the repetitive sequence (RS2) (Figure 5) [9,17,35]. The core is ~ 4.50 kb in 
length and contains six genes including ctxAB, zot (encodes for the zonula occludens toxin), cep 
(encodes for the core-encoded pilin), ace (encodes for the accessory cholera toxin) and orfU 
(encodes for a product of unknown function) respectively (Figure 5) [9,17,35]. The proteins 
responsible for bacteriophage packing and secretion are Zot, Ace, OrfU and Psh and the protein 
responsible for the assembly of CTXΦ is Zot [9,17,19,35]. The RS2 (2.7 kb) encodes for four 
open reading frames (ORF) namely, rstA (function in replication); rstB (function in integration); 
rstC (induce ctxAB expression) and rstR (function in regulation) (Figure 5), which together is 
responsible for site-specific recombination into the chromosome of non-toxigenic V. cholerae  
O1 isolates at a specific attachment (att) site, which is termed attRS [9,17,19,35]. CTX 
bacteriophage genomes are classified into two types based on nucleotide sequence variations of 
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the rstR gene, which includes the CTXΦ classical (CTXclassΦ) and CTXΦ El Tor (CTXETΦ) 
[19,37]. Several V. cholerae O1 El Tor variants have been described [19], which possess 
characteristics of both biotypes and this is further discussed in section 1.8.  
 
1.7.2 Vibrio pathogenicity island (VPI) 
 
The TCP acts as both a mediator for bacterial colonization to the intestinal epithelial cells and as 
a receptor for the bacteriophage (CTXΦ) entry into the bacterium [9]. The function of the TCP is 
augmented with a potential accessory colonization factor, ACF, which is coded by the acf gene 
[9,38]. The TCP-ACF gene cluster is located on the ~ 40 kb VPI and is characteristic of both 
epidemic and pandemic isolates of V. cholerae O1 [9,17,38,39]. The major subunit of the TCP is 
encoded by the tcpA gene [9,38,39]. The formation and function of the pilus assembly is the 
responsibility of at least 15 other genes located next to tcpA on the tcp gene cluster [9,39]. The 
toxT, tcpP and tcpH genes located on the pathogenicity island, encode for regulators of virulence 
genes, which may be necessary for the transfer and integration of the VPI (Figure 6) [9,38]. A 
study done by Karaolis et al. revealed that the VPI has a low guanine and cytosine (G + C) 
content of ~ 35 % suggesting acquisition of the pathogenicity island was from another source 
[9,38].  
 
1.7.3 Regulation of the Cholera Toxin (CT) and toxin co-regulated pilus (TCP) 
 
The regulation of the CT, TCP and ACF is mediated by the ToxR regulatory system, [9,17]. The 
ToxR is a 32 kilodalton (kDa) transmembrane protein that regulates the expression of the CT in 
response to appropriate environmental signals by means of a regulatory cascade [9,17]. ToxS is a 
sensory membranous protein encoded by the toxS gene, which activates ToxR [9]. ToxR is 
encoded by the toxR gene and mediates the expression of ToxT, which is encoded by the toxT 
gene and is present in the cytoplasm (Figure 6) [9]. The ToxR protein binds to a 7 bp tandem 
repeat DNA sequence upstream of the ctxAB, which results in the elevated expression of the CT 
[9].  
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Figure 6 Regulation of the cholera toxin and toxin co-regulated pilus. 
 
1.8 Molecular epidemiology and genetic characterization of toxigenic Vibrio cholerae O1 

The epidemiological surveillance of cholera was limited due to the lack of suitable genotyping 
applications [6,9]. Recent developments of several DNA-based typing systems, have allowed 
scientists to investigate the epidemiology of toxigenic V. cholerae O1 [6,9,40,41]. Such advances 
have enabled the establishment of large databases of characterized organisms [6,9,40,41]. 
Genotyping systems have the potential to establish relatedness of isolates from disease epidemics 
and provide information on the geographical distribution, source or origin of infection 
[6,9,40,41].  
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Various DNA-based molecular techniques namely, pulsed-field gel electrophoresis (PFGE) 
analysis, direct genomic restriction enzyme analysis (DGREA), randomly amplified polymorphic 
DNA (RAPD), amplified fragment length polymorphism (AFLP), repetitive extragenic 
palindromic PCR (REP-PCR), ribotyping, multi locus sequence typing (MLST), enterobacterial 
repetitive intergenic consensus-based polymerase chain reaction (ERIC-PCR), microarray, 
plasmid fingerprinting and variable number of tandem repeats (VNTR), have been shown to be 
useful in the epidemiology, ecology and genetic exchange of V. cholerae [6,40,41]. Although 
many studies have shown these applications to be useful, one must consider both the rapidity and 
discriminatory power towards the species of interest [6,40,41]. The latest molecular applications 
such as whole genome sequencing has become the method of choice for the analysis and 
comparison of V. cholerae isolates [42]. 
 
PFGE analysis is recognized as the “gold standard” of genotyping applications [40]. The 
principle of PFGE is based on the digestion of genomic DNA with rare-cutting restriction 
enzymes followed by gel electrophoresis using pulsating polarized electric currents [6,40,41]. 
PFGE has been successfully applied for the analysis of clonal relatedness of V. cholerae (clinical 
and environmental sources) and has been evaluated as an epidemiological tool for outbreak 
investigations [6,40,41,43]. PFGE demonstrates both geographical and temporal stability and has 
shown to be more discriminatory than ribotyping [6,41].  
 
V. cholerae O1 biotype classical and El Tor isolates display different phenotypic and genotypic 
properties [12,19]. Several V. cholerae O1 El Tor variants have been described and possess both 
characteristics of both biotypes [6,19]. These variants have been described in Bangladesh, Asia 
and Africa [19,44]. V. cholerae O1 altered El Tor variants produce the CT of the classical 
biotype, which is coded by the ctxB1 gene and can be biotyped by means of conventional 
phenotypic assays [12,19]. V. cholerae O1 hybrid variants produce the CT of either biotype as 
they carry both rstRCla and rstREl genes, but cannot be biotyped by means of conventional 
phenotypic assays [12,19]. For the characterization of ctxAB and rstR genes, nucleotide sequence 
analysis is required. This can be accomplished by PCR of the genes followed by Sanger-type 
DNA nucleotide sequencing. Alternatively, should whole genome sequencing data be available, 
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then the nucleotide sequences of genes could be obtained by extraction of gene sequences from 
whole genome sequencing data [37]. PCR was developed in 1985 and has since proved to be a 
powerful detection tool in various scientific areas [45,46]. Direct sequencing remains the “gold 
standard” for the identification of unknown products of PCR amplification [45,46].  
 
1.9 Mechanisms of antimicrobial resistance in toxigenic Vibrio cholerae O1 
 
V. cholerae  O1 does not generally cause systemic infections and antimicrobial agents are not 
required in the treatment of cholera however, there are advantages of combining oral rehydration 
therapy with the use of antimicrobial agents [47]. Antimicrobial resistance has resulted in 
treatment complications of cholera [47,48]. Prior to the 1970s, V. cholerae O1 remained 
susceptible to antimicrobial agents [48]. This changed in 1976 during a worldwide survey that 
was conducted on randomly selected isolates [48]. This survey showed that ~ 3 % of the V. 
cholerae  O1 isolates were antimicrobial-resistant to frequently used antimicrobial agents [48]. 
During the 1950s, the recommended antimicrobial agent furazolidone was widely used for the 
specific and symptomatic treatment of bacterial or protozoal diarrhoea in children [48]. 
However, during the late 1980s the majority of enteric pathogens have developed resistance to 
furazolidone and as a result, now has limited applications [48]. Analysis of antimicrobial 
susceptibility profiles of V. cholerae O1 from different regions of the world showed that for the 
period of 1938 to 1993, isolates were resistant to one to three antimicrobial agents and for the 
period of 1994 to 2005, isolates were resistant to three to eight antimicrobial agents including the 
fluoroquinolone, ciprofloxacin [48]. To emphasize how quickly antimicrobial resistance has 
developed in V. cholerae O1, a study done by Towner et al. in 1980 reported on isolates 
recovered during the fourth cholera epidemic in Tanzania that were susceptible to tetracycline 
[49]. However, after five months of extensive treatment with tetracycline, 76 % of V. cholerae 
O1 were shown to be resistant to tetracycline and other antimicrobial agents [49].  The increased 
minimum inhibitory concentrations (MICs) to ciprofloxacin coupled with resistance to older 
antimicrobial agents have forced clinicians to use a broad-spectrum macrolide, azithromycin for 
the treatment of cholera [50].  
 
 



Bacteria possess various molecular mechanisms for antimicrobial resistance, which are either 
intrinsic (natural) or acquired [51-53]. Human and animal populations are potential reservoirs for 
antimicrobial resistance genes [52,54,55]. Antimicrobial resistance genes either are present in 
nature already or have the potential to emerge by mutation [53]. For example, rapid mutation 
was observed with the TEM β-lactamase, which was first reported in 1963 in Athens [53]. 
Several mechanisms of antimicrobial resistance have been well described for V. cholerae O1 
[47,48,51]. Resistance mechanisms include, exporting antimicrobial agents before it can reach its 
target site by means of an efflux pump, spontaneous mutations in genetic material and through 
the exchange of conjugative plasmids, conjugative transposons, integrons or self-transmissible 
chromosomally integrating SXT elements [47,48,51]. 
 
1.9.1 Efflux systems 
 
Bacterial efflux pumps are transport proteins, which are involved in the expulsion of toxic 
substrates within cells into the environment [56]. Efflux pumps might be specific for 1 substrate 
or a variety of compounds [56]. Two major groups of efflux pumps have been described for V. 
cholerae. These pumps are distinguished based energy sources namely, Adenosine tri-phosphate 
(ATP) hydrolysis and proton-motive force (PMF) [47,48,57]. Families belonging to the PMF 
include the multidrug and toxic compound extrusion (MATE), major facilitator superfamily 
(MFS), resistance-nodulation-cell division (RND) and small multidrug resistance (SMR) 
[47,48,57]. An example of a V. cholerae ATP-driven pump is VcaM, which is an ATP-binding 
cassette (ABC) multidrug resistance efflux pump [47]. VcaM confers antimicrobial resistance to 
tetracyclines, fluoroquinolones and anthracyclines [47]. In Gram-negative bacteria, the RND 
family is of particular interest because of its broad substrate specificity and mode of action [57]. 
V. cholerae encodes six RND efflux systems, which may suggest why this organism is highly 
adaptable in contaminated environments as well as survival in the host [57]. For example, the 
VexH RND efflux pump does not only function in the transport of antimicrobial agents out of the 
bacterial cell but also contributes in the production, regulation and expression of the CT and 
TCP. [57].  
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1.9.2 Spontaneous mutations in chromosomal DNA 
 
Antimicrobial resistance by chromosomal mutation is natural to all bacteria [52,53]. These 
mutations occur spontaneously in replicating bacteria as a result of imperfect fidelity of DNA 
replication, termed vertical evolution [43,52]. It is proposed that antimicrobial agents that target 
multiple sites within the bacterial cell are more likely to be at lower risk of acquiring resistance 
via chromosomal mutation [52]. However this is limited as illustrated by quinolone resistance 
[52]. Fluoroquinolone resistance has been reported since early 2002 and has been the 
antimicrobial agent of choice in the treatment of various infectious diseases including cholera 
[48].  Quinolones target both DNA gyrase and topoisomerase IV, which are essential for DNA 
replication [52]. Quinolone resistance is usually associated with amino acid substitutions in the 
quinolone resistance-determining region (QRDR) of DNA gyrase (GyrA/GyrB) and 
topoisomerase IV (ParC/ParE) proteins [47,48]. Quinolone resistance due to chromosomal 
mutations detected in GyrA andParC has been reported in V. cholerae O1 [58-60]. 

1.9.3 Horizontal gene transfer through mobile genetic elements 
 
Antimicrobial resistance by gene acquisition refers to prior existence of antimicrobial-resistant 
genetic determinants that are then acquired by other bacteria, termed horizontal evolution 
[43,51,52,55]. 
 
 One of the common modes for the dissemination of antimicrobial resistance genes are 
conjugative resistance plasmids, which are able to promote cell to cell transfer of DNA [48,61]. 
Plasmids are “self-replicating circular pieces of DNA, smaller than the genome, which encode 
their transfer by replication into another bacterial strain or species” [53]. Plasmid-encoded 
antimicrobial resistance includes the majority of classes of antimicrobial agents currently in 
clinical use [61]. These include cephalosporins, fluoroquinolones and aminoglycosides. V. 
cholerae O1, prior to the 1970s was susceptible to tetracycline [47,48]. As a result of extensive 
use of this oral antimicrobial agent, V. cholerae O1 has now become resistant, particularly in 
many African countries [47,48]. For example, V. cholerae O1 isolates collected during the 
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Somali cholera epidemic for the period 1985 to 1986 were shown to harbour two incompatible 
(Inc) C groups plasmids conferring resistance to ampicillin, kanamycin, streptomycin 
sulfonamide and tetracycline [62]. 
 
An integrative conjugative element (ICE) is a self-transmissible, mobile genetic element, which 
possess both plasmid-like (transfer by means of conjugation) and bacteriophage-like (not self-
replicating) characteristics [63,64]. The term ICE was introduced by Burrus et al. in 2002 and 
includes conjugative transposons [63,64]. The SXT element is an example of an ICE of V. 
cholerae [47,48,64,65]. The 99.5 kb ICE, SXTMO10 was first identified in clinical isolates of V. 
cholerae O139 from Madras, India and confers resistance to sulfamethoxazole, streptomycin, 
trimethoprim and chloramphenicol [47,48,64,65]. Several studies from Africa including South 
Africa have described V. cholerae O1 isolates harbouring the SXT element and its association in 
antimicrobial resistance [66-69]. 
 
An integron is a site-specific recombination gene capture system that consists of an integrase 
coded by the intI gene, a primary recombination site known as attI and an outward-orientated 
promoter Pc, at which short DNA sequences called gene cassettes are, inserted [48,61,70,71]. 
Integron-inserted gene cassettes usually consist of a single gene and an imperfect inverted repeat 
at the 3’ end of the gene called the attC site [70,72]. Presently, there are five classes of integrons 
[70]. Class 1 integrons are commonly found in clinical isolates as most known classes of 
antimicrobial agents belong to this class [70]. Class 4 and class 5 integrons are associated with V. 
species [70]. To date, over 100 integron-inserted gene cassettes have been identified [48]. A 
superintegron was initially discovered in V. cholerae which harboured hundreds of genes but 
with an unknown function [47,48,73,74]. Epidemic V. cholerae isolates from Africa harbouring 
class 1 integrons and class 2 integrons have previously been described [67,68,75-77]. 
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1.10 Background and setting of my research project 
 
As early as 1971, South Africa was considered at risk for the introduction and facilitation of 
spread of cholera in and around the country [78]. Risk factors included hot and humid summer 
seasons, the presence of sea-ports and overcrowded communities living in areas with unsafe 
water, sanitation and hygiene [78]. The first cholera epidemic described in South Africa occurred 
between 1980 and 1987 [78]. The first case was confirmed in October 1980 in an open 
community at Shongwe Hospital in KaNgwane, Mpumalanga Province [78]. Common 
epidemiological characteristics of cases showed that patients lived on farms at Malelane and had 
consumed open river water from the Crocodile-Malelane irrigation canal [78]. Majority of the 
patients were black South Africans residing in rural or deep rural areas with a relatively high 
annual rainfall of 600 millimetres [78]. A total of 25 251 laboratory-confirmed cases were 
reported with a CFR of ~ 1.4 %. Cholera outbreak isolates were characterized as V. cholerae O1, 
serotype Inaba, biotype El Tor [78]. The second cholera epidemic described in South Africa 
occurred between 1997 and 2005 [11]. The worst affected Province was KwaZulu-Natal [11]. 
For the years 2000 to 2002, more than a 100 000 cases were reported (Based on clinical 
diagnoses) with a CFR of less than ~ 1 % (for the period of 2001 to 2002) [11]. Cholera outbreak 
isolates were characterized as V. cholerae O1, serotype Ogawa, biotype El Tor and V. cholerae 
O1, serotype Inaba, biotype El Tor [11]. For the period 1 January 2008 to 31 May 2009, South 
Africa experienced two major outbreaks of cholera [79-82]. Within both outbreaks, organisms 
isolated from probable cholera cases identified at peripheral laboratories displayed resistance to 
three or more routinely tested antimicrobial agents.  
 
1.11 Study objectives 
 
The objectives of this study were: 
 
• To investigate South African outbreak isolates of V. cholerae O1, 1 January 2008 to 31 
May 2009. 
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• To determine the genetic diversity and cluster analysis of toxin-producing V. cholerae O1 
isolates by using PFGE analysis (1 January 2008 to 31 May 2009). 
• To screen for presence of the enzymatic subunit A of the CT (ctxA gene) and the toxin 
co-regulated pilus (tcpA gene) using PCR assays. 
• To determine the presence of amino acid mutations in the CT (ctxAB) by nucleotide 
sequencing. 
• To screen for the presence of antimicrobial resistance determinants by PCR. This 
included class 1 integrons (3’-CS and 5’-CS), class 2 integrons (intI2), plasmid-mediated 
quinolone resistance (PMQR) genes (qnrA, qnrB, qnrS, qnrC and qepA), quinolone 
resistance determinant (qnrVC3), ESBL producing genes (blaTEM, blaSHV and blaCTX-M), 
genes coding for the quinolone resistance-determining region (QRDR) of DNA gyrase 
(gyrA/gyrB) and topoisomerase IV (parC/parE), SXT element-integrase gene (SXTint) 
and associated SXT resistance genes (floR, sul2, dfrA1, dfr18, strA and strB) and the class 
A tetracycline resistance determinant (tetA). 
• To determine the presence of amino acid mutations in the QRDR of DNA gyrase and 
topoisomerase IV by nucleotide sequencing. 
• To characterize the sequence identity of PCR-positive ESBL genes by nucleotide 
sequencing. 
• To investigate the presence of resistance plasmids by the isolation of intact plasmid DNA 
(blaTEM). 
• To determine the genomic location of antimicrobial resistance genes using Southern blot 
hybridization assays (blaTEM). 
• To identify and track major 7th pandemic V. cholerae O1 variants. 
• To determine the MICs to azithromycin by both the Episolimeter test (Etest) and 
doubling agar dilution methods. 
• To investigate the presence of seven macrolide resistance determinants by PCR. This 
included mefA, ereA, ereB, ermB, mphA, mphB and mphD. 
• To characterize any of the seven macrolide resistance determinants found to be PCR-
positive by nucleotide sequencing.  
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Chapter Two 
Materials and Methods 
 
This chapter describes the general methods used in this study. Specific methods are described in 
the appropriate chapters. 
 
2.1 Collection, phenotypic identification, serological characterization and storage of 
bacterial isolates of Vibrio cholerae O1 
 
A probable case of cholera was defined by clinical signs and symptoms as discussed in Chapter 
one. At the Centre for Enteric Diseases (CED), a clinical laboratory-confirmed case of cholera 
was defined as a positive culture for V. cholerae O1, from stool specimens or rectal swabsfrom 
patients admitted to clinics or hospitals throughout South Africa for the years 2008 to 2009. 
Cultured V. cholerae isolates from environmental specimens such as Moore (sewer) pads or 
water were sent to the CED for confirmation and further characterization. Isolates sent from 
peripheral laboratories, were first cultured onto Dorset egg slopes (Diagnostic Media Products 
(DMP), NHLS, South Africa), before arriving at the CED. 
 
As part of routine characterization of V. cholerae O1 isolates received by the CED, all isolates 
were sub-cultured and streaked for single colonies onto non-selective media, 5 % sheep blood 
agar (DMP) as well as selective media, thiosulphate citrate bile salts sucrose agar (TCBS) 
(DMP) and incubated overnight at + 37 °C for the following day. Aseptic techniques were 
implemented. Cultured isolates were serogrouped and serotyped by slide agglutination. Various 
Pipetman® models (Gilson Inc., Middleton, United States of America) were used to aspirate the 
set volume of different liquids. 
 
A single colony for each cultured isolate was picked using a toothpick and emulsified on a glass 
slide (Thermo Fisher Scientific, Johannesburg (Pty), South Africa) containing ten microlitres (µl) 
of sterile 0.9 % saline (DMP). The turbid saline suspension was mixed by tilting the glass slide 
back and forth. The saline suspension was examined to ensure that no clumping formed as a 
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result of autoagglutination. Ten microlitres of polyvalent V. cholerae serogroup O1 antiserum 
(Mast Assure, Mast Group Ltd., Merseyside, United Kingdom) was added to this suspension and 
mixed as described above. If the emulsified suspension agglutinated, isolates were further 
characterized by means of serotyping. 
 
A single colony was picked using a toothpick and emulsified on a glass slide (Thermo Fisher 
Scientific) containing 10 µl of sterile 0.9 % saline (DMP) on both ends of the glass slide. Ten 
microlitres of monovalent Inaba antiserum (Mast Assure, Mast Group Ltd.) and 10 µl of Ogawa 
antiserum (Mast Assure, Mast Group Ltd.) were independently added of each other to each 
suspension and mixed as described above. The suspension that showed the strongest 
agglutination was recorded as positive. V. cholerae O1 isolates were stored at – 70 °C in tryptic 
soy broth with 10 % glycerol (DMP).  
 
2.2 Antimicrobial susceptibility testing 
 
The minimum inhibitory concentration (MIC) is defined as “The lowest concentration of 
antimicrobial agent required to inhibit growth of the bacteria”. MIC-determination and disk 
diffusion testing for each isolate were performed, as per the Clinical and Laboratory Standards 
Institute (CLSI), 2008 guidelines[1].  
 
Isolates were streaked for single colonies onto 5 % horse blood agar (DMP) and incubated 
overnight at + 37 °C for the following day. Three to four single colonies were picked using a 
flamed loop and resuspended in a glass tube containing five millilitres (ml) sterile 0.9 % saline 
(DMP) (one tube per a bacterial isolate). The turbidity for each isolate was measured against a 
blank tube containing 5 ml sterile 0.9 % saline (DMP). A microscan turbidity meter (DADE 
BEHRING, California, United States of America) was used to measure the absorbance and the 
turbidity was adjusted to ~ 0.05, which corresponds to a McFarland 0.50 or 1x108 colony 
forming units per millilitre (CFU/ml). This is to ensure that the density of bacterial inoculum is 
standardized. A cotton swab stick was dipped into the inoculum suspension and applied to 
eightMuller-Hinton agar plates (DMP) with the use of a retro C80 plate spreader (bioMérieux, 
 



Marcy-l’Etoile, France). Episolimetertests (Etest) were performed using antimicrobial agents in 
the form of ETest® strips (bioMérieux). Using a sterile forceps, two ETest® strips (bioMérieux) 
were appropriately applied to each plate. Aseptic techniques were implemented, whereby the 
forceps was flamed in between the application of each ETest® strip (bioMérieux). Antimicrobial 
agents together with the concentration range and MIC breakpoints for antimicrobial agents tested 
for surveillance purposes at the CED are described in Table 3. MIC interpretation for 
erythromycin was performed using a previously published method by Ng et al. [2]. The Mueller-
Hinton agar plates (DMP) containing the ETest® strips (bioMérieux) were incubated overnight at 
+ 37 °C for the following day. MIC results were recorded. Isolates resistant to third and fourth 
generation cephalosporins were further investigated for the presence of extended-spectrum β-
lactamase (ESBL) activity. 
 
ESBL activity was investigated by disk diffusion testing using MAST ID™ ESBL discs (Mast 
Assure, Mast Group Ltd.) as described by the CLSI 2008 guidelines.  Escherichia coli, American 
Type Culture Collection (ATCC) 25922 (ESBL-negative) and Klebsiella pneumoniae 
ATCC700603 (ESBL-positive) were used for quality control purposes. The inoculum suspension 
for each isolate was prepared as previously described. Only one Mueller-Hinton agar plate 
(DMP) was required per a bacterial isolate.  
 
All six MAST ID™ ESBL discs (Mast Assure, Mast Group Ltd.) were appropriately applied to 
each plate. MAST ID™ ESBL discs (Mast Assure, Mast Group Ltd.) included: ceftazidime (30 
µg), ceftazidime (30 µg) with clavulanate (10 µg); cefotaxime (30 µg), cefotaxime (30 µg) with 
clavulanate (10 µg); cefpodoxime (30 µg) and cefpodoxime (30 µg) with clavulanate (10 µg). 
The muller-hinton agar plates (DMP) containing the MAST ID™ ESBL discs (Mast Assure, Mast 
Group Ltd.) were incubated overnight at + 37 °C for the following day. MIC results were 
recorded.ESBL-positive results were recorded with respect to an increase in ratio of 1.5 or 
greater in zone diameter of inhibition by the cephalosporin disc containing clavulanate compared 
to the cephalosporin disc by itself. To determine whether isolates were susceptible, 
intermediately resistant, or resistant to a particular antimicrobial agent, isolates were referred to 
as non-susceptible if they were intermediately resistant or resistant to an antimicrobial agent. 
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Table 3 Antimicrobial concentration range and minimum inhibitory concentration (MIC) 
breakpoints for antimicrobial resistance using ETest® strips tested for surveillance purposes at 
the Centre for Enteric Diseases. 
 
Antimicrobial agent Antimicrobial concentration range of 
ETest® strips 
MIC breakpoint 
for resistance 
Ampicillin 0.016 µg/ml – 256 µg/ml MIC ≥ 16 µg/ml 
Augmentin 0.016 µg/ml – 256 µg/ml MIC ≥ 16 µg/ml 
Co-trimoxazole 0.002 µg/ml – 32 µg/ml MIC ≥ 16 µg/ml 
Trimethoprim 0.002 µg/ml – 32 µg/ml MIC ≥ 16 µg/ml 
Sulfamethoxazole 0.064 µg/ml – 1 024 µg/ml MIC ≥ 512 µg/ml 
Chloramphenicol 0.016 µg/ml – 256 µg/ml MIC ≥ 16 µg/ml 
Nalidixic acid  0.016 µg/ml – 256 µg/ml MIC ≥ 32 µg/ml 
Ciprofloxacin 0.002 µg/ml – 32 µg/ml MIC ≥ 2 µg/ml 
Tetracycline 0.016 µg/ml – 256 µg/ml MIC ≥ 8 µg/ml 
Kanamycin 0.016 µg/ml – 256 µg/ml MIC ≥ 32 µg/ml 
Streptomycin 0.064 µg/ml – 1 024 µg/ml MIC ≥ 64 µg/ml 
Imipenem 0.002 µg/ml – 32 µg/ml MIC ≥ 8 µg/ml 
Ceftriaxone 0.016 µg/ml – 256 µg/ml MIC ≥ 16 µg/ml 
Ceftazidime 0.016 µg/ml – 256 µg/ml MIC ≥ 16 µg/ml 
Cefepime 0.016 µg/ml – 256 µg/ml MIC ≥ 16 µg/ml 
Furazolidone 0.016 µg/ml – 256 µg/ml MIC ≥ 128 µg/ml 
Erythromycin* 0.016 µg/ml – 256 µg/ml MIC ≥ 3 µg/ml 
 
Abbreviations: Microgram per millilitre (µg/ml), greater than or equal to (≥) 
MIC interpretation was performed as per the Clinical and Laboratory Standards Institute (CLSI), 
2008 guidelines. 
*MIC interpretation was performed as per previously published method by Ng et al. in 2003. 
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2.3 Genotypic characterization of Vibrio cholerae O1 by pulsed-field gel electrophoresis 
(PFGE) analysis 
 
PFGE analysis was used to investigate the clonal relationship amongst the V. cholerae O1 
isolates. This method was performed according to an adaption from the PulseNet standardized 
protocol for V. cholerae incorporating single restriction enzyme digestion of the genomic DNA 
with NotI (Fermentas International Inc, Burlington, Canada) [3]. The reference strain, CDC-
H9812 Salmonella enterica serotype Braenderup was included as an internal control of known 
molecular size[4]. 
 
Figure 7 illustrates the schematic overview for the preparation of agarose plugs for PFGE 
analysis.Isolates were cultured on 5 % horse blood agar (DMP) and incubated overnight at + 37 
°C for the following day. Pure bacterial culture was collected using a cotton swab stick (Lasec) 
and resuspended in a 5 ml plastic tube (one tube per a bacterial isolate) containing 1 000 µl 
autoclaved cell suspension buffer (Appendix A1-A3). The turbidity for each isolate was 
measured against a blank 5 ml plastic tube containing 1 000 µl autoclaved cell suspension buffer. 
A microscan turbidity meter (DADE BEHRING) was used to measure the absorbance and the 
turbidity was adjusted to ~ 0.70. The tubes containing the inoculum suspension were kept on ice.  
 
Three-hundred microlitres of the inoculum suspension was transferred from the 5 ml plastic tube 
to a clean 1.5 ml Eppendorf tube (Eppendorf, Hamburg, Germany) (one tube per a bacterial 
isolate). For CDC-H9812, 200 µl of inoculum suspension was transferred. For the isolates, 15 µl 
of 20 milligrams per milliliter (mg/ml) proteinase-K (Roche Diagnostics, Mannheim, Germany) 
was added each 1.5 ml Eppendorf tube containing the 300 µl inoculum suspension (Appendix 
A4. For CDC-H9812, 20 µl of 10 mg/ml proteinase-K (Roche) was added (Appendix A5). The 
1.5 ml Eppendorf tubes containing both the inoculum suspension and proteinase-K were capped 
and incubated on a Stuart model SBH200D3 dry heating block (Barloworld Scientific Ltd, 
Staffordshire, United Kingdom) at + 37 °C for five minutes. Agarose plugs were then prepared. 
The SeaKem Gold® agarose (Lonza, Rockland, USA) used to prepare the agarose plugs was kept 
liquid at + 55 °C (Appendix A6-A8). 
 



For each isolate, 300 µl of 1 % SeaKem Gold® agarose (Lonza) (Weight to volume (w/v)) was 
added to the 1.5 ml Eppendorf tube containing both the inoculum suspension and proteinase-K. 
The agarose suspension was mixed by pipetting up and down. Three-hundred µl of this agarose 
suspension was then immediately transferred into a reusable plug mould (Bio-Rad Laboratories, 
California, United States of America) and allowed to solidify for ten minutes. For CDC-H9812, 
280 µl of 1 %SeaKem Gold® agarose (Lonza) : 1 % sodium dodecyl sulphate (SDS) (Merck 
KGaA, Darmstadt, Germany) (w/v) was added. The agarose suspension was mixed by pipetting. 
Two-hundred and eighty microlitres of this agarose suspension was then immediately transferred 
into a reusable plug mould (Bio-Rad) and allowed to solidify for ten minutes. This was followed 
by bacterial cell lysis to release the genomic DNA. The agarose plugs were transferred to Nunc 
50 ml graduated centrifuge tubes (Thermo Fisher Scientific) (one tube per a bacterial isolate) 
using a spatula. Aseptic techniques were implemented, whereby the spatula was wiped down 
with 70 % alcohol (DMP) in between each isolate. Five mililitres of cell lysis buffer (Appendix 
A9-A10) was added to each 50 ml test tube containing the agarose plug. The tubes were 
incubated for two hours at + 55 °C in a Julabo SW22 shaking water bath (JULABO 
Labortechnik GmbH, Seelbach, Germany) at 70 rotations per minute (rpm). This allowed for the 
lysis of the agarose plugs. After two hours, the tubes were taken out of the shaking water bath 
(JULABO Labortechnik GmbH). The cell lysis buffer was discarded. Fifteen mililitres of pre-
heated distilled water (+ 50 °C) was added to each tube. The tubes were incubated for 15 minutes 
at + 50 °C in the shaking water bath (JULABO Labortechnik GmbH) at 70 rpm. This allowed for 
the lyzed agarose plugs to be washed. The distilled water was discarded. This wash step was 
repeated twice. Fifteen mililitres of pre-heated Tris-disodium ethylenediaminetetra-acetic acid 
(TE) buffer was added to each tube (Appendix A11). The tubes were incubated for 15 minutes at 
+ 50 °C in the shaking water bath (JULABO Labortechnik GmbH) at 70 rpm. The TE buffer was 
then discarded. This wash step was repeated four times.  
 
Agarose plugs were stored away for further use in 14 ml polypropylene test tubes (Thermo 
Fisher Scientific) containing 3 ml TE buffer and kept refrigerated at + 2 ºC to + 8 ºC (one tube 
per a bacterial isolate). This was followed by restriction enzyme digestion of bacterial DNA. 
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Figure 7 Preparation of agarose plugs for pulsed-field gel electrophoresis (PFGE) analysis. 
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Figure 8 illustrates the schematic overview for the restriction enzyme digestion of total bacterial 
DNA contained in agarose plugs. For bacterial DNA digestion, an agarose plug was transferred 
to a glass slide (Thermo Fisher Scientific) using a spatula. Aseptic techniques were implemented. 
A thin slice of agarose, ~1 millimetre (mm) in width was cut using a disposable scalpel blade 
number (#) 22 (All Pro Medical Apparatus and Instruments Co., Ltd, Qingdao, China). The 
agarose slice was transferred from the glass slide to a 1.5 ml Eppendorf tube (Eppendorf) using a 
spatula (one tube per a bacterial isolate). Approximately three agarose slices of CDC-H9812 
were cut and prepared. One-hundred microlitres of restriction enzyme O-buffer mix (Appendix 
A12) was added to each 1.5 ml Eppendorf tube containing an agarose slice. For CDC-H9812, 
100 µl of restriction enzyme H-buffer mix (Appendix A13) was added. The 1.5 ml Eppendorf 
tubes were capped and incubated on a dry heating block (Barloworld Scientific Ltd) for 15 
minutes at + 37 °C. This step allowed for the agarose slice to adapt to the external environment. 
The 1.5 ml Eppendorf tubes (Eppendorf) were taken off the dry heating block (Barloworld 
Scientific Ltd), uncapped and the restriction enzyme buffer mix were aspirated out from each 1.5 
ml Eppendorf tube (Eppendorf). One-hundred and fifty microlitres of fresh restriction enzyme O-
buffer mix with NotI restriction enzyme (Appendix A14) was added to each 1.5 ml Eppendorf 
tube containing an agarose slice. For CDC-H9812, 150 µl of fresh restriction enzyme H-buffer 
mix with XbaI restriction enzyme (Appendix A15) was added. The 1.5 ml Eppendorf tubes were 
capped and incubated on a dry heating block (Barloworld Scientific Ltd) for 240 minutes at + 37 
°C. 
 
In order to halt the restriction enzyme reaction, the 1.5 ml Eppendorf tubes (Eppendorf) were 
taken off the dry heating block (Barloworld Scientific Ltd) and uncapped. The restriction enzyme 
buffer mix with restriction enzyme was aspirated out from each 1.5 ml Eppendorf tube 
(Eppendorf). Two-hundred microlitres of 0.5X Tris-Borate-EDTA (TBE) (Merck) buffer 
(Appendix A16-A17) was added to each 1.5 ml Eppendorf tube (Eppendorf). The 1.5 ml 
Eppendorf tubes (Eppendorf) were capped and incubated at room temperature (+ 25 °C) for ten 
minutes. Using a spatula, the agarose slices were removed from the 1.5 ml Eppendorf tube 
(Eppendorf) and loaded onto a 15 well gel comb (Bio-Rad) with gel casting tray (Bio-Rad). 
CDC-H9812 agarose slices were loaded on the first well, middle well and last well. A 1 % 
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SeaKem Gold® agarose (Lonza) gel (w/v) was prepared (Appendix A18). The molten agarose 
was cooled to + 50 °C and poured immediately into the gel casting tray with the gel comb 
containing the agarose slices. The gel was allowed to solidify for 25 minutesat room temperature. 
This was followed by electrophoresis. Approximately three litres (l) of 0.5X TBE (Merck) 
running buffer (Appendix A17) were prepared and poured into a contour-clamped homogenous 
electric field (CHEF-DR III) apparatus (Bio-Rad). The running buffer was cooled to + 14 °C. 
The gel comb was removed and the solidified gel was submerged in the electrophoresis tank. The 
electrophoresis running conditions was comprised of a two-block program at 200 volts (V). In 
the first block, the pulse times were set from an initial switch time of 2 seconds to a final switch 
time of 10 seconds with a run time of 14 hours at a gradient voltage of 6 volts per centimetre 
(V/cm). In the second block, the pulse times were set from an initial switch time of 20 seconds to 
a final switch time of 25 seconds with a run time of seven hours at a gradient voltage of 6 V/cm.  
 
Upon completion of the electrophoresis run, the gel was removed from the gel chamber of the 
CHEF-DR III (Bio-Rad) and placed in a plastic tray along with of 250 ml of ethidium bromide 
(EtBr, 10 mg/ml) staining solution (Appendix A19-A20). The plastic tray was oscillated on a 
Stuart SSL4 see-saw rocker (Barloworld Scientific Ltd) for 20 minutes at room temperature. The 
EtBr staining solution was discarded and 250 ml of distilled water was added. The plastic tray 
was oscillated on a Stuart SSL4 see-saw rocker (Barloworld Scientific Ltd) for 30 minutesat 
room temperature. This step allowed for the gel to de-stain. The distilled water was discarded 
and the image of the gel was captured on the Molecular Imager® Gel DocTM XR System (Bio-
Rad) using the Quantity One program software (Bio-Rad). The image of the gel as shown in 
Figure 9 was saved in a TIFF format (*.tif), which is required for further analysis using the 
BioNumerics™ (version 6) software program (Applied Maths, Sint-Martens-Latem, Belgium). A 
dendrogram was generated and compared by using an unweighted pair group method with 
arithmetic averages (UPGMA) analysis. Cluster analysis was conducted using a dice co-efficient 
with both an optimization value and tolerance factor of 1.5 %. For this study, PFGE clusters 
were defined by groups of PFGE banding patterns, which have similarity values of greater than 
or equal to (≥) 95 %. 
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Figure 8 Restriction enzyme digestion of total bacterial DNA contained in agarose plugs.  
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Figure 9 Pulsed-field gel electrophoresis (PFGE) image of ten V. cholerae O1 isolates digested 
with NotI restriction enzyme using the PulseNet standardized protocol for V. cholerae. Lane S 
Salmonella Braenderup strain CDC-H9812 digested with XbaI restriction enzyme. 
 
2.4 Crude extraction of genomic DNA 
 
V. cholerae O1 isolates and PCR-positive control isolates were cultured on 5 % sheep blood agar 
(DMP) and incubated overnight at + 37 °C for the following day. A half loopful of bacterial 
culture was resuspended in a clean 1.5 ml Eppendorf tube (Eppendorf) (One tube per a bacterial 
isolate) containing 400 µl autoclaved TE Buffer (Appendix A11). Aseptic techniques were 
implemented. Tubes were capped and incubated for 25 minutes at + 95 °C on a dry heating block 
(Barloworld Scientific Ltd).  The 1.5 ml Eppendorf tubes (Eppendorf) were taken off the dry 
heating block (Barloworld Scientific Ltd) and allowed to cool at room temperature. The 1.5 ml 
Eppendorf tubes (Eppendorf) containing the boiled cell suspensions were vortexed using a 
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GENIE2 vortex (Scientific Industries, Inc., New York, United States of America). The tubes 
were centrifuged in a balanced Eppendorf 5415R table-top centrifuge (Eppendorf) at 12 000 rpm 
for three minutes. The tubes were uncapped and 50 µl of the supernatant was transferred into a 
clean 1.5 ml Eppendorf tube (Eppendorf) containing 450 µl autoclaved TE Buffer and this served 
as the template DNA for the PCR assays.  
 
The 1.5 ml Eppendorf tubes (Eppendorf) containing the supernatant was stored for further use in 
the freezer at - 10 °C to - 20 °C. 
 
2.5 Polymerase chain reaction (PCR) amplification 
 
Polymerase chain reaction (PCR) was performed for the screening and amplification of genes 
coding for particular virulence determinants, antimicrobial resistance determinants and the 
quinolone resistance-determining region (QRDR) of DNA gyrase and topoisomerase IV. All 
PCR primers (100 micromolar (µM) stock concentrations) used in this study were synthesized by 
Inqaba Biotechnical Industries (Inqaba Biotechnical Industries, Hatfield, South Africa). The 16S 
rRNA gene was amplified and this served as an internal control as all bacteria contain this gene, 
which is essential for cell function. A no template control was included in all PCR assays to 
exclude contamination. 
 
2.5.1 Detection and analysis of the enzymatic A subunit of the cholera toxin (CT) 
 
A multiplex PCR assay was implemented to simultaneously detect for bacteria [5] and to identify 
CT producing V. cholerae O1 isolates [6] by the presence of the 16S rRNA gene and the CT 
enzymatic A subunit, ctxA gene. A 25 µl PCR reaction was prepared in a 200 µl thin-walled, flat-
capped PCR tube (Axygen Inc., California, United States of America) for each study isolate and 
the positive control, V. cholerae O1 ATCC9458. A standard-3 PCR assay consisting of 35 
amplification cycles was set up using a Bio-Rad (iCycler) thermal cycler (Bio-Rad). Expected 
sizes for the PCR amplicons are shown below (Appendix B1). 
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Target genes  Expected size (~ bp) 
ctxA 301 
16S rRNA 726 
 
2.5.2 Detection and analysis of the toxin co-regulated pilus (TCP) 
 
A multiplex PCR assay was implemented to simultaneously characterize CT producing V. 
cholerae O1 isolates as either classical or El Tor biotypes by the presence of the TCP, tcpA gene 
[6] (Appendix B2). A 25 µl PCR reaction was prepared in a 200 µl thin-walled, flat-capped PCR 
tube (Axygen Inc.) for each test isolate and positive controls, V. cholerae O1 ATCC9458 and V. 
cholerae O139 VIBCH05. A standard-3 PCR assay consisting of 35 amplification cycles was set 
up using a Bio-Rad (iCycler) thermal cycler (Bio-Rad). Expected sizes for the PCR amplicons 
are shown below. 
 
Target genes  Expected size (~ bp) 
tcpA-classical 617 
tcpA-El Tor 471 
 
2.5.3 Detection and analysis for extended spectrum β-lactamases (ESBLs) 
 
V. cholerae O1 isolates that displayed extended spectrum β-lactamase (ESBL) activity against 
third generation cephalosporins; ceftazidime (MIC ≥ 16 µg /ml), ceftriaxone (MIC ≥ 16 µg/ml) 
and cefepime (MIC ≥ 16 µg/ml) were further characterized. Single PCR assays were 
implemented to detect for the presence of blaTEM, blaSHV and blaCTX-M [7,8] (Appendix B3). A 25 
µl PCR reactionwas prepared in a 200 µl thin-walled, flat-capped PCR tube (Axygen Inc.) for 
each test isolate and positive controls, Klebsiella pneumoniae ATCC51503, Klebsiella 
pneumoniae ATCC700603 and Klebsiella pneumoniae D-17. Positive control isolates were 
kindly provided, courtesy of the Antimicrobial Resistance Reference Unit. A standard-3 PCR 
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assay consisting of 35 amplification cycles was set up using a Bio-Rad (iCycler) thermal cycler 
(Bio-Rad). Expected sizes for the PCR amplicons are shown below. 
 
Target genes  Expected size (~ bp) 
blaTEM 840 
blaSHV  846 
blaCTX-M 550 
 
2.5.4 Detection and analysis for class 1 and class 2 integrons 
 
Single PCR assays were implemented to detect for the presence of the 3’-CS and 5’-CS 
conserved segments of the class 1 integron and the conserved region of the integron-encoded 
integrase intI2 gene of the class 2 integron [9-11] (Appendix B4). A 25 µl PCR reaction was 
prepared in a 200 µl thin-walled, flat-capped PCR tube (Axygen Inc.) for each test isolate and 
the positive control, Escherichia coli 803Rif:p3iANG. Escherichia coli 803Rif:p3iANG, was 
kindly provided, courtesy of Doctor Daniela Ceccarelli.  A standard-3 PCR assay consisting of 
35 amplification cycles was set up using a Bio-Rad (iCycler) thermal cycler (Bio-Rad). Expected 
sizes for the PCR amplicons are shown below. 
 
Target genes  Expected size (~ bp) 
3’-CS 800 
5’-CS 870 
intI2 450 
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2.5.5 Detection and analysis for the tetracycline resistance determinant, SXT element-
integrase and SXT associated resistance genes 
 
Single PCR assays were implemented to detect for the presence of the SXT element-integrase 
gene (SXTint), associated SXT resistance genes (floR, sul2, dfrA1, dfr18, strA and strB) [12]and 
the class A tetracycline resistance determinant (tetA) [13] (Appendix B5). A 25 µl PCR reaction 
was prepared in a 200 µl thin-walled, flat-capped PCR tube (Axygen Inc.) for each test isolate 
and positive controls, Escherichia coli CAG18439:SXTMO10 and CED isolate TCD273377. 
Escherichia coli CAG18439:SXTMO10 was kindly provided, courtesy of Doctor Daniela 
Ceccarelli. A standard-3 PCR assay consisting of 35amplification cycles was set up using a Bio-
Rad (iCycler) thermal cycler (Bio-Rad). Expected sizes for the PCR amplicons are shown below. 
 
Target genes  Expected size (~ bp) 
SXTint 592 
floR 526 
sul2 625 
dfrA1 372 
dfr18 389 
strA 383 
strB 470 
tetA 950 
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2.5.6 Detection and analysis for plasmid-mediated quinolone resistance (PMQR) genes and 
quinolone resistance determinants 
 
Single PCR assays were implemented to detect for the presence of the plasmid-mediated 
quinolone resistance (PMQR) genes qnrA, qnrB, qnrS, qnrC and qepA and the quinolone 
resistance determinant qnrVC3 [14-16] (Appendix B6). A 25 µl PCR reaction was prepared in a 
200 µl thin-walled, flat-capped PCR tube (Axygen Inc.) for each test isolate and positive 
controls, Escherichia coli pMG252, Escherichia coli pMG298, Escherichia coli pMG306, 
Escherichia coli pAT851 and Proteus mirabils 06-498. Positive control isolates were kindly 
provided, courtesy of Doctor George A. Jacoby. A standard-3 PCR assay consisting of 35 
amplification cycles was set up using a Bio-Rad (iCycler) thermal cycler (Bio-Rad). Expected 
sizes for the PCR amplicons are shown below. 
 
Target genes  Expected size (~ bp) 
qnrA 657 
qnrB 566 
qnrS 585 
qnrC 307 
qepA 596 
qnrVC3 521 
 
2.5.7 Detection and analysis of genes encoding for the DNA gyrase and topoisomerase IV of 
the quinolone resistance-determining region (QRDR) 
 
Single PCR assays were implemented to detect for the presence of genes coding for the 
quinolone resistance-determining region (QRDR) of DNA gyrase (gyrA/gyrB) and 
topoisomerase IV (parC/parE) [14] (Appendix B7). A 25 µl PCR reaction was prepared in a 200 
µl thin-walled, flat-capped PCR tube (Axygen Inc.) for each test isolate and positive control, 
CEDisolate TCD273377. PCR assays both consisting of 35 amplification cycles were set up 
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using a Bio-Rad (iCycler) thermal cycler (Bio-Rad). Expected sizes for the PCR amplicons are 
shown below. 
 
Target genes  Expected size (~ bp) 
gyrA 239 
gyrB 309 
parC 248 
parE 268 
 
2.6 Detection and size analysis of PCR-positive products using conventional agarose gel 
electrophoresis 
 
The detection and size of the PCR product was determined using conventional agarose gel 
electrophoresis (Appendix C). Upon completion of the PCR, the 200 µl thin-walled PCR tubes 
(Axygen Inc.) were uncapped and 3 µl of loading buffer was added to each tube. The PCR 
products were mixed by pipetting up and down. A 1.5 % Seakem LE agarose (Lonza) gel (w/v) 
was prepared. The molten agarose was cooled to + 50 °C. Approximately 6 µl of the 10 mg/ml 
EtBr stock solution was added to the molten agarose and mixed before being poured into the 
UVTP gel tray (Bio-Rad) with the fixed height comb (Bio-Rad).  
 
The gel was allowed to solidify for 25 minutes at room temperature. The comb was removed and 
the solidified gel was submerged in the Sub-Cell® GT base (Buffer chamber) (Bio-Rad) 
containing cold 1X Tris : acetate : EDTA (TAE) running buffer. Approximately 6 µl of the PCR 
product for each isolate was loaded in a separate well. Sizes were compared alongside either a 
HyperLadder™ IV or HyperLadder™ I molecular weight marker (Bioline, Boston, United States 
of America) or Marker III (Roche). Approximately 3 µl of the appropriate molecular weight 
marker was loaded in the first, middle and last well of the gel.  Conventional gel electrophoresis 
was performed using a Thermo EC105 power supply (The Scientific Group, Midrand, South 
Africa) at 140 V for 45 minutes. The image of the gel was captured on the gel documentation 
system (Bio-Rad) using the Quantity One program software (Bio-Rad). 
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2.7 Nucleotide sequencing of PCR-positive amplicons 
  
A 50 µl PCR reaction was prepared in a 200 µl thin-walled, flat-capped PCR tube (Axygen Inc.). 
The volumes required for a 25 µl PCR reaction were doubled and the cycle PCR conditions 
remained the same. To visualize the synthesis of the PCR-positive amplicons, 5 µl of the PCR 
product was loaded with 1 µl of loading buffer on a 1.5 % Seakem LE agarose gel (Lonza). Sizes 
were compared alongside the appropriate molecular weight marker, HyperLadder™ IV molecular 
weight marker (Bioline) or HyperLadder™ I molecular weight marker (Bioline). Agarose gels 
were prepared and PCR-products were resolved as described in section 2.6.  
 
The resultant 45 µl PCR-positive product was purified as per the manufacturer’s guidelines using 
the MSB® Spin PCRapace clean-up kit (Invitek, Berlin, Germany) and served as template DNA 
in the cycle sequencing PCR reaction using the ABI Prism® BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, Foster City, California) and an Applied Biosystems Model 
3500 automated genetic analyzer.  
 
The 45 µl PCR-positive product was transferred to a clean 1.5 ml Eppendorf tube (Eppendorf) 
(one tube per a bacterial isolate) containing 250 µl binding buffer 1 (Invitek). The PCR mixture 
was mixed by pipetting up and down. The mixed PCR mixture was transferred to a 2 ml receiver 
tube with a spin filter (Invitek) (one tube per a bacterial isolate). The tube was capped and 
centrifuged in a table-top centrifuge (Eppendorf) at 12 000 rpm for three minutes. The spin filter 
was transferred to a 1.5 ml receiver tube (Invitek) (one tube per a bacterial isolate). 
Approximately 10 µl of distilled water was added to the centre of the column of the spin filter. 
The tube was capped and incubated at room temperature for one minute. The capped tube was 
centrifuged in a table-top centrifuge (Eppendorf) at 10 000 rpm for one minute. The spin filter 
was discarded and the resultant cleaned-up PCR product served as template DNA for cycle 
sequencing PCR. The concentration and purity of the nucleic acid without dilution was measured 
using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). The concentration and 
purity of purified DNA required for each isolate was ~ 50 to 100 nanograms per microlitre 
(ng/µl). 
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Approximately 1 µl of undiluted purified DNA was pipetted onto the receiving optic fiber 
(pedestal) of the Nanodrop 1000 spectrophotometer. The sampling arm holding the source optic 
fiber was brought into contact with the liquid DNA creating a column. The spectral measurement 
was made using the operating software program, NanoDrop 1000 V3.7 (Thermo Fisher 
Scientific). Approximately 2 µl of undiluted purified DNA was used in each cycle sequencing 
PCR reaction. 
 
A 15 µl cycle sequencing PCR reaction using the ABI Prism® BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems) was prepared in a 200 µl thin-walled, flat-capped PCR 
tube (Axygen Inc.) (Appendix D). A standard-2 PCR assay consisting of 25 amplification cycles 
was set up using a Bio-Rad (iCycler) thermal cycler (Bio-Rad) (Appendix D). 
 
The 15 µl cycle sequencing PCR products were purified as per the manufacturer’s guidelines 
using the QIAGEN DyeEx® 2.0 Spin Kit (QIAGEN gmbH, Hilden, Germany). Capped DyeEx® 
2.0 spin columns were vortexed using a GENIE2 vortex (Scientific Industries) and the bottom 
closure of the columns snapped off.  The capped DyeEx® 2.0 spin columns were placed in 2 ml 
collection tubes and centrifuged in a balanced Eppendorf 5415R table-top centrifuge (Eppendorf) 
at a calculated speed of 3 000 rpm for three minutes. The capped DyeEx® 2.0 spin columns were 
removed and transferred to clean 1.5 ml Eppendorf tubes (Eppendorf) and uncapped. The 15 µl 
cycle sequencing PCR products were transferred onto the centre of the slanted gel-bed surface of 
the DyeEx® 2.0 spin column (one tube per a bacterial isolate) and capped. The 1.5 ml Eppendorf 
tubes containing the DyeEx® 2.0 spin columns were centrifuged in an Eppendorf 5415R table-
top centrifuge (Eppendorf) at a calculated speed of 3 000 rpm for three minutes. The tubes were 
removed and the spin columns discarded.  
 
The 1.5 ml Eppendorf tubes containing the gel-filtrated DNA products were uncapped and 
vacuum-dried in a balanced Speed Vac Concentrator vacuum centrifuge (Savant, GMI 
Incorporated, Minnesota, United States of America) for 60 minutes. Vacuum-dried DNA 
products were reconstituted in 15 µl of Hi-Di formamide (Applied Biosystems). The 1.5 ml 
Eppendorf tubes containing the 15 µl reconstituted DNA products were capped, vortexed using a 
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GENIE2 vortex (Scientific Industries) and incubated for three minutes at + 95 °C on a dry 
heating block (Barloworld Scientific Ltd).  The tubes were immediately placed on ice. The tubes 
were vortexed using a GENIE2 vortex (Scientific Industries) and centrifuged for 10 seconds in a 
balanced Eppendorf 5415R- centrifuge (Eppendorf).  
 
The 15 µl products were transferred to a MicroAmp optical 96-well reaction plate (Applied 
Biosystems) (one well per DNA sample) and placed in an Applied Biosystems Model 3500 
automated genetic analyzer. The DNA samples were sequenced using the “3500 Data Collection 
Software V1.0” (Applied Biosystems) operating program.  The run module “RapidSeq50-POP7” 
(Applied Biosystems) was applied. This run module was selected based on a read length of ~ 500 
bp, which could be determined within 40 minutes.  
 
DNASTAR Lasergene® software (version 8.1) (DNASTAR, Inc., Madison, Wisconsin) was used 
to analyze the nucleotide sequences, and sequence identity was determined at the DNA database 
of the National Center for Biotechnology Information (NCBI) using the nucleotide-nucleotide 
BLAST algorithm (Accessed from http://www.ncbi.nlm.nih.gov/BLAST.html; November 2010). 
 
2.8 Identification and preparation of plasmid DNA 
 
Characterization of bacterial isolates harboring resistance plasmids was investigated using a 
previously described method by Kado and Liu [17]. This protocol served as a screening tool to 
detect small and large plasmids. 
 
Selected isolates were cultured and streaked for single colonies on Luria-Bertani (LB) agar 
plates. Selected isolates that displayed ESBL activity were cultured on LB agar plates (Appendix 
E1) containing 2 µg/ml ceftriaxone (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) 
(Appendix E2). Aseptic techniques were implemented. Inoculated LB agar plates were incubated 
overnight at + 37 °C for the following day. Single colonies were inoculated in Nunc 50 ml 
graduated centrifuge tubes (Thermo Fisher Scientific) (one tube per a bacterial isolate) 
containing 10 ml of LB broth (Appendix E3). Selected isolates that displayed ESBL activity 
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were inoculated in 10 ml LB broth containing 20 µl of 2 µg/ml ceftriaxone (Sigma). The 
inoculated 50 ml test tubes containing the LB broth with ceftriaxone were capped and incubated 
overnight at + 37 °C for the following day. Un-inoculated LB agar plates and LB broth were 
included as negative controls. This was essential to exclude contamination.  
 
Approximately 1.5 ml of the cell culture was transferred from the 50 ml test tube to a clean 1.5 
ml Eppendorf tube (Eppendorf) (one tube per a bacterial isolate). The 1.5 ml Eppendorf tubes 
(Eppendorf) containing the cell cultures were capped and centrifuged in a table-top centrifuge 
(Eppendorf) at 12 000 rpm for five minutes. The tubes were uncapped and the supernatant was 
removed from each tube. As a result the bacterial pellet was left behind in the tube. These tubes 
were kept on ice.  
 
Each bacterial pellet was resuspended in 20 µl of cold autoclaved 1Х E-Buffer (Appendix E4-
E5). One-hundred microlitres of lysis solution (Appendix E6) was added to the 1.5 ml Eppendorf 
tube (Eppendorf) containing the resuspended bacterial pellet. The suspensions were mixed by 
inverting the capped tubes ten times. The 1.5 ml Eppendorf tubes (Eppendorf) containing the 
lyzed suspensions were incubated for 60 minutes at + 55 °C on a dry heating block (Barloworld 
Scientific Ltd).  
 
The tubes were taken off the dry heating block and 100 µl of phenol : chloroform : isoamyl 
alcohol (Appendix E7) was added to each tube. The suspensions were mixed by inverting the 
capped tubes ten times. The tubes were centrifuged in a table-top centrifuge (Eppendorf) at 12 
000 rpm for five minutes to release and separate the bacterial plasmid DNA in solution. The 
tubes were uncapped and 100 µl of the aqueous phase of the supernatant was transferred into a 
clean 1.5 ml Eppendorf tube (Eppendorf) (one tube per a bacterial isolate).  The 1.5 ml 
Eppendorf tubes (Eppendorf) containing the plasmid DNA was placed on ice for 20 minutes. 
Plasmid DNA was stored away for further use in the freezer at - 10 °C to - 20 °C.  To screen for 
resistance plasmids, extracted plasmid DNA was resolved by PFGE. 
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Approximately 40 µl of extracted plasmid DNA of each selected isolate was loaded together 
with 10 µl of loading buffer on a 1 % SeaKem Gold® agarose (Lonza) gel (w/v) (Appendix 
A18). This is followed by electrophoresis using a CHEF-DR III apparatus (Bio-Rad) containing 
3 l of 0.5X TBE (Merck) running buffer (Appendix A17) cooled to a temperature of + 14 °C.  
The gel was prepared as previously described. The electrophoresis running conditions was 
comprised of a one-block program at 200 V. The pulse times were set from an initial switch time 
of 5 to a final switch time of 15 seconds with a run time of 16 hours at a gradient voltage of 6 
V/cm. Sizes were compared alongside a supercoiled molecular size standard, BAC-TrackerTM 
(EPICENTRE® Biotechnologies, Madison, Wisconsin). The first, middle and last well of the gel 
each contained 15 µl of BAC-TrackerTM (EPICENTRE® Biotechnologies).  
 
Upon completion of the electrophoresis run, the gel was stained (Appendix A20), de-stained and 
the image captured on the gel documentation system (BioRad) using the Quantity One program 
software (Bio-Rad) as previously described in section 2.3. 
 
2.9 Southern hybridization analysis 
 
Southern blot hybridization studies were performed on plasmid DNA separated by PFGE to 
determine whether ESBL resistance genes are located on plasmids. The sizes of plasmid DNA 
were analyzed using the Quantity One program software (Bio-Rad) and estimated by comparison 
alongside a supercoiled molecular size standard, BAC-TrackerTM (EPICENTRE® 
Biotechnologies). The protocol was carried out according to the Roche manufacturer’s 
guidelines, which are readily available (Accessed from https://www.roche-applied-
science.com/sis/lad/index.jsp; November 2010). Digoxigenin (DIG)-labeled probes and 
unlabelled controls were first generated with the PCR DIG Probe Synthesis Kit (Roche) 
(Appendix F1-F2). A 50 µl PCR reaction was prepared in a 200 µl thin-walled, flat-capped PCR 
tube (Axygen Inc.) for each hybridization target gene (DIG-Labelled) and unlabelled control. 
Compared to the unlabelled control PCR reaction, the DIG-labelled PCR reaction contained the 
PCR DIG mix. A standard-3 PCR assay consisting of 30 amplification cycles was set up using a 
Bio-Rad (iCycler) thermal cycler (Bio-Rad) (Appendix F3). To visualize the synthesis of the 
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DIG-labelled probes and unlabelled controls, 5 µl of the PCR product was loaded with 1 µl of 
loading buffer on a 1.5 % Seakem LE agarose gel (Lonza) (Appendix C). Sizes were compared 
alongside either with HyperLadder™ I molecular weight marker (Bioline) or Marker III (Roche). 
The gel was prepared and resolved as previously described in section 2.6. 
 
An “In-house” Southern blot apparatus required for the capillary transfer of plasmid DNA to the 
nylon membrane was set up as shown in Figure 10. Following the completion of the PFGE 
analysis, a Southern blot was prepared. Before the Southern blot could be prepared, the separated 
DNA on the gel had to be denatured to single-stranded DNA. The hybridization target gene was 
less than 5 kb. Therefore, it was not necessary to depurinate the gel. The gel was first submerged 
in denaturation solution (Appendix F4) in a plastic tray. The plastic tray was oscillated on a see-
saw rocker (Barloworld Scientific Ltd) for 15 minutes at room temperature. The denaturation 
solution was discarded and fresh denaturation solution was added. This was done twice. The gel 
was rinsed with distilled water. The gel was then submerged in neutralization solution (Appendix 
F5). The plastic tray was oscillated on a see-saw rocker (Barloworld Scientific Ltd) for 15 
minutes. The neutralization solution was discarded and fresh neutralization solution was added. 
This was done twice. The gel was transferred to another plastic tray consisting of 20X Sodium 
chloride, Sodium citrate buffer (SSC) (Roche) (Appendix F6) and incubated for ten minutes at 
room temperature. This allowed for the gel to adjust to the external environment. The Southern 
blot was set up as follows. Firstly, a bridge was created in a plastic tray in order for the gel to be 
appropriately positioned. The plastic tray was filled to a shallow level (~ 300 ml) with 20X SSC 
buffer. A piece of pre-soaked (20X SSC buffer) Whatman® 3 MM paper (Merck) was placed 
over the bridge resting in 20X SSC buffer. The air bubbles were removed by gently rolling a 5 
ml pipette across the bridge. The denatured gel was placed over the pre-soaked Whatman® 3 MM 
paper. A piece of positively charged nylon membrane (Roche) (cut to size) that has been pre-
soaked in 2X SSC buffer (Appendix F7) was placed over the denatured gel. 
 

	

 
 
Figure 10 An “In-house” Southern blot apparatus.  
 

	

The air bubbles were removed by gently rolling a 5 ml pipette across the positively charged 
nylon membrane. Dry Whatman® 3 MM paper (Merck) (cut to size) was placed on top of the 
positively charged nylon membrane. This was followed by a stack of paper towels. A Glass plate 
was placed on top of the stack of paper towels, followed by a weight piece of 500 g in mass. The 
Southern blot transfer was incubated overnight at room temperature for the following day. The 
next step involved fixing the denatured DNA to the positively charged nylon membrane. 
 
The damp membrane was briefly rinsed with 2X SSC buffer and was baked in a drying oven 
incubator (Labex) for 120 minutes at + 80 °C. The dried membrane was taken out of the drying 
oven. The volume of hybridization buffer DIG Easy Hyb (Roche), was determined according to 
the surface area (centimetre squared (cm2)) of the membrane. The surface area of the membrane 
was 294 cm2. The membrane was placed in a borosilicate glass tube with sealing end cap 
(hybridization tube) (Techne, Cambridge, United Kingdom). Approximately 30 ml of DIG Easy 
Hyb (Roche) was added to the hybridization tube and was capped. The capped hybridization tube 
was placed in a rotating drive ring of the Techne Hybridiser HB-1D (Techne).  
 
The capped hybridization tube was incubated at + 42 °C for 30 minutes. This pre-hybridization 
step allowed for the membrane to adapt to the external environment. In this protocol, the optimal 
hybridization temperature of + 42 °C was recommended on the basis that the hybrid type 
generated was DNA : DNA (DIG-probe : target gene). The hybridization tube was taken out of 
the Techne Hybridiser, the tube was uncapped and the excess hybridization buffer poured out. 
The next step involved the hybridization of the DIG-labelled probe to the target DNA.  
 
The DIG-labelled probe was diluted in DIG Easy Hyb (Roche) to a final working concentration 
of 2 µl/ml. A Southern blot was performed for the hybridization target gene. The DIG-labelled 
probe was first denatured. Approximately 21 µl of DIG-labelled probe was transferred to a clean 
1.5 ml Eppendorf tube (Eppendorf) along with 50 µl of distilled water. The tube was capped and 
incubated for five minutes at + 95 °C on a dry heating block (Labex). The capped tube was taken 
off the dry heating block and immediately place on ice. The denatured DIG-labelled probe was 
immediately transferred to a 14 ml polypropylene test tube (Lasec) containing 10.50 ml DIG 
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Easy Hyb (Roche). Once again, the volume of DIG Easy Hyb (Roche) was determined according 
to the surface area (cm2) of the membrane. This suspension was immediately added to the 
hybridization tube containing the pre-hybridized membrane. The hybridization tube was capped 
and placed in a rotating drive ring of the Techne Hybridiser (Techne). The capped hybridization 
tube was incubated overnight at + 42 °C for the following day. The hybridization tube was taken 
out of the Techne Hybridiser, the tube was uncapped and the excess DIG-labelled hybridization 
buffer poured out. The next step involved stringent washing of the membrane. 
 
The membrane was placed in a plastic tray along with 200 ml low stringency buffer (Appendix 
F9). The plastic tray was oscillated on a see-saw rocker (Merck) for five minutes at room 
temperature. The low stringency buffer was discarded and fresh low stringency buffer was 
added. This was done twice. Two-hundred mililitres of pre-heated high stringency buffer 
(Appendix F10) was added to the plastic tray. The plastic tray was incubated for 15 minutes at + 
65 °C in the shaking water bath (Labotec) at 70 rpm. The high stringency buffer was discarded 
and fresh high stringency buffer was added. This was done twice. The A chromogenic method 
with anti-dioxigenin-alkaline phosphatase (AP) antibody (Roche) was used for the detection of 
the DIG-probe : target gene hybrid on the membrane.  
 
Advantages of using this method include: chromogenic signals can be visualized without the use 
of exposure film and two or more colour substrates can be used in combination to detect more 
than one target. The AP colour substrate used in this protocol was a combination of nitro blue 
tetrazolium chloride (NBT) with 5-Bromo-4-chloro-3-indolyl phosphate (BCIP). As a result, a 
blue precipitate is formed and can be seen with the naked eye.   
 
The membrane was first washed and blocked using the DIG Wash and Block Buffer Set (DNase 
and RNase-free) (Roche). The DIG Wash and Block Buffer Set stock solutions were diluted to 
produce a 1:10 final working solution. The membrane was transferred to a plastic tray containing 
100 ml of 1X washing buffer (Roche). The plastic tray was oscillated on a see-saw rocker 
(Merck) for two minutes at room temperature. The 1X washing buffer was discarded and 100 ml 
of 1X blocking solution (Roche) was added. The plastic tray was oscillated on a see-saw rocker 
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(Merck) for 30 minutes at room temperature. The 1X blocking solution was discarded. The 
antibody solution was prepared. 
 
The tube containing the anti-dioxigenin-AP antibody (Roche) was centrifuged in a table-top 
centrifuge (Merck) at 10 000 rpm for five minutes. Approximately 4 µl of the anti-dioxigenin-AP 
antibody (Roche) was added to a 50 ml test tube (Lasec) containing 16 ml of 1X blocking 
solution (Roche). The 20 ml of antibody solution was transferred to the plastic tray containing 
the blocked membrane. The plastic tray was oscillated on a see-saw rocker (Merck) for 30 
minutes at room temperature. The antibody solution was discarded and 100 ml of fresh 1X 
washing buffer (Roche) was added.  The plastic tray was oscillated on a see-saw rocker (Merck) 
for 15 minutes at room temperature. The 1X washing buffer was discarded. This step was done 
twice. Approximately 20 ml of 1X detection buffer (Roche) was added. The plastic tray was 
oscillated on a see-saw rocker (Merck) for three minutes at room temperature. The 1X detection 
buffer was discarded. This allowed for the membrane to adjust to the external environment.  
 
The NBT/BCIP colour substrate solution was prepared as follows. Fifty microlitres of NBT 
(Roche) along with 37.5 µl of BCIP (Roche) was added to a clean 1.5 ml Eppendorf tube 
(Eppendorf) containing 112.5 µl of distilled water. The 200 µl NBT/BCIP solution was 
transferred to a 14 ml polypropylene test tube (Lasec) containing 10 ml of fresh 1X detection 
buffer (Roche). This colour substrate solution was poured over the membrane. The plastic tray 
was incubated overnight in a dark cupboard at room temperature for the following day. The 
colour reaction was stopped by adding 50 ml TE buffer to the membrane. The membrane was 
air-dried for further analysis. 
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Chapter Three 
 
Molecular characterization of Vibrio cholerae O1 associated with an outbreak of cholera in 
the Mpumalanga Province, South Africa, May to July 2008 
 
This chapter has been published in 2011 in the Journal of Clinical Microbiology (volume 49, 
pages 2976-2979). The first author was responsible for the molecular characterization of the V. 
cholerae O1 outbreak isolates and preparation of the manuscript for publication. The second 
author was responsible for the supervision and oversight of methods necessary to complete this 
chapter. The third author was responsible for the serological characterization and the 
antimicrobial susceptibility testing of the V. cholerae O1 outbreak isolates. The last author was 
responsible for supervision and guidance on the content of this chapter.  
 
3.1 Introduction 
 
During May to July 2008, an outbreak of cholera associated with illegal miners on a gold mine in 
the Ehlanzeni district of the Mpumalanga Province, South Africa was identified [1,2]. Thirty-
four laboratory-confirmed cases of cholera, including five deaths, were reported related to this 
outbreak [1,2]. Eighteen cases were confirmed from illegal miners (~ 53 %), six cases from close 
contacts (~ 18 %) and ten cases from other sources (~ 29 %) [1-3]. This study proposed to 
investigate the molecular epidemiology and mechanism of antimicrobial resistance of toxigenic 
V. cholerae O1 isolates using various molecular techniques. 
 
3.2 Materials and Methods 
 
3.2.1 Bacterial isolates and phenotypic characterization 
 
Thirty-one isolates (~ 91 %) out of the 34 laboratory-confirmed clinical cases were received by 
the CED [3]. V. cholerae pathogens were isolated from both stool (~ 58 %) and rectal swab (~ 42 
%) specimens[3]. Confirmatory identification was done using standard microbiological 
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techniques (section 2.1). MIC testing for each isolate was performed as per the CLSI 2008 
guidelines (section 2.2).  
 
3.2.1.1 Involvement of efflux pumps 
 
To determine the role of an active efflux pump as a possible mechanism of quinolone resistance, 
susceptibility to nalidixic acid was investigated using agar dilution MIC testing [4] in the 
presence and absence of two efflux pump inhibitors (EPIs), reserpine and phenylalanyl arginine-
β-naphthylamide (PAβN) (Sigma). Reserpine and PAβN were tested independently of each other 
and added to molten Mueller-Hinton agar (Appendix G1) at a final concentration of 20 µg/ml for 
reserpine [5] (Appendix G2) and 40 µg/ml for PaβN [6] (Appendix G3).  
 
Antimicrobial-free control plates were included. A doubling dilution series of increased 
concentration for nalidixic acid (Sigma) starting from 0.015 µg/ml to 512 µg/ml was prepared [7] 
(Appendix G4). Twenty millilitres of molten Mueller-Hinton containing both the diluted 
nalidixic acid and either EPI were mixed by swirling the container and poured in 90 mm petri 
dishes. Mueller-Hinton agar plates were allowed to set at room temperature. Bacterial inoculum 
suspensions (one tube per bacterial isolate) were prepared as described in section 2.2. This initial 
inoculum (McFarland 0.50 or 1x108 CFU/ml) was then diluted ten-fold. One-hundred microlitres 
of the initial inoculum was transferred to a 1.5 ml Eppendorf tube containing 900 µl of sterile 0.9 
% saline. Four-hundred microlitres of the diluted inoculum suspensions were transferred to 
multi-point inoculator wells (Figure 11). The inoculum replicating apparatus was then placed on 
the specimen plate of a multipointeliteTM inoculator (Mast Assure, Mast Group Ltd.) (Figure 11). 
Mueller-Hinton agar plates were inoculated starting from the control plate followed by the 
lowest concentration (0.015 µg/ml) to the highest concentration (512 µg/ml). Replicator pins 
transferred about 10 µl of the inoculum to the Mueller-Hinton agar plate (Figure 11) containing 
both nalidixic acid and EPI.  Plates were air dried at room temperature to allow for the inoculum 
spots to dry. Plates were incubated overnight at + 37 °C for 18 hours. The MIC corresponded to 
the lowest concentration of nalidixic acid without visible bacterial growth.   
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Figure 11 Agar dilution susceptibility testing. 
 
Inoculum suspensions transferred 
to wells of a multi-point 
inoculator apparatus. 
Replicator pins 
Multi-point inoculator 
apparatus 
Replicator pins transferring ~10 
µl of the inoculum to the 
Mueller-Hinton agar plate. 
Mueller-Hinton agar plate 
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3.2.2 Genotypic characterization 
 
3.2.2.1 Pulsed-field gel electrophorsis (PFGE) analysis 
 
All 31 isolates were characterized by PFGE analysis using the PulseNet standardized protocol 
for V. cholerae (section 2.3).  
 
3.2.2.2 Detection for virulence determinants 
 
Crude DNA extracts were prepared (section 2.4), and these served astemplate DNA in the PCR 
assays. Conventional PCR was performed on all 31 isolates for the detection of both the ctxA and 
tcpA genes respectively (sections 2.5.1 and 2.5.2).
 
3.2.2.3 Detection for antimicrobial resistance determinants 
 
Ten out of the 31 isolates were selected for further analysis. Due to time and financial 
constraints, selected isolates were chosen to be representative of different antimicrobial 
susceptibility profiles and chosen to be representative of different PFGE patterns. Conventional 
PCR was performed on all ten isolates for the detection of particular antimicrobial resistance 
determinants (sections 2.5.3 to 2.5.7).  
 
The detection and size of the PCR products were determined using conventional agarose gel 
electrophoresis (section 2.6). 
 
PCR-positive amplicons (blaTEM, gyrA, gyrB, parC and parE) were purified (section 2.7) and 
served as template DNA in the cycle sequencing PCR assays (section 2.8). DNASTAR 
Lasergene® software was used to analyze the nucleotide sequences and sequence identity was 
determined at the DNA database of the NCBI (section 2.7). Amino acid sequences obtained for 
GyrA, GyrB, ParC and ParE were compared with a quinolone susceptible isolate of V. cholerae 
O1, N16961 (GenBank accession no. NC_002505). 
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3.2.2.4 Isolation of plasmid DNA and Southern blot hybridization analysis 
 
Intact plasmid DNA was prepared, as previously described by Kado and Liu (section 2.8). Cell 
lysates (40 µl) with plasmid DNA were resolved by PFGE analysis (section 2.8). For Southern 
blot hybridization studies, a DIG-labeled probe blaTEM was generated (section 2.9). Southern blot 
hybridizations on plasmid DNA separated by PFGE analysis was performed to determine the 
location and size of the plasmid encoding for blaTEM.  
 
3.3 Results 
 
3.3.1 Bacterial isolates and antimicrobial susceptibility patterns 
 
All 31 isolates were characterized as V. cholerae O1 serotype Ogawa. All 31 isolates were 
shown to have the same antimicrobial susceptibility profile. All were susceptible to 
ciprofloxacin, erythromycin and imipenem, but resistant to ampicillin, augmentin, trimethoprim, 
sulfamethoxazole, co-trimoxazole, chloramphenicol, nalidixic acid, tetracycline, and 
streptomycin. All 31 isolates displayed ESBL activity with further resistance to the third-
generation cephalosporin, ceftazidime (MIC 64 µg/ml). 
 
3.3.2 Genes encoding for virulence determinants 
 
PCR analysis revealed that 30 out of 31 (~ 97 %) isolates were positive for the CT and all 
isolates were positive for the El Tor biotype. 
 
3.3.3 PFGE analysis 
 
All 31 isolates showed a very similar PFGE NotI-profile and were determined to be highly clonal 
at a 95% pattern similarity value on dendrogram analysis.  
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3.3.4 Genes conferring antimicrobial resistance 
 
PCR analysis of class 1 integrons and class 2 integrons showed that all ten isolates were PCR-
negative for the 3’CS, 5’CS and intI2 respectively. Amplification of the SXT element showed 
that all ten isolates were PCR-positive for the integrase gene, SXTint and associated SXT 
resistance genes encoding for chloramphenicol (floR), sulfamethoxazole (sul2), trimethoprim 
(dfrA1) and streptomycin (strA and strB). All ten isolates were PCR-positive for the tetA gene, 
which confers resistance to tetracycline. 
 
3.3.5 ESBL activity and identified ESBL genes 
 
All ten isolates were PCR-positive for blaTEM but were PCR-negative for blaSHV and blaCTX-M. 
PCR and nucleotide sequence analysis showed that all ten isolates produced TEM-63 β-
lactamase coinciding with a ceftazidime MIC 64 µg/ml. In addition, all ten isolates showed the 
presence of a single plasmid of ~ 140 kb in size (Figure 12). Southern blotting and DNA probing 
analysis demonstrated that blaTEM encoding for the TEM-63 β-lactamase, was located on a 
plasmid (~140 kb) in all ten isolates (Figure 12).   
 
3.3.6 Chromosomal mutations in the QRDR of DNA gyrase and topoisomerase IV 
 
PCR analysis of PMQR genes and the quinolone resistance determinant showed that all ten 
selected isolates were PCR-negative for qnrA, qnrB, qnrS, qnrC, qepA and qnrVC3 respectively. 
All ten isolates harboured mutations in GyrA and ParC but no changes were observed in GyrB 
and ParE. In GyrA, an amino acid substitution of serine by isoleucine was detected at codon 83 
(S83-I) (Figure 113) and in ParC, an amino acid substitution of serine by leucine was detected at 
codon 85 (S85-L) (Figure 14). 
 



Figure 12 (A) Plasmid DNA isolation from the ten selected V. cholerae O1 isolates. (B) 
Southern blot hybridization of plasmid DNA probed with DIG-blaTEM from ten selected V. 
cholerae O1 isolates. 
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Figure 13 Alignment report showing the amino acid sequences of DNA gyrase subunit A (GyrA) for V. cholerae O1, biotype El Tor, 
strain  
Abbreviations:Alanine (A), cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), isoleucine 
(I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), serine (S), threonine (T), valine 
(V), tryptophan (W) tyrosine (Y) and the blue arrow indicates the position of amino acid substitution. N16961 accession number 
NC_002505 and isolate, TCD273377. 
 
 
 
 
 
 
Figure 14 Alignment report showing the amino acid sequences of DNA topoisomerase IV subunit A (ParC) for V. cholerae O1, 
biotype El Tor, strain N16961 accession number NC_002505 and isolate, TCD273377. 
Abbreviations:Alanine (A), cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), isoleucine 
(I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), serine (S), threonine (T), valine 
(V), tryptophan (W) tyrosine (Y) and the blue arrow indicates the position of amino acid substitution.  
TCD273377 
N16961 
Consensus 
TCD273377 
N16961 
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3.4 Discussion 
 
In this study, all 31 isolates were characterized as V. cholerae O1 serotype Ogawa, a serotype, 
which is generally associated with outbreaks of cholera through Africa [8,9]. Molecular analysis 
revealed that all 31 isolates were TCP-positive for the El Tor variant and 30 out of the 31 isolates 
characterized were positive for the CT. This study showed the presence of a TCP-positive, CT-
negative V. cholerae O1 isolate. Various distributions of virulence determinants (including TCP-
positive, CT-negative) have been previously described in V. cholerae O1 isolates [10]. Possible 
explanations for the low prevalence of TCP-positive, CT-negative V. cholerae O1 isolates could 
be (i) decreased enrichment of these isolates in the intestine of the host or (ii) these isolates are 
converted quickly into TCP-positive, CT-positive V. cholerae O1 isolates by the filamentous 
bacteriophage, CTXΦ either in the intestine of the host or in the environment [10]. It has been 
suggested that TCP-positive, CT-negative V. cholerae O1 isolates do not cause extensive cholera 
due to the reduced interaction of these isolates in the intestinal environment of the host [10]. In 
this study, V. cholerae O139 Bengal isolates were not identified. Prior to 2010, V. cholerae O139 
Bengal has particularly not been reported in Africa [11]. A joint study done between 
Mozambique and South Africa showed the presence of V. cholerae O139 Bengal isolated from 
coastal water in Beira, Mozambique [11].  
 
All 31 isolates displayed the same antimicrobial susceptibility profile and were resistant to 
multiple classes of antimicrobial agents screened for surveillance purposes. All 31 isolates 
described in this study were susceptible to ciprofloxacin and imipenem. Widespread resistance to 
antimicrobial agents namely nalidixic acid, ciprofloxacin, co-trimoxazole, chloramphenicol, 
tetracycline, cephalexin and ampicillin have been described in V. choleraebut have largely 
remained susceptible to third-generation cephalosporins [12,13]. The use of third-generation 
cephalosporins is not yet recommended for the treatment of cholera [13] however, a report from 
Mozambique has suggested the use of the cephalosporins as an option for treatment [8].  
Treatment with fluoroquinolones has until recently been the antimicrobial of choice in the 
management of severe cholera and other diarrhoeal illnesses [9,13,14]. Antimicrobial resistance 
to ciprofloxacin has been reported in V. cholerae O1 in southern Asia [14-16]. In parts of Africa 
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namely southern and western Africa, reduced susceptibility to ciprofloxacin in V. cholerae O1 
has also been described [17,18]. To date, reported data or literature to support reduced 
susceptibility or resistance to imipenem in V. cholerae O1 has not been described. 
 
Results obtained in this study have revealed the first incidence of TEM-63 β-lactamase 
producing, multidrug-resistant toxigenic V. cholerae O1 isolates recovered in South Africa. 
There has been no previous report of TEM-63 β-lactamase producing isolates of V. cholerae O1 
worldwide. Plasmid-mediated ESBLs have been globally reported and are widespread among 
members of the family Enterobacteriaceae [19,20]. A study done by Petroni et al. characterized 
V. cholerae O1 outbreak isolatesrecovered in Argentina where plasmid-mediated CTX-M type 
and PER-2 type β-lactamases hydrolyzing cefotaxime, ceftazidime and cefepime were detected 
using isoelectric focusing and PCR-RFLP analysis [19]. More recently, a study done by Mandal 
et al. characterized an AmpC β-lactamase and carbapenemase producing V. cholerae O1 
pathogen isolated from a paediatric patient in India [21]. Another study done by Walsh et al. 
described New Delhi metallo-β-lactamase (NDM-1) producing V. cholerae isolates recovered 
from seepage water and tap water swab specimens in New Delhi [22]. TEM-63 β-lactamase has 
previously been described in Enterobacteriaceae from South Africa [20,23]. The isolation of 
TEM-63 β-lactamase producing isolates of Klebsiella pneumoniae between 1994 and 1996 was 
first described from a teaching hospital in Durban, South Africa in 2001 by Essack et al.[23]. In 
this study all ten selected isolates harboured a single ~ 140 kb plasmid. This finding correlates 
with plasmid profiling analysis done by Essack et al, whereby Klebsiella pneumonia isolates 
contained plasmids of a similar size encoding for TEM-63 β-lactamase[23].  
 
PCR analysis for the detection of the class A tetracycline resistance determinant (tetA) yielded an 
amplicon of ~ 950 bp in all ten selected isolates.The presence of the tetA gene may possibly 
confer tetracycline resistance. Tetracycline has been used extensively in Africa, until resistance 
became common due to the presence of incompatibility group C plasmids[9].Tetracycline 
resistance determinants are generally found on transposons and as a result are able to move 
around for instance, by inserting into conjugative plasmids [24]. Tetracycline resistance encoded 
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by the tetA gene in African and Laotian strains of V. cholerae O1 was previously reported by 
Dalsgaard et al. in 2001 and Iwanaga et al. in 2004 [25,26].  
 
Class 1 and class 2 integrons were not present in all ten selected isolates.This may suggest the 
involvement of other mechanisms of antimicrobial resistance. Studies have shown that V. 
cholerae O1 isolates harbouring class 1 integrons isolated in Asian countries before 1996 may 
have spread to Africa [27], as epidemic V. cholerae isolates from Africa contain class 1 integrons 
[9,27]. Since 2000, several studies done in Africa have described class 1 and class 2 integrons 
responsible for antimicrobial resistance in V. cholerae O1 [9,25,28-30]. Gene cassettes 
conferring antimicrobial resistance to nearly every important class of antimicrobial agent 
including quinolones have been described [31-33]. The spread of resistance genes is the result of 
lateral gene transfer (LGT), also known as horizontal gene transfer [31,32]. 
 
In this study, antimicrobial resistance to chloramphenicol, sulfamethoxazole, trimethoprim and 
streptomycin can be explained by the acquisition of the SXT element. PCR analysis for the 
detection of the SXT integrase gene yielded an amplicon of ~ 592 bp in all ten selected isolates. 
To determine the contribution of the SXT element to antimicrobial resistance patterns of each 
isolate, the presence of floR, sul2, dfrA1, dfr18, strA and strB were investigated respectively. 
These are typical clustered resistance genes, which are capable of differentiating among SXT 
variants [30]. All ten selected isolates were PCR-positive for five of the six SXT associated 
resistance genes with the exception of the dfr18 gene, as dfrA1 is characteristic of SXTET and not 
SXTMO10 [34,35]. Findings from a previous study have shown that R391, an ICE isolated from a 
clinical strain of Providencia rettgeri in South Africa, is functionally and genetically related to 
SXTMO10 and more than 25 related ICEs within the SXT/R391 family  [36]. Variant types of the 
SXT element have previously been described in other Vibrio species such as V. vulnificus, V. 
metschnikovii, V. fluvialis and V. parahaemolyticus [34]. 
 
The PMQR genes were not detected in all ten selected isolates. To date, five major qnr 
determinants and two additional PMQR genes namely qnrA, qnrB, qnrC, qnrD, qnrS, qepA and 
aac(6’)-Ib-cr have been described [37]. Qnr proteins belong to the pentapeptide repeat family 
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and are responsible for protecting the DNA gyrase and topoisomerase IV from quinolones [37]. 
The AAC(6’)-Ib-cr protein is responsible for acetylation of ciprofloxacin, while the QepA is a 
novel efflux pump and is responsible for transporting unwanted compounds [37]. In V. cholerae, 
a qnr homolog, qnrVC1 has been described for isolates recovered in Brazil [33]. This 
determinant was shown to be located on the superintegron and has not been shown to confer 
transferable quinolone resistance [33]. A study done by Kim et al. showed that qnrVC3, which 
was shown to be 100 %  identical to qnrVC1 in amino acid composition was harboured on the 
SXT element of clinical V. cholerae O1 isolates recovered from patients seen at the Dhaka 
Hospital in Bangladesh [33,38]. Isolates containing the qnrVC3 gene were shown to display 
reduced susceptibility to ciprofloxacin [33]. To date, reported data or literature to support PMQR 
in V. cholerae O1 in Africa have not been described. 
 
This study found that, there was no involvement of an active efflux pump in quinolone 
resistance, as there was no difference in MIC values obtained following two-fold serial agar 
dilution testing in the presence and absence of reserpine or PaβN. In addition this study, the 
proposed mechanism for quinolone resistance to nalidixic acid is the accumulation of two 
chromosomal mutations detected in GyrA (S83-I) and ParC (S83-L) as PMQR genes were not 
detected. The findings of these two mutations correlate with previous studies done by Kim et al. 
in 2010 and Baranwal et al. in 2002 [16,33]. With regard to quinolone resistance, multiple 
mutations are usually needed to be clinically significant, as wild-type pathogens are highly 
susceptible to these antimicrobial agents [37]. It has been reported that the single amino acid 
mutation in GyrA exhibits reduced susceptibility to ciprofloxacin to a MIC 0.5 µg/ml [6] a 
finding also shown in this study. In the study done by Baranwal et al. in India in 2002, the 
authors demonstrated that amino acid substitutions within the QRDR (GyrA and ParC) in 
combination with an active efflux pump may be responsible for elevated MIC levels for 
quinolones in clinical V. cholerae isolates [16].  
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3.5 Conclusion 
 
The results presented in this study underscore the rapidity at which antimicrobial resistance 
amongst enteric pathogenic bacteria, V. cholerae O1 in particular is developing within South 
Africa. The isolation of epidemic-prone V. cholerae O1 isolates which are resistant to third 
generation cephalosporins is of public health concern in South Africa and globally. The 
mechanism of such resistance is plasmid-borne and given the effortless nature in which plasmids 
can be transferred from one bacterial species to the next, there exist concerns of the transfer of an 
ESBL-based resistance mechanism to bacteria associated with other community-acquired 
infections. The available treatment options for the management of such cases will be complicated 
in an era where new antimicrobial agents are a rare find and advocacy for antimicrobial 
stewardship is slow to find its feet in developing countries such as South Africa. This is a 
problem that an already resource constrained health system can do without.   
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Chapter Four 
 
Molecular characterization of Vibrio cholerae O1 isolates associated with a country wide 
outbreak of cholera in South Africa, 2008 to 2009 
 
This chapter was published in 2013 in the Journal of Infectious Diseases (volume 208, 
supplement 1, pages S39-45). The first author was responsible for the molecular characterization 
of the V. cholerae O1 outbreak isolates and preparation of the manuscript for publication. The 
second author was responsible for the supervision and oversight of methods necessary to 
complete this chapter. The third author was responsible for molecular characterization of the V. 
cholerae O1 outbreak isolates, which included PFGE analysis and PCR-analysis of the virulence 
determinants. The fourth author was responsible for the serological characterization and the 
antimicrobial susceptibility testing of the V. cholerae O1 outbreak isolates. The last author was 
responsible for supervision and guidance on the content of this chapter.  
 
4.1 Introduction 
 
During mid-November 2008 to April 2009, South Africa experienced an outbreak of cholera 
following the importation of cases (individuals seeking health care in South Africa) associated 
with an outbreak in Zimbabwe [1-3]. This outbreak was initially identified in Musina of the 
Limpopo Province, South Africa. All nine Provinces were affected [3]. A total of 12 706 clinical 
cases meeting the clinical (suspect) case definition were reported by the Department of Health 
[3]. Of the total number of cases, 1 114 cases (~ 9 %) were laboratory-confirmed and 65 deaths 
were recorded with a CFR of 0.5 % [3]. The majority of the laboratory-confirmed cases isolated 
were recovered from both the Mpumalanga Province (~ 33.8 %) and the Limpopo Province (~ 
53.5 %) respectively [3]. Local transmission and infection could have been a result of 
contaminated water supplies, poor sanitation, infrastructure and poor access to potable water 
sources [3]. Within the same cholera outbreak, a new outbreak was identified in the North West 
Province [4]. For the period 1 November 2008 to 22 March 2009, the majority of cholera cases 
(76 out of 90 cholera cases) related to this consecutive outbreak were linked to farms in the Brits 
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area with no formal sanitation [4]. Source of infection could have been water, which may have 
been supplied by boreholes [4]. This study proposed to investigate the molecular epidemiology, 
mechanism of antimicrobial resistance and to characterize seventh pandemic toxigenic V. 
cholerae O1 isolates using various molecular techniques. 
 
4.2 Materials and Methods 
 
4.2.1 Bacterial isolates and phenotypic characterization 
 
For the period, November 2008 to April 2009, a total of 720 isolates, sub-cultured on Dorset’s 
Egg Medium (DMP) were sent for analysis at the CED [5]. V. cholerae isolates received were 
recovered from four environmental (~ 0.6 %), 598 stool (~ 83.0 %) and 118  swab (~ 16.4 %) 
specimens [5]. Confirmatory identification was done using standard microbiological techniques 
(section 2.1). MIC testing methods for each isolate were performed as per the CLSI 2008 
guidelines (section 2.2). 
 
4.2.2 Genotypic characterization 
 
4.2.2.1 Pulsed-field gel electrophorsis (PFGE) analysis 
 
From the 720 Isolates, 248 (~ 34.4 %) isolates (clinical and environmental) were characterized 
by PFGE analysis using the PulseNet standardized protocol for V. cholerae (section 2.3). Due to 
time and financial constraints, isolates chosen for PFGE analysis were selected based on 
antimicrobial susceptibility profiles. 
 
4.2.2.2 Detection for virulence determinants 
 
A random number generator was used to select 90 isolates for further analysis; a criterion for 
selection was to ensure that all PFGE banding patterns were represented. Isolates chosen were 
selected based on DNA fingerprint patterns. Crude DNA extracts were prepared (section 2.4), 
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and these served as template DNA in the PCR assays. Conventional PCR was performed for the 
detection of both the ctxA and tcpA genes respectively (sections 2.5.1 and 2.5.2).
 
4.2.2.3 Detection for antimicrobial resistance determinants 
 
Conventional PCR was performed on all 90 isolates for the detection of particular antimicrobial 
resistance determinants (sections 2.5.3 to 2.5.7). PCR-positive amplicons (blaTEM, gyrA, gyrB, 
parC and parE) were purified (section 2.7) and served as template DNA in the cycle sequencing 
PCR assays (section 2.8). DNASTAR Lasergene® software was used to analyze the nucleotide 
sequences and sequence identity was determined at the DNA database of the NCBI (section 2.7).  
Amino acid sequences obtained for GyrA, GyrB, ParC and ParE were compared with a 
quinolone susceptible isolate of V. cholerae O1, N16961 (GenBank accession no. NC_002505). 
 
4.2.2.4 Isolation of plasmid DNA and Southern blot hybridization analysis 
 
Intact plasmid DNA was prepared, as previously described by Kado and Liu (section 2.8). Cell 
lysates (40 µl) with plasmid DNA were resolved by PFGE analysis (section 2.8). For Southern 
blot hybridization studies, a DIG-labeled probe blaTEM was generated (section 2.9). Southern blot 
hybridizations on plasmid DNA separated by PFGE analysis was performed to determine the 
location and size of the plasmid encoding for blaTEM. 
 
4.2.2.5 Molecular characterization of Vibrio cholerae seventh pandemic variants  
 
Four southern African isolates recovered from the two cholera outbreaks in South Africa over the 
years 2008 to 2009 (Chapter Three [6] and Chapter Four [5]) were further characterized. 
Extended analysis included PCR amplification and nucleotide sequencing (sections 2.6 and 2.7) 
of the complete coding regions for both the CT gene, ctxAB and TCP gene, tcpA as previously 
described [7] as well as tracking of V. cholerae seventh pandemic variants by characterizing 
highly related genomic sequences as previously described by Spagnoletti et al. [8]. 
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4.2.2.5.1 Cholera toxin 
 
A single PCR assay was implemented to detect for the presence of the entire coding region of the 
CT (Appendix H1). A PCR reaction was prepared in a 200 µl thin-walled, flat-capped PCR tube 
(Axygen Inc.). A step-down PCR assay consisting of 40 amplification cycles was set up using a 
Bio-Rad (iCycler) thermal cycler (Bio-Rad). The expected size of the ctxAB gene is ~ 1350 bp in 
length. Nucleotide sequences obtained for ctxAB were compared with V. cholerae O1, biotype El 
Tor, strain N16961 accession number NC_002505 and V. cholerae O1, biotype classical, strain 
569B accession number VCU25679. 
 
4.2.2.5.2 Toxin co-regulated pilus 
 
A single PCR assay was implemented to detect for the presence of the entire coding region of the 
tcpA gene (Appendix H2). A PCR reaction was prepared in a 200 µl thin-walled, flat-capped 
PCR tube (Axygen Inc.). A standard-3 PCR assay consisting of 35 amplification cycles was set 
up using a Bio-Rad (iCycler) thermal cycler (Bio-Rad).The expected size of the tcpA gene is ~ 1 
234 bp in length.Nucleotide sequences obtained for tcpA were compared with V. cholerae O1, 
biotype El Tor, strain CIRS101accession number ACVW01000010. 
 
4.2.2.5.3 Mobilome 
 
Two multiplex PCR assays aimed at characterizing the mobilome, which consists of genomic 
islands (GIs), prophages and integrative conjugative elements (ICEs) of V. cholerae O1 and 
O139, were performed (Appendix H3). PCR reactions were prepared in 200 µl thin-walled, flat-
capped PCR tubes (Axygen Inc.). tandard-3 PCR assays consisting of 35 amplification cycles 
were set up using a Bio-Rad (iCycler) thermal cycler (Bio-Rad).Expected sizes for the PCR 
amplicons for both multiplex PCR assays are shown below. 
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Target genes for  
multiplex PCR 1 
Expected size (~ bp) Target genes for 
multiplex PCR 2 
Expected size (~ bp) 
VSP-II integrase 170 TLC phage 449 
Prototypical VSP-II 245 Kappa phage 230 
SXT/R391 ICEs integrase 505 GI 12 571 
SXT Hotspot IV 357 GI 14 142 
ICEVchInd5 Hotspot IV 423 GI 15 348 
ICEVchMoz10 Hotspot IV 712   
 
4.3 Results 
 
4.3.1 Bacterial isolates 
 
All 720 isolates were confirmed as V. cholerae O1. Of the 720 isolates, 708 (~ 98.3%) isolates 
were characterized as serotype Ogawa, while the remaining 12 isolates (~ 1.7%) were 
characterized as serotype Inaba. V. cholerae O139 isolates were not identified. 
 
4.3.2 Antimicrobial susceptibility patterns 
 
Antimicrobial susceptibility testing was not performed on the four environmental isolates as it 
was not included in the standard operating procedure implemented in the CED, thus were not 
included in the study. At the beginning of the cholera outbreak, the antimicrobial susceptibility 
patterns of the clinical isolates were shown to be identical. However, a few months into the 
cholera outbreak (January 2009), antimicrobial susceptibility patterns were shown to be altered. 
All 716 isolates were shown to be susceptible to ciprofloxacin and imipenem. All 716 isolates 
were shown to be resistant to co-trimoxazole and nalidixic acid. Of the 716 isolates, 298 isolates 
(~ 41.6 %) were resistant to chloramphenicol and 176 isolates (~ 24.6 %) were resistant to 
erythromycin. Sixteen isolates (~ 2.2 %) demonstrated resistance to ampicillin and tetracycline. 
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Six isolates (~ 1.0 %) displayed ESBL activity and showed to be resistant to third-generation 
cephalosporin, ceftriaxone (MIC ≥ 16 µg/ml). 
 
4.3.3 PFGE analysis 
 
Analysis of the 248 isolates showed 25 DNA fingerprint patterns (Figure 15). Pattern 12 was the 
most commonly identified pattern in 64 (~ 25.8 %) out of the 248 isolates. The PFGE banding 
patterns only showed subtle differences with all fingerprint patterns showing similarity at ≥ 90.9 
%, which suggested that all isolates were very closely related. 
 
4.3.4 Genes conferring antimicrobial resistance 
 
PCR analysis of class I and class 2 integrons showed that all 90 isolates were PCR-negative for 
both the 3’-CS and 5’-CS conserved segments as well as the intI2 gene respectively. Of the 90 
isolates analysed, seven isolates (~ 7.8 %) were PCR-positive for the tetA gene. All 90 isolates 
were PCR-positive for the SXT element-integrase and five associated SXT resistance geneswith 
the exception of the dfr18 gene.  
 
4.3.5 ESBL activity and identified ESBL genes 
 
Six (~ 6.7 %) out of the 90 isolates that displayed ESBL activity against third generation 
cephalosporins were further characterized using PCR amplification to detect for the presence of 
blaTEM, blaSHV and blaCTX-M respectively. All six isolates were PCR-positive for the blaTEM gene 
and nucleotide sequencing was shown to encode for the TEM-63β-lactamase. Analysis for 
plasmid DNA showed that all six isolates harboured a 140 kb plasmid. Southern blot 
hybridization and DNA probing showed that this blaTEM gene was located on this single plasmid. 
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Figure 15 Dendrogram of PFGE fingerprint patterns of V. cholerae O1 isolates (NotI-digestion) associated with the cholera outbreak 
in South Africa, November 2008 to April 2009. “*” indicates the most commonly identified pattern. 
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4.3.6 Chromosomal mutations in the QRDR of DNA gyrase and topoisomerase IV 
 
All 90 isolates were PCR-negative to all five qnr genes as well as the quinolone resistance 
determinant (qnrA, qnrB, qnrS, qnrC, qepA and qnrVC3). Nucleotide sequencing results showed 
that all 90 isolates harboured two amino acid mutations detected in GyrA (S83-I) and ParC (S85-
L). Amino acid substitutions were not observed in GyrB and ParE for all 90 isolates. 
 
4.3.7 Molecular characterization of Vibrio cholerae seventh pandemic variants 
 
All 90 isolates were virulent as they all possessed the ctxA gene encoding for the CT and all were 
PCR-positive for the tcpA-El Tor gene encoding for the TCP. 
 
The complete coding region of the ctxAB gene (~ 1 350 bp) was amplified from the four selected 
V. cholerae O1 isolates recovered from the two separate cholera outbreaks in South Africa over 
the years 2008 to 2009 (section 4.2.2.5). Amino acid sequences of ctxA for all four isolates were 
shown to be identical to ctxA of V. cholerae O1, biotype El Tor, strain N16961 accession 
number NC_002505 and V. cholerae O1, biotype classical, strain 569B accession number 
VCU25679. Figure 16 is an alignment report of the ctxB amino acid sequence. As shown, V. 
cholerae O1, biotype El Tor, strain N16961 is differentiated from V. cholerae O1, biotype 
classical, strain 569B by two amino acid substitutions. The first amino acid substitution is 
located at codon 39. V. cholerae O1, biotype El Tor, strain N16961 contains a tyrosine (Y), 
while V. cholerae O1, biotype classical, strain 569B contains a histidine (H). The second amino 
acid substitution is located at codon 68. V. cholerae O1, biotype El Tor, strain N16961 contains 
an isoleucine (I), while V. cholerae O1, biotype classical, strain 569B contains a threonine (T). 
As shown, all four selected isolates matched the amino acid sequence of ctxB gene of V. 
cholerae O1, biotype classical, strain 569B. 
 
Nucleotide sequences of the tcpA gene for the four selected isolates were shown to be identical 
V. cholerae O1, biotype El Tor, strain CIRS101 (tcpETCIRS).  
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Figure 16 Alignment report showing the amino acid sequence of ctxB of four selected V. cholerae O1, serotype Ogawa, biotype El 
Tor isolates, TCD306373, TCD325765, TCD273214 and TCD273377; V. cholerae O1, biotype El Tor, strain N16961 accession 
number NC_002505 and V. cholerae O1, biotype classical, strain 569B accession number VCU25679. Amino acid residues that match 
the consensus sequence displayed on top are hidden. Amino acid residues that do not match the consensus sequence displayed on top 
are shown.  
 
Abbreviations: Alanine (A), cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), 
isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), serine (S), threonine 
(T), valine (V), tryptophan (W) and tyrosine (Y). 
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The mobilome of isolates was characterized by combining the PCR results for the two multiplex 
PCR reactions. An identical mobilome profile pattern was determined for the selected isolates. 
Multiplex PCR 1 amplified amplicons for the VSP-II integrase (~ 170 bp), ICEVchInd5 Hotspot 
IV (~ 423 bp) and the SXT integrase(~ 505 bp). Multiplex PCR 2 amplified the amplicon for 
prophage TLC (~ 449 bp). PCR results for both multiplex PCR assays are shown in Figure 17.  
 
 
Figure 17 PCR amplification and detection of particular genetic markers in multiplex PCR 1 and 
multiplex PCR 2 for three V. cholerae O1 isolates. PCR-amplified products were separated on a 
1.5 % (w/v) agarose gel.  
 
Abbreviations: M HyperLadder™ IV (100 bp molecular weight marker), NTC no template 
control. 
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4.4 Discussion 
 
During the cholera epidemic described in South Africa, a small percentage of isolates 
characterized were serotyped as Inaba. Serotype conversion is due to a mutation in the rfbT gene, 
which is responsible for switching [9,10]. V. cholerae O1 classical variants of the TCP were not 
identified in this study. This finding is supported by previous studies that have showed that V. 
cholerae O1 classical biotype isolates are not recovered in Africa [11]. 
 
The initial resistance patterns of isolates analyzed in this study were identical, but a few months 
into the outbreak (January 2009) it was altered to include reduced susceptibility to 
chloramphenicol, tetracycline andmacrolides. During antimicrobial treatment all bacteria in the 
human body are exposed to selective pressure of the antimicrobial agent [12]. The 
gastrointestinal tract is highly exposed particularly during rehydration therapy [12]. As a result, 
naturally resistant bacteria harbouring a genetic pool of antimicrobial-resistant determinants have 
the potential to transfer these genes to other bacteria within the human gastrointestinal tract [12]. 
In this study, each isolate was resistant to at least three classes on antimicrobial agents namely 
sulfonamides, quinolones and aminoglycosides. As previously discussed in section 3.4, V. 
cholerae O1 has established different mechanisms to combat the effects of antimicrobial agents.  
 
PFGE analysis was shown to be an effective molecular tool to characterize V. cholerae O1 
isolates recovered from the outbreak, as it was able to distinguish the PFGE banding patterns 
evaluated in this study from other patterns in the database of southern African isolates (Results 
not shown). PFGE analysis identified 25 NotI restriction patterns. Isolates displayed minor 
diversity in their PFGE patterns showing > 90 % similarity value. The predominant PFGE 
pattern identified, pattern 12 was shown to be related to isolates with the 
KZGS12.0088/KZGN11.0092 pattern and its close variant, KZGS12.0089/KZGN11.0092 from 
Afghanistan, Cameroon, India, Nepal, Oman, Pakistan and Haiti [7]. The 
KZGS12.0088/KZGN11.0092 pattern is recognized as a relatively new PFGE pattern as it was 
first describedin thePulseNet USAdatabase in 2005 in isolates from travellers returning from 
India [7].  
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Although all 90 isolates in this study were PCR-positive for the El Tor variant of the TCP, ctxB 
genotyping of the four selected isolates showed that all four isolates expressed the encoded ctxB 
allele for the CT of the classical biotype. To support this finding, V. cholerae O1 isolates from 
this 2008 to 2009 South African outbreak were further analyzed in a study done by Talkington et 
al to investigate the similarity to the Haiti V. cholerae O1 outbreak isolates using PFGE. They 
showed that South African V. cholerae O1 isolates carried the classical ctxB-1 allele and the 
rstREl [7]. These characteristics define the isolates as “altered El Tor“ [7,13]. Although, V. 
cholerae O1 isolates from South Africa and Haiti share the same PFGE restriction pattern, 
isolates from Haiti were shown to carry the ctxB-7 allele, which was first documented in V. 
cholerae O1 isolates recovered from a cholera outbreak in Orissa, India in 2008 [7]. To confirm 
the similarity in the PFGE fingerprint patterns between the South African and Haiti V. cholerae 
O1 isolates, whole genome sequencing was performed [14]. Comparative analysis showed that 
the Haiti V. cholerae O1 isolates clustered away from the South African isolates [14]. V. 
cholerae O1 biotype El Tor variants expressing a classical CT were first described in 2002 by 
Nair et al. among clinical isolates collected for the years 1991 to 1994 [15]. Several ctxB alleles 
have been have been described among V. cholerae isolates of different biotypes and serogroups 
[13]. These alleles differ by amino acid substitutions within the ctxB gene [13]. In Africa, V. 
cholerae O1, biotype El Tor variants expressing a classical CT have been described in Nigeria, 
Cameroon, Mozambique and Zambia [16-18]. Isolates displayed typical characteristics of the El 
Tor biotype based on phenotypic assays but carried the CTXclassΦ [16-18].  
 
In order to better understand the genetic organization and track seventh pandemic V. cholerae 
O1, biotype El Tor isolates, southern African isolates, each recovered from the two separate 
cholera outbreaks in South Africa over the years 2008 to 2009 were further characterized. 
Findings from Figure 17 formed a small part of the study. It was used as a snapshot to determine 
if there were differences in the mobilome patterns of the isolates from the two reported 
outbreaks. An identical mobilome profile pattern was determined for the selected isolates. 
Combining the PCR results for the isolates in this study showed a profile B. Profile B is one of 
twelve profiles that have been described, profile A to profile L [8]. Profile B belongs to the 
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reference strain CIRS101 (ctxB-1/tcpETCIRS) as reported by Spagnoletti et al. V. cholerae O1, 
biotype El Tor, strain CIRS101 was first isolated in Dhaka, Bangladesh in 2002 [8].  
 
4.5 Conclusion 
 
V. cholerae O1 El Tor variants are well adapted pathogens that have the ability to spread both 
efficiently and expeditiously. The use of mobilome characterization data enabled us to 
characterize and uncover the source of the southern African isolates. Global networks such as 
PulseNet, standardized protocols and innovative epidemiological tools for characterizing 
pathogenic isolates, are invaluablefor the understanding of how enteric pathogens are transmitted 
globally. Global travel has decreased the duration under which outbreaks spread and increased 
the likelihood that a potential pathogen may cross a border. Strengthening global resources such 
as PulseNet, developing innovative epidemiological tools and adhering to standardized protocols 
are key as they can all be used a means identifying and managing potential public health 
concerns such as outbreaks of cholera.  
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Chapter Five 
 
Azithromycin susceptibility in recent antimicrobial-resistant Vibrio cholerae O1 altered El 
Tor variant isolates in South Africa. 
 
5.1 Introduction 
 
Protein biosynthesis is an essential process in all living cells [1]. The ribosome, which consists of 
two subunits is the universal cellular organelle responsible for this process [1]. The bacterial 
ribosome consists of a small 30S subunit and a large 50S subunit [1,2]. The small 30S subunit 
consists of a 16S ribosomal ribonucleic acid (rRNA) chain of ~ 1 500 bp together with 20 to 21 
ribosomal proteins [1,2]. The large 50S subunit is composed of two RNA chains of ~ 3 000 bp, 
namely the 23S rRNA and 5S rRNA together with 31 to 35 ribosomal proteins [1,2]. The small 
30S subunit provides the decoding centre, which is responsible for the selection of the 
aminoacyl-transfer RNAs (tRNAs) based on the order of codons in the messenger RNA (mRNA) 
[1,2]. The amino acids are assembled into a polypeptide chain in the catalytic site known as the 
peptidyl transferase center (PTC), which is located in the large 50S subunit [1,2]. The newly 
assembled polypeptide chains exit the ribosome by means of the nascent peptide exit tunnel 
(NPET), which begins at the PTC and extends through the body of the large 50S subunit [1,2]. 
The NPET contains a pocket or binding site of high affinity for antimicrobial agents such as 
kelotides as well as the macrolides, lincosamides and streptogramins (MLS) group [1,3-5]. 
Although MLS are chemically distinct, they are considered together as most of these 
antimicrobial agents share overlapping binding sites on the large 50S subunit and many bacteria 
possess antimicrobial-resistant genes to more than one than antimicrobial agent in this group 
[4,6]. 
 
Macrolides were first introduced into medical practice during the early 1950s and are recognized 
as an important class of antimicrobial agents [7-9]. Macrolides are viewed as an excellent class 
of antimicrobial agents with high potency and low toxicity [2,9]. They have an excellent safety 
and tolerability profile, which includes children and pregnant women and are generally used in 
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place of penicillin in β-lactam allergic individuals [9]. Macrolide antimicrobial agents are 
characterized based on their possession of a multi-membered lactone ring consisting of 12 to 16 
carbon atoms together with one or more sugars (amino sugars, non-nitrogenous or both) attached 
[7,10,11]. Erythromycin was the first 14-membered macrolide to be used in medical practice and 
was shown to be active against Gram-positive and certain Gram-negative pathogenic bacteria 
such as Campylobacter species and Neisseria gonorrhoeae [2,7,9,12]. It is still used to treat 
respiratory tract, skin and soft tissues and genitaltract infections [7]. An important characteristic 
of macrolides that may contribute to their effectiveness is that they accumulate within the 
leukocytes and can improve the immune system [10,13]. A study done using mice demonstrated 
that phagocytes may be a possible mechanism to transport intracellular macrolides and release it 
to sites of infection [10,13]. Since the target ribosome is intracellular, macrolides must cross 
either one membrane barrier in Gram-positive bacteria or two membrane barriers in Gram-
negative bacteria [14]. Therefore the mechanism of uptake of macrolides by the bacterium is 
essential [14]. Gram-negative bacilli such as Escherichia coli and Salmonella species are 
naturally unaffected by MLS antimicrobial agents due to the impermeability of the outer 
membrane [10,11,14]. However certain Gram-negative bacteria such as Haemophilus, 
Bordetella, Legionella, Campylobacter, Chlamydia, Treponema, Helicobacter, Mycoplasma and 
Pasteurella species are susceptible to them [10,11,14].  
 
Macrolides act by binding to the bacterial ribosome and thereby inhibit protein synthesis [2,9-
11,15,16]. This is achieved by binding of the macrolide in the upper chamber of the NPET, 
between the PTC and the constriction formed by the ribosomal proteins L4 and L22 [1,2,17-19]. 
The binding site is made up of rRNA nucleotides, which belong to domains II and V of the 23S 
rRNA [2,17].  The lactone ring of the antimicrobial agent interacts with rRNA residues 2057, 
2058 and 2611 (residues are numbered according to Escherichia coli 23S rRNA and will used 
throughout this chapter), which are responsible for the formation of the tunnel wall on the side of 
the PTC A site [2,17]. Another way for macrolides to inhibit protein synthesis, is to interact with 
partially assembled 50S precursors causing nucleolytic degradation of unassembled precursors 
and as a result, stall the assembly process [20].  
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Azithromycin (CP-62,993; 9a-methyl-9-deoxo-9-dihydro-9a-aza-homoerythromycin A), a semi-
synthetic derivative of erythromycin A is a 15-membered macrolide, which was first produced 
by PLIVA, a pharmaceutical company in 1980 [13]. The interest in this antimicrobial agent was 
sparked by the investigation on the effects of treatment with azithromycin on Gram-negative 
bacilli from cystic fibrosis patients [12]. Azithromycin is chemically distinct from erythromycin 
A by the presence of a methyl-substituted nitrogen in the lactone ring as shown in Figure 18 and 
was shown to have improved in vivo potency over erythromycin A against localized soft tissue 
infections as well as enhanced activity against a broader range of Gram-negative bacteria 
[7,9,12,13,21].  
 
 
Figure 18 Chemical structures of azithromycin and erythromycin A. Picture adapted from 
Retsema et al, 1987. 
 
Azithromycin is not generally used in the treatment of Enterobacteriaceae infections. However, 
it has been shown to be effective in the treatment of quinolone–resistant typhoid and paratyphoid 
fever caused by Salmonella enterica serotypes Typhi and Paratyphi A, B and C [21,22]. It has 
been recommended by the American Academy of Paediatrics for the treatment of shigellosis in 
children and by the WHO as a second-line treatment for adults [22]. Azithromycin has the ability 
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to penetrate and reach high concentrations within leukocytes, which is why it is effective against 
intracellular bacteria [9,13]. Though azithromycin is concentrated intracellularly, this creates 
difficulties in defining clinical MIC breakpoints [9]. Therefore, one cannot assume that bacterial 
isolates with decreased susceptibility to erythromycin in vitro will be resistant to azithromycin in 
vivo[9].  
 
Although, no clinical azithromycin MIC breakpoints are available for Enterobacteriaceae by the 
Clinical and Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) states that Salmonella and Shigella isolates with MICs less 
than or equals to (≤) 16 µg/ml for azithromycin should be considered wild-type organisms that 
are responsive to treatment [21]. Previous studies have reported MICs for azithromycin in 
Salmonella enterica serotype Typhi isolates ranged from 4 µg/ml to 64 µg/ml[22]. Bacterial 
resistance to MLSs are due to nucleotide changes in intrinsic genes or by the acquisition of 
antimicrobial resistance determinants carried on mobile genetic elements [12,23,24]. 
Mechanisms of macrolide resistance have been well characterized in clinical isolates of Gram-
positive bacteria [9,11,25-27]. Macrolide resistance occurs in three ways namely, (i) enhanced 
efflux activity, (ii) modification of the target site by methylation or amino acid mutations that 
inhibit binding of the antimicrobial agent to its ribosomal target and (iii) by the inactivation of 
the antimicrobial agent [11,23-29]. All three resistance mechanisms to macrolides have also been 
reported in Gram-negative bacteria in particular, the family Enterobacteriaceae [12,23-25,29]. 
 
The genes involved in the regulation of efflux pump activity produce proteins, which transport 
the antimicrobial agent out of the bacterial cell and allow for the the ribosomes to function 
normally [12]. Seventeen different genes have been described, which code for either ATP 
transporters or Major Facilitator Transporters and the genes necessary to perform this function 
[4,23]. In Gram-negative bacteria, the two most commonly found efflux genes described, mef(A) 
and msr(D) were shown to be responsible for conferring macrolide resistance to erythromycin 
[12,29].  
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Ribosomal target modification generally occurs by the acquisition of the erythromycin ribosome 
methylase (erm) gene, which codes for an enzyme that methylates a single adenine at residue 
2058 (A2058 in Escherichia coli), anessential macrolide target binding site in the PTC of23S 
rRNA[24]. Erm methylases either add one or two methyl groups to A2058 [6,12,17,24,26-28]. 
This modification inhibits the binding of MLS to the large 50S subunit [6,12,17,24,26-28]. There 
are currently 33 different erm genes, of which erm(A), (B), (C), (F), (G) and (Q) have been 
identified in Gram-negative bacteria [4,12,23]. In addition, erm(B) is the most commonly found 
gene amongst Gram-positive and Gram-negative bacteria [23,24]. In pathogenic bacteria, erm 
determinants are generally disseminated by conjugal transfer either by plasmids or transposons 
[23,24]. Ribosomal target modification may also arise from nucleotide changes in the genes 
encoding for the 23S rRNA domain V and the ribosomal proteins L4 and L22 [12,16,28,30,31]. 
Mutations in ribosomal proteins L4 and L22 affect the conformation of 23S rRNA and as a result 
prevent the binding of the antimicrobial agent to the ribosomal target site [12,16,28,30,31]. 
Nucleotide changes in the 23S rRNA genes have been reported in pathogenic Gram-negative 
bacteria, for example Campylobacter species, Chlamydia trachomatis, Haemophilus influenza, 
Helicobacter pylori and Neisseria gonorrhoeae[12]. Nucleotide changes in the 23S rRNA and 
the ribosomal proteins L4 and L22 that confer antimicrobial resistance to erythromycin have 
been reported in laboratory-mutants of Escherichia coli [12,24,31].   
 
A total of 19 inactivation enzymes have been described [23]. These include two lyases, 11 
transferases, two esterases and four phosphorylases [23]. Antimicrobial inactivation by esterases 
and phosphorylases confer resistance to 14-membered and 15-membered macrolides but not to 
lincosamides [12,24]. Erythromycin esterases encoded by the both the ere(A) and ere(B) genes, 
break down the lactone ring in the macrolide thus generating an inactive product [12,24,27,29]. 
These esterases are generally found in Gram-negative bacteria and are spread by plasmids as 
well as by class 1 and class 2 integrons [12]. A study done in 2002 by Thungapathra et al. 
described a V. cholerae isolate carrying the erythromycin esterase encoding ere(A2) resistance 
determinant on a class 1 integron [32]. Macrolide phosphorylases encoded by the mph(A), 
mph(B), mph(C) and mph(D) genes add a phosphate group to the macrolide antimicrobial agent 
hence inactivating it[12]. Macrolide phosphorylase genes mph(A), mph(B) and mph(D) are 
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generally found in Gram-negative bacteria[12,29]. The mph(C) gene is found in both Gram-
positive and Gram-negative bacteria [12,23].  
The chapter proposed to investigate the antimicrobial susceptibility to azithromycin amongst 
South African isolates of V. cholerae O1 and to investigate the presence of typical macrolide 
resistance determinants commonly associated with the family Enterobacteriaceae. 
 
5.2 Materials and Methods 
 
5.2.1 Bacterial isolates 
 
One-hundred V. cholerae O1 El Tor variant isolates, ten selected isolates further characterized in 
Chapter three and 90 selected isolates further characterized in Chapter Four were included in this 
study.  
 
5.2.2 Antimicrobial susceptibility testing 
 
A comparative study using both the Etest and agar dilution methods was conducted. Based on 
previously published literature for wild type isolates of Salmonella and Shigella the tentative 
breakpoint for resistance to azithromycin of > 16 µg/ml was applied to these V. cholerae O1 
isolates. For quality control purposes, Staphylococcus aureus ATCC29213 was used. The target 
MIC range for the control isolate on Mueller-Hinton agar was between 0.5 µg/ml - 2 µg/ml.  
 
5.2.2.1 Episolimeter test (Etest) method 
 
MICs for azithromycin were determined using the Etest® for all 100 isolates as previously 
described in section 2.2. The antimicrobial concentration range for azithromycin ETest® strip 
was between 0.016 µg/ml – 256 µg/ml.  
 
5.2.2.2 Doubling agar dilution method 
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Susceptibility to azithromycin was investigated using agar dilution MIC testing as described in 
section 3.2.1.1. A doubling dilution series of increased concentration was prepared for 
azithromycin (Sigma) (Appendix I1). An antimicrobial-free control plate was included. The 
antimicrobial concentration for the agar dilution ranged between 0.015 µg/ml and 16 µg/ml. 
 
5.2.3 Genotypic characterisation 
 
5.2.3.1 Detection for macrolide resistance determinants 
 
Single PCR assays were implemented to detect for the presence of seven macrolide resistance 
determinants, mefA, ereA, ereB, ermB, mphA, mphB and mphD respectively (Appendix I2) [29]. 
A 25 µl PCR reaction was prepared in a 200 µl thin-walled, flat-capped PCR tube (Axygen Inc.). 
For each PCR assay, a standard-3 PCR assay consisting of 35 amplification cycles was set up 
using a Bio-Rad (iCycler) thermal cycler (Bio-Rad). Positive control Streptococcus pneumoniae 
# 15 (PCR-positive for mefA and ermB) was kindly provided, courtesy of the Dr. Nicole Wolter 
from the Centre for Respiratory Diseases and Meningitis. Expected sizes for the PCR amplicons 
are shown below. For ereA, ereB, mphA, mphB and mphD, artificial chimeric DNA constructs to 
serve as positive control DNA as described in section 5.2.3.2 were constructed. The detection 
and size of the PCR products were determined using conventional agarose gel electrophoresis 
(section 2.6). 
 
Target gene Expected size for wild-
type isolates (~ bp) 
mefA 324 
ereA 420 
ereB 303 
ermB 639 
mphA 403 
mphB 889 
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mphD 436 
 
5.2.3.2 Internal control DNA constructs 
 
Artificial chimeric DNA constructs were created and these served as internal positive controls 
for the detectionof ereA, ereB, mphA, mphB and mphD respectively. The method for creating 
these constructs was adapted from Hoorfar et al. [33]. This method involved two rounds of PCR.  
 
The purpose of the first PCR was to create a chimeric DNA construct, which consisted of a non-
relevant template DNA of known size flanked by the target for macrolide specific PCR-primers. 
Figure 19 illustrates how an internal positive control for mphA was created. In this study the eae 
gene, which encodes for an outer membrane protein called intimin for Enteropathogenic 
Escherichia coli, ATCC43887 was used. This gene is ~ 482 bp in size and served as the 
backbone for designing chimeric primers. Both forward and reverse primers used in the initial 
PCR contained nucleotide sequences for both the eae gene and the macrolide resistance 
determinant, mphA.  
 
A 50 µl PCR reaction was prepared in a 200 µl thin-walled, flat-capped PCR tube (Axygen Inc.). 
For each PCR assay, a standard-3 PCR assay consisting of 35 amplification cycles was set up 
using a Bio-Rad (iCycler) thermal cycler (Bio-Rad).The detection and size of the PCR products 
were determined using conventional agarose gel electrophoresis and the resultant 45 µl PCR-
positive product was purified as per the manufacturer’s guidelines using the MSB® Spin 
PCRapace clean-up kit (Invitek, Berlin, Germany) (section 2.7).

Figure 20 shows the PCR amplification and detection of both the eae gene (~ 482 bp) and mphA-
eae chimeric DNA construct (~ 522 bp). The purpose of the second round of PCR was amplify 
this mphA-eae chimeric DNA construct using the initial macrolide specific PCR-primers for 
mphA as described in section 5.3.2.1. Expected sizes for the PCR amplicons are shown below. 
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Figure 19 Schematic overview of creating internal positive control DNA for the detection of the 
macrolide resistance determinant, mphA. 
 
Target gene Expected size  for positive 
control DNA constructs (~ bp) 
ereA-eae 524 
ereB-eae 519 
mphA-eae 522 
mphB-eae 524 
mphD-eae 523 
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Figure 20 PCR amplification and detection of the eae (~ 482 bp) gene in lane 1 and the internal 
positive control, mphA-eae (~ 522 bp) in lane 2. PCR-amplified products were separated on a 1.5 
% (w/v) agarose gel. LaneM, HyperLadder™ IV (100 bp molecular weight marker). 
 
5.2.4 Statistical analysis 
 
The modes and ranges of both the Etest and agar dilution method MIC results were calculated 
from the results of the azithromycin testing. The two methods used in this study were not 
qualified as “gold standards”. A “gold standard” is recognized as a test, which determines 
absolutely and without error whether an isolate is resistant (sensitivity) or susceptible 
(specificity) [34]. For consistency of comparison, the upper MIC limit of 16 µg/ml was the 
greatest value for the MIC range of the agar dilution. To analyze the degree of agreement 
between the Etest and the agar dilution method results for two independent samples, the Mann 
Whitney test was performed. Measurement of the association between the tests was provided by 
performing a Spearman correlation coefficient for the agar dilution method and the Etest from 
the results of the azithromycin testing. 
100 bp 
200 bp 
300 bp 
400 bp 
500 bp 
600 bp 
M M 
eae mphA-eae 
1 2 
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5.3 Results 
 
5.3.1 Azithromycin susceptibility testing 
 
For all 100 selected isolates, the MIC range for the Etest method was from 0.19 µg/ml to 0.38 
µg/ml. No growth was observed at a concentration of 0.5 µg/ml for the agar dilution. For 
consistency of comparison, the upper MIC limit of 16 µg/ml was the greatest value for the MIC 
range of the agar dilution. The mode MIC of the agar dilution (0.5 µg/ml) was one MIC dilution 
factor greater than that of the Etest (0.25 µg/ml).  
 
5.3.2 Detection for macrolide resistance determinants 
 
All 100 selected isolates were PCR-negative for all seven macrolide resistance determinants. 
 
5.3.3 Statistical analysis 
 
Statistical comparison of the results of the Etest and agar dilution showed that the agreement of 
susceptibility was 100 %. The agreement of MIC values based on the nearest similar dilution 
factor was 97 % (P  > 0.05; Mann-Whitney test showed no significant difference) and a positive 
MIC correlation at 0.99 (P < 0.01; Spearman correlation coefficient, highly significant 
correlation). 
 
5.4 Discussion 
 
The agreement of MIC values between the two azithromycin susceptibility testing methods is 
evidence of consistency as both methods produced comparable results, as illustrated by the 
highly significant correlation. All 100 South African V. cholerae O1 isolates investigated in this 
study would be considered susceptible to azithromycin provided that the tentative breakpoint of 
≤ 16 µg/ml is applied (the EUCAST value for wild-type isolates of Salmonella enterica and 
Shigella species). This may suggest that the South African V. cholerae O1 isolates recovered 
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from patients with cholera have not been subjected to selective pressures (azithromycin 
exposure). The result of exposure to antimicrobials, including azithromycin, could have led to 
the selection of antimicrobial-resistant isolates that may have mutated to acquire azithromycin 
resistance. Although these results are positive from a public health perspective, in terms of 
treatment strategy, these values need to be correlated against observed clinical responses to 
azithromycin therapy in patients with cholera in a trial setting as previously described in 
Bangladesh [35,36].  
 
Without such investigation conjecture regarding the appropriate treatment does and/or duration 
will remain a contentious issues amongst clinicians. The result of such indecisiveness, due to a 
lack of convincing evidence, may result in clinicians underdosing and underprescribing 
azithromycin for the treatment of cholera. The practice of exposing the bacterium to sub-optimal 
levels of this key antimicrobial will provide the selective pressure for increased susceptibility or 
full resistance resulting in non-clinical response. From a pubic health perspective, this may lead 
to the partial or total loss of an antimicrobial to treat an epidemic prone pathogen, polypharmacy 
and significant increases in costs to treat severe or complicated cases of cholera.Non-clinical 
response to azithromycin therapy has been described in the United Kingdom from a patient 
returning from Pakistan [37]. Salmonella enterica serotype Paratyphi A was isolated from blood 
culture specimens with observed MIC values between 64 µg/mland 256 µg/ml [37]. In addition, 
reduced susceptibility to ciprofloxacin was observed and treatment with azithromycin was 
changed to intravenous third-generation cephalosporin, ceftriaxone [37]. In the same study done 
by Rai et al., non-clinical response to azithromycin therapy was described in 19 patients infected 
with nalidixic acid-resistant Salmonella enterica serotype Typhi [38]. As a result treatment was 
changed from azithromycin to oral third-generation cephalosporins or amoxicillin as per the 
standard guidelines [38]. A recent study done by Kobayashi et al. from Japan described non-
clinical response to azithromycin therapy in a Japanese patient returning from India [39]. 
Salmonella enterica serotype Paratyphi A was isolated from a blood culture specimen with 
observed MIC value of 8 µg/ml by Etest [39]. This resulted in a change of treatment from 
azithromycin to ceftriaxone [39]. A study done by Boumghar-Bourtchai et al. in France in 2008 
also reported non-clinical response to azithromycin in the treatment of Shigella sonnei (MIC ≥ 
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64 µg/ml) isolated from children < 15 years of age during an outbreak [40]. A study done by 
Howie et al. in the United States in 2010, described reduced susceptibility to azithromycin in 
Shigella sonnei isolates from routine surveillance at the National Antimicrobial Resistance 
Monitoring System, reported outbreaks and historical collections [41]. Antimicrobial 
susceptibility testing included broth microdilution and doubling agar dilution procedures [41]. 
Observed MIC values were clustered at 8 µg/ml while three isolates displayed an elevated MIC 
value of 64 µg/ml [41,42].  
 
Unfortunately there exists a dearth of studies from Africa that describe the azithromycin 
antimicrobial susceptibility patterns in V. cholerae O1 isolates. A study done by Mahmud et al. 
described azithromycin susceptibility patterns of V. cholerae O1 isolated from Sierra Leone in 
2012 using the Etest method [43]. The MIC values for these isolates ranged from 0.125 µg/ml to 
0.5 µg/ml [43]. These MIC values were comparable with results shown in this study. A study 
done in Zimbabwe described V. cholerae O1 El Tor variants collected during the cholera 
epidemic in 2008 displaying reduced susceptibility to azithromycin but their MIC values were 
not stated [44]. Studies from Asia show similar results to those in Africa but are also limited in 
nature.A study done in Vietnam (also using the Etest method) showed that 95 % of the V. 
cholerae O1 isolates displayed MIC values ≤ 2 µg/ml and 1 % of the isolates displayed MIC 
values ≥ 8 µg/ml (MIC range 0.25 µg/ml to 32 µg/ml) [45]. A study done by Faruque et al. 
reported on the first multidrug-resistant (isolates were resistant to furazolidone, tetracycline, 
erythromycin and co-trimoxazole) V. cholerae O1 isolates observed in Matlab, Bangladesh in 
October 2004 [46].  Prior to 2004, V. cholerae O1 isolates recovered were observed to be 
sensitive to tetracycline, erythromycin, and ciprofloxacin [46]. Further investigation showed that 
17 out of 35 isolates were resistant to both erythromycin and azithromycin based on disc-
diffusion and Etest methods [46]. The Etest MIC values of V. cholerae O1 isolates shown to be 
azithromycin-resistant ranged from 0.75 µg/ml to 3 µg/ml [46]. This published study showed 
how rapidly reduced susceptibility to azithromycin was observed in a period of three years [46]. 
Azithromycin MIC values obtained in this present study are comparable with previous studies on 
V. cholerae O1 as described above. The results of this present study could be used to inform 
CLSI and EUCAST in their attempts to determine standardized MIC breakpoints for V. cholerae 
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O1. However, literature suggests that this may not be the pattern for other enteric bacteria of 
clinical importance. 
 
Reduced susceptibility to azithromycin has been reported in enteric pathogenic organisms 
belonging to the family Enterobacteriaceae. For example, elevated MIC values (Etest MIC ≥ 
256 µg/ml, doubling agar dilution MIC range 500 µg/ml to 1000 ug/ml) were in observed in 
Campylobacter jejuni isolates recovered from children less than five years of age in Kolkata, 
India for the years 2010 to 2012 [47]. A study done in the Netherlands in 2014, described 
azithromycin MIC values (2 µg/ml to 256 µg/ml) in Salmonella enterica serotypes Typhi and 
Paratyphi A, B and C isolated from ill returning travellers [22]. A study done by Gunell et al. 
investigated the in vitro activity of azithromycin in 1 237 non-typhoidal Salmonella enteric 
isolates recovered from Finnish patients for the years 2003 to 2008 [48]. Non-typhoidal 
Salmonella enterica isolates that showed reduced susceptibility to fluoroquinolones displayed 
azithromycin MIC values ≥ 32 µg/ml based on the doubling agar dilution method [48]. A study 
from Pakistan investigated the in vitro activity of azithromycin in Salmonella enterica serotypes 
Typhi and Paratyphi A, B and C isolates [49]. Salmonella enterica serotypes Typhi and 
Paratyphi A and C displayed azithromycin MICs in the range of 2 µg/ml to 12 µg/ml, while 
Salmonella enterica serotype Paratyphi B displayed azithromycin MICs in the range of 2µg/ml 
to 48 µg/ml based on the Etest method [49]. A study done by Rai et al. cited that azithromycin 
MIC values obtained for Salmonella isolates examined in India (24 µg/ml) were not comparable 
with MIC values obtained for Salmonella isolates from the Western countries (MIC range 4 
µg/ml to 8 µg/ml) [38]. Since there are no defined azithromycin MIC breakpoints for Salmonella 
enterica, justifying the treatment with azithromycin becomes a challenge particularly for patients 
with enteric fever, as well as for patients who have travel history to and from developing 
countries such as India [38].  
 
In the present study, all 100 South African V. cholerae O1 isolates examined were PCR-negative 
for all seven macrolide resistance determinants (mefA, ereA, ereB, ermB, mphA, mphB and 
mphD), which are known to be commonly found in Gram-negative bacteria respectively. These 
results augment the azithromycin MIC values obtained in this study for both the Etest (0.19 
 



µg/ml to 0.38 µg/ml) and doubling agar dilution methods (0.5 µg/ml). Escherichia coli has been 
shown to harbour a range of common macrolide resistance determinants associated with 
increased MICs for erythromycin [25].  
 
One-hundred and ninety Escherichia coli isolates recovered from various countries (French 
Guiana, Senegal, France, Niger and Vietnam) were examined [25]. Twenty isolates examined 
from Senegal (MIC range 64 µg/ml to 128 µg/ml) were shown to be PCR-negative for the 
detection of  macrolide resistance determinants [25]. However, of the 29 isolates recovered from 
children in Niger (MIC range 64 µg/ml to 1 024 µg/ml), nine isolates were shown to be PCR-
positive for the mphA gene [25]. Plasmid-mediated transfer of antimicrobial resistance genes 
have been described between Escherichia coli and Shigella species [25,50]. The Shigella sonnei 
isolates described by Boumghar-Bourtchai et al. was shown to harbour a 90 kb plasmid 
containing the the mphAgene, which encodes for a macrolide 2'-phosphotransferase [47]. 
Following the report by Howie et al. a publication from the United States reported by Sjȍlund-
Karlssonet al., described outbreak Shigella sonnei isolates displaying azithromycin MICs > 16 
µg/ml as well as harbouring a plasmid containing the the mphA gene [49]. Reduced susceptibility 
to azithromycin in Campylobacter is due to nucleotide changes in the genes encoding for the 23S 
rRNA domain V [42]. Macrolide-resistant Campylobacter jejuni isolates examined in the study 
by Mukherjee et al. showed that these isolates contained a point mutation, A2075G and isolates 
that displayed a MIC of 1000 µg/ml was shown to present with a different point mutation, 
A2074C [42]. The non-typhoidal Salmonella enterica isolates examined by Gunell et al. showed 
that out of the 1 237 isolates, nine isolates presented with point mutations in genes rlpD and rlpV 
encoding for the 50S ribosomal proteins, L4 and L22 [43]. Three Salmonella enterica 
Montevideo isolates harboured single point mutations in both genes (rlpD C379T and 
rlpVG25A), while the remaining six isolates (three Salmonella enterica Blockley, one 
Salmonella enterica Saintpaul and two Salmonella enterica Typhimurium) harboured a single 
point mutation in rlpD, G235A [43]. These studies illustrate that further analyses are required if 
this is to be observed in V. cholerae.  
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5.5 Conclusion 
 
The MIC values and PCR results reported in this study provides a foundation for the surveillance 
of azithromycin susceptibility and to determine MIC breakpoints for V. cholerae O1 isolates 
circulating in South Africa. The global circulation of V. cholerae O1 with increased 
azithromycin MIC values and different mechanisms of macrolide resistance is of public health 
importance particularly amongst those at most risk populations such as children and immune 
suppressed individuals in developing countries. Although the molecular findings following this 
investigation were negative, from a public health outlook it is a positive report, whereby 
azithromycin can be used as a treatment option for severe diarrhoeal disease. However, due to a 
lack of comprehensive linking to patients’ clinical history it cannot be determined for certain to 
what antimicrobial agents or environmental factors these V. cholerae O1 isolates were exposed 
to. These isolates were a subset of the total number of V. cholerae O1 isolates submitted to the 
CED for analysis, therefore additional, resource-intensive examination is required. Investigations 
of other macrolide resistance determinants such as mph(C) or mutations in the 23S rRNA or 
ribosomal proteins L4 and L22 were not attempted as the study V. cholerae O1 isolates displayed 
low MIC values (≤ 0.38 µg/ml). This is the first report describing azithromycin susceptibility 
amongst South African V. cholerae O1 isolates linking phenotypic observations with molecular 
characteristics. 
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Chapter Six 
Limitations 
 
A total of 720 V. cholerae O1 isolates were characterized during the country wide outbreak of 
cholera in South Africa during 2008 to 2009 (section 4.2.1). Therefore only a limited percentage 
of patients had stool cultures taken for examination and ~ 50 % of the positive stool cultures 
were received by the CED. It is believed nevertheless that these findings do represent the 
outbreak and the impact of the disease as a whole given the nature of cholera and the rapidity 
with which the outbreak spread. Full molecular analysis was not conducted on all V. cholerae O1 
isolates collected through normal surveillance activities. Surveillance activities carried out by the 
CED are dependent on peripheral laboratories submitting isolates. Many V. cholerae O1 isolates 
were not submitted (section 4.1). 
 
In this study, PFGE analysis was able to distinguish different NotI restriction patterns described 
in both outbreaks (Chapter Three and Chapter Four). This point can be supported with results 
obtained from antimicrobial susceptibility testing, suggesting that V. cholera O1 isolates 
collected from both cholera outbreakswere highly clonal originating from an independent point-
source. Due to limited resources and time constraints, only one molecular subtyping method was 
used. It would have been advantageous to compare PFGE analysis with another method such as 
multiple-locus variable-number of tandem repeat analysis (MLVA) [1,2] or MLST [3] to 
compare genomic variation within V. cholerae O1 isolates collected in South Africa (sections 
3.3.3 and 4.3.3).  
 
Antimicrobial susceptibility data for furazolidone were not included in the antimicrobial profile 
of the isolates described as MIC testing for furazolidone was not determined for all V. cholerae 
O1 isolates. Furazolidone MIC testing was only done for V. cholerae O1 isolates collected in 
2009 and not for 2008. Data not described in this study showed that ~ 74 % of the isolates from 
the Limpopo Province and ~ 51 % of the isolates from the Mpumalanga Province displayed 
reduced susceptibility to furazolidone (MIC ≥ 128 µg/ml). Due to financial and time constraints 
extended analysis was not possible. If funding and time were feasible, it would have been 
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interesting to further analyze the identified plasmid DNA with the antimicrobial resistance 
marker (blaTEM) in order to determine the plasmid incompatibility group as well as the frequency 
of transfer of theantimicrobial resistance marker [4,5]. Furthermore it would have been 
interesting to determine whether the tetA gene is located on the plasmid or SXT element as 
previously described by Iwanaga et al. [6]. It would have also been valuable to investigate 
molecular mechanisms of antimicrobial resistance to nitrofurans [7,8]. Antimicrobial resistance 
genes that are now mobile in clinical isolates probably originated as determinants with a fixed 
chromosomal origin [9]. Global gene flow occurs in multiple directions, therefore allowing the 
introduction of new antimicrobial resistance genes into clinical isolates and transporting 
clinically relevant antimicrobial resistance genes back into the broader bacterial population [9]. 
V. cholerae possess the mechanisms to acquire and share resistance genes from direct contact 
with intrinsically resistant bacteria through mobile genetic elements and share these genes with 
other commensal microorganisms or enteric pathogens [10].  
 
In this study, nucleotide sequencing of the ctxAB gene (section 4.3.7) of the four selected isolates 
showed that all four isolates expressed the encoded ctxB allele for the CT of the classical biotype 
and were defined as altered El Tor. It has been shown that typical V. cholerae O1, biotype El Tor 
and classical isolates did not originate from a recent common ancestor but instead, seem to be 
independent derivatives with distinct phylogenetic histories [11]. Atypical V. cholerae O1, 
biotype El Tor isolates most likely arose through LTG of CTXclassΦ and as a result, genotypes 
with the classical ctxB-1 allele (results shown in this study) have spread to Asia and Africa, 
including South Africa [12]. A report by le Roux et al. described whole genome sequencing of 
the first bacterial genome of a South African V. cholerae O1 isolate (G4222) [13]. This clinical 
isolate was recovered in South Africa during the 2000-2001 cholera epidemic [13]. It would be 
advantageous to perform whole genome sequencing in order to understand and track emerging 
epidemic isolates particularly antimicrobial-resistant atypical V. cholerae O1, biotype El Tor 
isolates, which are appearing worldwide [11,13-17].  
 
All 100 selected isolates were PCR-negative for all seven macrolide resistance determinants and 
were considered susceptible to azithromycin based on the EUCAST criterion; these results have 
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created a platform whereby further analyses can be done. Doubling agar dilution and Etest 
methods are not qualified as “gold standards” [18].  Although broth microdilution is recognized 
as the “gold standard”, it may not have added additional information in the absence of the 
macrolide resistance genes. This added MIC testing method would lend further strength to future 
findings related to the azithromycin MIC susceptibility breakpoints. The development of 
antimicrobial resistance by bacteria in order to survive under environmental pressure may confer 
a selective advantage [19]. To overcome the loss of fitness and survive in a competitive 
environment bacteria generate mutations with increased frequency [19-21]. It may be of clinical 
interest to create and select azithromycin-resistant V. cholerae O1 laboratory mutants by 
exposing azithromycin-susceptible (MICs ≤ 16 µg/ml) V. cholerae O1 isolates to sub-inhibitory 
concentrations of azithromycin. 
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Chapter Seven 
General Discussion and Conclusion 

The V. cholerae O1 isolates investigated from each outbreak were resistant to multiple 
antimicrobial agents, including resistance to β-lactam antimicrobial agents and displayed almost 
similar antimicrobial resistance patterns. Sixteen V. cholerae O1 isolates (ten isolates 
characterized in Chapter Three and six isolates characterized in Chapter Four) were positive for a 
plasmid-borne ESBL (TEM-63 β-lactamase) resistance mechanism previously associated with 
hospital acquired infections [1]. A possible explanation for this observation could be the 
previously unsuccessful management of patients with a sexually transmitted infection (STI) with 
third-generation cephalosporins [2-4]. A study conducted in the United Kingdom described the 
anal-oral transmission of antimicrobial-resistant (including resistance to azithromycin and third-
generation cephalosporins) Shigella flexneri serotype 3a in men-who-have-sex-with-men, 
suggesting that alternate sexual behaviour provided the catalyst for transmission [4]. Human 
behaviour may be a more influencial factor than this study was able to ascertain as a possible 
mechanism contributing to the spread of antimicrobial-resistant TEM-63 producing V. cholerae 
O1 isolates. In South Africa, first-line treatment for a male patient exhibiting a STI is a single 
dose of cefixime (400 mg) administered orally and doxycycline (100 mg) administered orally, 
twice a day for seven days (accessed from 
http://www.nicd.ac.za/assets/files/STI%20Book%202008%20Edited(1).pdf; November 2014). 
Comment cannot be made on the study isolates ability to share (as donor or receiver) the various 
resistance genes described, as these characteristics never investigated - usually investigated by 
bacterial conjugation assays. V. cholerae possess the mechanisms to acquire and share resistance 
genes from direct contact with intrinsically resistant bacteria through mobile genetic elements 
and share these genes with other commensal microorganisms or enteric pathogens [5]. 
 
Traveller’s diarrhoea (TD) is one of the most common illnesses affecting individuals who 
journey across international borders [6,7]. Suspected imported cases of cholera in travellers 
emphasize the need for rigorous evaluation if the patient with severe watery diarrhoea has 
recently visited a cholera endemic country [8]. The increase in antimicrobial resistance, 
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geography and clinical illness influences the selection and use of antimicrobial agents [7,9]. A 
study using either co-trimoxazole or doxycycline in the treatment of TD showed that they were 
effective in many parts of the world however; the development of widespread resistance to these 
antimicrobial agents has emerged [10]. Although, fluoroquinolones (ciprofloxacin, ofloxacin, 
norfloxacin and levocloxacin) have shown to be more effective than rifaxamine in the treatment 
of inflammatory diarrhoea, antimicrobial resistance has been reported in other enteric pathogens 
such as Campylobacter and Shigella species [6,7,10]. Azithromycin has shown to be highly 
effective in the treatment of TD and likely would be effective as a chemoprophylactic 
antimicrobial agent [6,7,10]. However antimicrobial resistance to macrolides remains a serious 
clinical concern [11,12]. 
 
The antimicrobial-resistant V. cholerae O1 isolates investigated from each outbreak (Chapter 
Four) were characterized as altered El Tor variants. This altered El Tor variant is currently 
recognized as the most successful variant in that isolates belonging to this type have almost 
replaced the prototype El Tor in Asia and many parts of Africa, particularly East Africa and now 
South Africa [13]. As aforementioned, the CT is accountable for the major clinical signs and 
symptoms of cholera [14-17] thus, changes in the genetic material encoding for the CT could 
alter the clinical appearance of cholera [17,18]. A study done by Siddique et al. in Bangladesh, 
showed that a higher proportion of patients presented with severe dehydration following the 
isolation and identification of V. cholerae O1 El Tor variants in 2006 [17,19]. In addition, other 
studies have also described an increase in severity of disease during cholera outbreaks one of 
them being the Haitian cholera outbreak [17,20,21]. The differentiation of V. cholerae O1 
isolates into biotype does not change the clinical management of patients presenting with cholera 
[17]. However, it is of public health and epidemiological importance in determining the source 
and spread of infection particularly, in countries where sanitation and access to clean drinking 
water are limited [17].  
 
South Africa is one of many countries involved in improving health and achieving the eight 
Millennium Development Goals (MDGs); (1) eradicate extreme poverty and hunger, (2) achieve 
universal primary education, (3) promote gender equality and promote and empower women, (4) 
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reduce child mortality, (5) improve maternal health, (6) combat HIV/AIDS, malaria and other 
diseases, (7) ensure environmental sustainability and (8) global partnership for development by 
2015 (accessed from http://www.health-e.org.za/2014/07/01/motsoaledi-sounds-post-mdg-
agenda/ and http://www.un.org/millenniumgoals/beyond2015-faqs.shtml; November 2014) [22].  
In the MDGs report (accessed from 
http://mdgs.un.org/unsd/mdg/Resources/Static/Products/Progress2014/English2014.pdf; 
November 2014) published in July 2014, according to MDG 7C, many people worldwide still 
rely on unsafe water sources. Between 1990 and 2012, 2.3 billion more people have gained 
access to cleansources of drinking water. However 748 million peoplestill draw their water from 
anunimproved source of which, Sub-Saharan Africa was shown to be the highest. In addition, 
between 1990 and 2012 almost two billion people obtained access to improved sanitation. 
However in 2012, it was shown that one billion people still make use of open defecation 
facilities, of which prevalence is greatest in Southern Asia, Oceania and Sub-Saharan Africa. It 
was also shown that about seven out of ten people without access to improved sanitation 
facilities and clean drinking waterreside in rural areas. In low-income and middle-income 
countries, transmission of pathogenic organisms (bacterial, viral or parasitic) responsible for 
gastrointestinal infections generally occurs through contaminated food or drinking water [23,24]. 
In addition, the absence of effective public health measures in developing countries significantly 
impact health burdens following these gastrointestinal infections [24]. In developing countries, 
the infrastructure required to provide basic sanitation and access to clean drinking water is 
beyond the countries financial constraints [24].  
 
In South Africa, water quality has severely decreased due to constant disposal of industrial and 
domestic waste into the Vaal River [25]. The Vaal River supply the water requirements of 
communities in Gauteng, the Free State, North West and Northern Cape Provinces [25]. 
Microbiological  pollution is one many problems affecting water quality [25]. Water sources 
such as rivers, boreholes and fountains used by rural communities for domestic and drinking 
purposes are generally contaminated by faeces and lack treatment [26]. A study done by Keshav 
et al. described the isolation of V. cholerae O1 in 17 out of 74 stool samples collected from cows 
[27]. These samples were collected close to water sources used by villagers in rural areas of the 
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Limpopo Province in South Africa. Another study done in the Venda region of the Limpopo 
Province reported on the bacterial contamination of Vhuswa, a local weaning food used by 
mothers and caretakers to supplement breastfeeding and quality of stored water in rural 
households [26]. Enteric pathogens namely, Salmonella, Shigella, Escherichia coli and 
Campylobacter were isolated from the Vhuswa samples [26]. Water samples (spring water and 
standpipe water) used to prepare Vhuswa and for drinking were shown to be of poor quality as 
all four enteric pathogens described previously were isolated [26]. A study done by Singh et al. 
investigated the microbiological quality of drinking water from ground-tanks and community 
tankers and its association to health outcomes (for example diarrhoea and vomiting) in particular 
water quality, demographic distribution as well as sanitation and hygiene education in two 
peri-urban areas [28]. The results from this study showed that  households with children under 
five yearsof age using open-topped containers had the poorest water quality overall [28]. 
Households with ground-tanks had the best water quality at point-of-use, however; did not have 
the lowest occurrence of health effects [28]. In addition, it was shown that households that 
practiced open defecation had higher levels of Escherichia coli in their drinking water as well as 
higher rates of adverse health outcomes [28]. 
 
This study was conducted in an attempt to describe the molecular epidemiology and mechanism 
of antimicrobial resistance of V. cholerae O1 isolated from outbreaks in South Africa over recent 
years (2008 to date). Antimicrobials decrease the number of V. cholerae bacilli being shed by an 
infected individual thereby reducing the risk of spread of the disease. In terms of infectious 
disease epidemic control any intervention at the beginning of the epidemic that can potentially 
limit the number of cases and effectively reduce overall morbidity and mortality is viewed as 
essential. Controlling an epidemic of V. cholerae with treatment of initial cases with effective 
antimicrobials in conjunction with rehydration may be the answer. As a result volumes of 
diarrhoea may be reduced, potentially reducing hospitalization, dependence on intravenous 
rehydration and reduced risk of downstream complications from dehydration. An added more 
important advantage is that the initial investment in treating cholera patients with an efficacious 
antibiotic upfront will save treatment, hospitalization and potential complication costs. The 
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downstream benefit to the health system is that resources saved can be directed to primary health 
care or preventative medicine which is of a greater importance.  
 
The priority for investigation of such an intervention, however, is no greater in resource limited 
settings as more often than not it is these areas that are worst affected by outbreaks of V. 
cholerae. This is due to, either partly or entirely, poor healthcare and sanitation infrastructure, or 
in vulnerable populations due to natural disaster, e.g. earthquakes, or unnatural disasters such as 
wars where people are displaced and forced into cramped settlements with poor sanitation. 
Failure to identify epidemics in their infancy can result in large scale outbreaks within these 
settings. The priority then quickly shifts to limiting complicated cases, general morbidity and 
overall mortality and this is where an efficacious antibiotic comes into its own as a tool for 
public health. 
 
All this is impossible without proper regulations and that means standardized MIC breakpoints to 
inform treatment strategy. Treatment with the incorrect doses of antibiotics will drive resistance 
during and after the epidemic resulting in strains that are hard to treat. The results presented in 
Chapter Five are suggestive that azithromycin could be used as a treatment option for V. 
cholerae infection however the public health usefulness will be lost without aforementioned 
standardization of MIC breakpoints. However, V. cholerae continues to evolve and develop new 
ways to resist antimicrobial action, therefore highlighting the extent and severity of cholera as 
well as the rapidity of spread of the disease. Evidence of this was presented in Chapter Three, as 
resistance to a third generation cephalosporin poses further treatment challenges for severe or 
complicated cases. The default when faced with a non-clinical response to antimicrobial 
treatment is to opt for treatment with a third generation cephalosporin, however with mounting 
evidence that V. cholerae isolates harbor ESBL resistance genes will limited treatment options 
further (Chapter Three). The global public health fear is the introduction of such a highly 
adaptable pathogen, such as the V. cholerae O1 El Tor circulating South Africa, into a vulnerable 
population, which may give rise to yet another cholera epidemic with increased morbidity and 
mortality as experienced in the last nationwide outbreak (Chapter Four). Therefore investigating 
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and understanding the mechanisms of antimicrobial resistance is vital for treatment availability 
not just for cholera, but other community-acquired infections (Chapter Five).  
 
This study has illustrated that an active laboratory-based surveillance system with clinical 
support incorporating innovative, cutting-edge molecular and phenotypic assays is an essential 
element in the process of identification and monitoring of epidemic prone organisms such as V. 
cholerae O1. Evidence of this was presented in Chapters Three and Four, which described the 
two most prominent outbreaks of cholera South Africa has experienced in recent history. 
Without the existing surveillance network in South Africa these outbreaks may not have been 
described in the detail that it has been. The analysis conducted on isolates from these separate 
outbreaks was key to defining the isolates and sources of the outbreaks as distinct. The public 
health response as a result was directed accordingly, that is a defined population (illegal miners) 
versus a nationwide outbreak (Chapters Three and Four). The other key element to an active 
laboratory-based surveillance system with clinical support is to work in partnership with larger, 
global networks such as PulseNet International in the monitoring of epidemic-prone organisms 
isolated from South Africa and globally so that public health interventions can be initiated 
timeously to limit spread of disease and overall morbidity and mortality (Chapter Four). 
 
As the world reflects on the impending 2015 United Nations deadline for achieving the MDGs, it 
is with great concern that the countries that will not meet all their targets by 2015 are in Africa. 
However, in relation to MDG 7, which is to ensure environmental sustainability, South Africa 
has achieved the Target 7C which is to halve, by 2015, the proportion of people without 
sustainable access to safe drinking water and basic sanitation. Although such reports are 
promising in terms of service delivery to a vulnerable population and from a public health point-
of-view in limiting the spread and of waterborne pathogens, recent reports have suggested that 
South Africa sits on the cusp of a water crisis due to failing infrastructure, poor planning and 
inefficient water use. South African water quality can rival any of the developed nations as safe, 
drinkable water is a mere turn-of-the-tap away however water-borne pathogens such as V. 
cholerae require nothing but a small breakdown in an efficient system to result in a nation-wide 
outbreak.  
 



7.1 References  
 
 1.  Essack SY, Hall LM, Pillay DG, McFadyen ML, Livermore DM (2001) Complexity and 
diversity of Klebsiella pneumoniae strains with extended-spectrum beta-lactamases isolated 
in 1994 and 1996 at a teaching hospital in Durban, South Africa. Antimicrobial Agents and 
Chemotherapy 45: 88-95. 
 2.  Bignell C and Fitzgerald M (2011) UK national guideline for the management of 
gonorrhoea in adults, 2011. International Journal of STD and AIDS22: 541-547. 
 3.  Ison CA, Hussey J, Sankar KN, Evans J, Alexander S (2011) Gonorrhoea treatment failures 
to cefixime and azithromycin in England, 2010. Eurosurveillance 16: 19833. 
 4.  Baker KS, Dallman TJ, Ashton PM, Day M, Hughes G, Crook PD, Gilbart VL, Zittermann 
S, Allen VG, Howden BP, Tomita T, Valcanis M, Harris SR, Connor TR, Sintchenko V, 
Howard P, Brown JD, Petty NK, Gouali M, Thanh D, Keddy K, Smith AM, Talukder KA, 
Faruque SM, Parkhill J, Baker S, Weill F, Jenkins C, Thomson NR (2015) Intercontinental 
dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-
sectional study. The Lancet Infectious Diseases 15:913-921. 
 5.  Kitaoka M, Miyata ST, Unterweger D, Pukatzki S (2011) Antibiotic resistance mechanisms 
of Vibrio cholerae. Journal of Medical Microbiology 60: 397-407. 
 6.  Hill DR and Beeching NJ (2010) Travelers' diarrhea. Current Opinion in Infectious 
Diseases 23: 481-487. 
 7.  de la Cabada BJ and Dupont HL (2011) New developments in traveler's diarrhea. 
Gastroenterology and Hepatology 7: 88-95. 
 8.  Steffen R, Acar J, Walker E, Zuckerman J (2003) Cholera: assessing the risk to travellers 
and identifying methods of protection. Travel Medicine and Infectious Disease 1: 80-88. 
 9.  Ngandjio A, Tejiokem M, Wouafo M, Ndome I, Yonga M, Guenole A, Lemee L, Quilici 
ML, Fonkoua MC (2009) Antimicrobial resistance and molecular characterization of Vibrio 
cholerae O1 during the 2004 and 2005 outbreak of cholera in Cameroon. Foodborne 
Pathogens and Disease 6: 49-56. 
 10.  Diemert DJ (2006) Prevention and self-treatment of traveler's diarrhea. Clinical 
Microbiology Reviews19: 583-594. 
 



 11.  van Hoek AH, Mevius D, Guerra B, Mullany P, Roberts AP, Aarts HJ (2011) Acquired 
antibiotic resistance genes: an overview. Frontiers in Microbiology 2: 1-27. 
 12.  Talkington D, Bopp C, Tarr C, Parsons MB, Dahourou G, Freeman M, Joyce K, Turnsek 
M, Garrett N, Humphrys M, Gomez G, Stroika S, Boncy J, Ochieng B, Oundo J, Klena J, 
Smith A, Keddy K, Gerner-Smidt P (2011) Characterization of toxigenic Vibrio cholerae 
from Haiti, 2010-2011. Emerging Infectious Diseases 17: 2122-2129. 
 13.  Spagnoletti M, Ceccarelli D, Colombo M (2012) Rapid detection by multiplex PCR of 
genomic islands, prophages and integrative conjugative elements in Vibrio cholerae 7th 
pandemic variants. Journal of Microbiological Methods 88: 98-102. 
 14.  Nelson EJ, Harris JB, Glenn Morris Jr J, Calderwood SB, Camilli A (2009) Cholera 
transmission: the host, pathogen and bacteriophage dynamic. Nature Reviews Microbiology 
7: 693-702. 
 15.  Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB (2012) Cholera. The Lancet 
379: 2466-2476. 
 16.  Etinosa O, Igbinosa EO, Okoh AI (2009) Toxigenic Vibrio cholerae strains and their 
associated malaises. African Journal of Medical Research 3: 200-211. 
 17.  Mukhopadhyay AK, Takeda Y, Balakrish NG (2014) Cholera outbreaks in the El Tor 
biotype era and the impact of the new El Tor variants. Current Topics in Microbiology and 
Immunology 379:17-47. 
 18.  Safa A, Nair GB, Kong RY (2010) Evolution of new variants of Vibrio cholerae O1. 
Trends in Microbiology 18: 46-54. 
 19.  Siddique AK, Nair GB, Alam M, Sack DA, Huq A, Nizam A, Longini IM, Jr., Qadri F, 
Faruque SM, Colwell RR, Ahmed S, Iqbal A, Bhuiyan NA, Sack RB (2010) El Tor cholera 
with severe disease: a new threat to Asia and beyond. Epidemiology and Infection 138: 
347-352. 
 20.  Kanungo S, Sah BK, Lopez AL, Sung JS, Paisley AM, Sur D, Clemens JD, Nair GB (2010) 
Cholera in India: an analysis of reports, 1997-2006. Bulletin of the World Health 
Organization 88: 185-191. 
 



 21.  Piarroux R, Barrais R, Faucher B, Haus R, Piarroux M, Gaudart J, Magloire R, Raoult D 
(2011) Understanding the cholera epidemic, Haiti. Emerging Infectious Diseases 17: 1161-
1168. 
 22.  Chopra M, Lawn JE, Sanders D, Barron P, Abdool Karim SS, Bradshaw D, Jewkes R, 
Abdool KQ, Flisher AJ, Mayosi BM, Tollman SM, Churchyard GJ, Coovadia H (2009) 
Achieving the health Millennium Development Goals for South Africa: challenges and 
priorities. The Lancet 374: 1023-1031. 
 23.  Santosham M, Chandran A, Fitzwater S, Fischer-Walker C, Baqui AH, Black R (2010) 
Progress and barriers for the control of diarrhoeal disease. The Lancet 376: 63-67. 
 24.  Vohra P and Blakely GW (2013) Easing the global burden of diarrhoeal disease: can 
synthetic biology help? Systems and Synthetic Biology 7: 73-78. 
 25.  Jordaan K and Bezuidenhout CC (2013) The impact of physico-chemical water quality 
parameters on bacterial diversity in the Vaal River, South Africa. Water SA 39: 385-396. 
 26.  Potgieter N, Obi CL, Bessong PO, Igumbor EO, Samie A, Nengobela R (2005) Bacterial 
contamination of Vhuswa-a local weaning food and stored drinking-water in impoverished 
households in the Venda region of South Africa. Journal of Health, Population and 
Nutrition 23: 150-155. 
 27.  Keshav V, Potgieter N, Bernard TG (2011) Detection of Vibrio cholerae O1 in animal 
stools collected in rural areas of the Limpopo Province. Water SA 36: 167-171. 
 28.  Singh U, Lutchmanariyan R, Wright J, Knight S, Jackson S, Langmark J, Vosloo D, Rodda 
N (2013) Microbial quality of drinking water from ground-tanks and tankers at source and 
point-of-use in eThekwini Municipality, South Africa, and its relationship to health 
outcomes. Water SA 39: 663-673. 
 
 
  
 



Appendices 
 
Appendix A: Pulsed-field gel electrophoresis (PFGE) 
 
A1: 1.00 M Tris (pH 8.00) 
121.1 g Tris (Merck KGaA, Darmstadt, Germany)  
Dissolve in 800 ml distilled water 
Adjust to pH 8.00 with a laboratory pH meter (WTW GmbH, Weilheim, Germany) using 32 % 
Hydrochloric acid (HCl) (Merck) or sodium hydroxide (NaOH) pellets (Merck)   
Adjust final volume to 1000 ml with distilled water 
Sterilize the mixture by autoclaving (120 ºC for 15 minutes at 1 kg/cm2) 
Store at room temperature (+ 25 ºC) 
 
A2: 0.50 M EDTA (pH 8.00) 
186.1 g disodium ethylenediaminetetra-acetic acid (EDTA) (Merck) 
Dissolve in 800 ml distilled water 
Adjust to pH 8.00 with 32 % HCl (Merck) or NaOH pellets (Merck) 
Adjust final volume to 1000 ml with distilled water 
Sterilize the mixture by autoclaving 
Store at room temperature 
 
A3: Cell suspension buffer (100 mM Tris : 100 mM EDTA, pH 8.00) 
10 ml of 1 M Tris, pH 8.00 
20 ml of 0.5 M EDTA, pH 8.00 
Dissolve in 70 ml distilled water 
Sterilize the mixture by autoclaving 
Store at room temperature 
 
 
 
 

	

A4: Proteinase-K (20 mg/ml) 
20 mg Proteinase-K (Roche Diagnostics, Mannheim, Germany) 
Dissolve in 1 ml TE buffer, pH 8.00 
Prepare fresh and keep on ice 
 
A5: Proteinase-K (10 mg/ml) 
10 mg Proteinase-K (Roche) 
Dissolve in 1 ml TE buffer, pH 8.00 
Prepare fresh and keep on ice 
 
A6: Sodium dodecyl sulphate (10 %) 
10 g sodium dodecyl sulphate (SDS) (Merck) 
Dissolve in 100 ml distilled water 
Store at room temperature 
 
A7: 1 % SeaKem Gold® agarose (Preparation of agarose plugs for V. cholerae) 
0.2 g SeaKem Gold® agarose (Lonza, Rockland, USA)  
Dissolve in 20 ml of TE buffer 
Dissolve agarose by boiling in the microwave 
Store at room temperature 
 
A8: 1 % SeaKem Gold® agarose : 1 % SDS (Preparation of agarose plugs for Salmonella) 
0.25 g SeaKem Gold® agarose (Lonza)  
Dissolve in 22.5 ml of TE buffer with 2.5 ml 10 % SDS  
Dissolve agarose by boiling in the microwave 
Store at room temperature 
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A9: Cell lysis buffer for Salmonella (5 ml/plug) 
5 ml of 0.50 M EDTA, pH8.00 
1 % (50 mg) N-lauroylsarcosine sodium salt (sarcosyl) (Sigma-Aldrich Chemical Co., St. Louis, 
MO, USA) 
50 µl of 10 mg/ml Proteinase-K (Roche) 
Prepare fresh and keep at room temperature 
 
A10: Cell lysis buffer for V. cholerae (5 ml/plug) (50 mM Tris : 50 mM EDTA, pH 8.00) 
250 µl of 1.00 M Tris, pH8.00 
500 µl of 0.50 M EDTA, pH8.00 
Dissolve in 4.25 ml distilled water 
50 mg sarcosyl (Sigma) 
50 µl of 10 mg/ml Proteinase-K (Roche) 
Prepare fresh and keep at room temperature 
 
A11: Tris-EDTA (TE) buffer (10 mM Tris : 1 mM EDTA, pH 8.00) 
10 ml of 1 M Tris, pH 8.00 
2 ml of 0.5 M EDTA, pH 8.00 
Dissolve in 988 ml distilled water 
Sterilize the mixture by autoclaving 
Store at room temperature 
 
A12: Restriction enzyme O-buffer mix (Per agarose slice) 
90 µl distilled water 
10 µl 10X O-buffer (Fermentas International Inc, Burlington, Canada) 
Prepare fresh and keep on ice 
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A13: Restriction enzyme H-buffer mix (Per agarose slice) 
90 µl distilled water 
10 µl 10X H-buffer (Roche) 
Prepare fresh and keep on ice 
 
A14: Restriction enzyme O-buffer mix with NotI restriction enzyme (Per agarose slice) 
132 µl distilled water 
15 µl 10X O-buffer (Fermentas) 
3 µl NotI restriction enzyme (Fermentas) 
Prepare fresh and keep on ice 
 
A15: Restriction enzyme H-buffer mix with XbaI restriction enzyme (Per agarose slice) 
132 µl distilled water 
15 µl 10X H-buffer (Roche) 
3 µl XbaI restriction enzyme (Roche) 
Prepare fresh and keep on ice 
 
A16: Tris : borate : EDTA (TBE)  
10Х TBE (Merck) 
Store at room temperature 
 
A17: 0.5Х TBE  
50 ml 10Х TBE 
Dissolve in 950 ml distilled water 
 
A18: 1 % SeaKem Gold® agarose gel (Preparation for a PFGE run) 
1.5 g SeaKem Gold® agarose (Lonza)  
Dissolve in 150 ml of 0.5Х TBE 
Dissolve agarose by boiling in the microwave 
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A19: Ethidium bromide (EtBr) stock solution (10 mg/ml) 
500 mg ethidium bromide (Merck) 
Dissolve in 50 ml distilled water 
Store in the dark in the fridge at + 2 °C to + 8 °C 
 
A20: EtBr staining solution 
25 µl of ethidium bromide (10 mg/ml) 
Dissolve in 250 ml of 0.5X TBE 
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Appendix B: Polymerase Chain Reaction (PCR) 
 
B1: Detection and analysis of the internal amplification control and detection of enzymatic 
A subunit of the cholera toxin (ctxA) 
 
PCR primer sets 
 
Primer pair(s) Primer sequence  
(5’to 3’) 
Target gene Expected size 
of PCR 
product (~bp) 
PCR-positive control 
isolate(s) 
16SrRNA-B GATTAGATACCCTGGTAGTCC 
16S rRNA 726 V. cholerae O1 ATCC9458 
16SrRNA-r ACGGCTACCTTGTTACGACTT 
ctxA-f CTCAGACGGGATTTGTTAGGCACG ctxA 301 V. cholerae O1 ATCC9458 
ctxA-r TCTATCTCTGTAGCCCCTATTACG 

PCR cocktail mix  
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water 14.5 
10X PCR Gold Buffer (Applied Biosystems, Foster City, California) 2.5 
25 mM Magnesium chloride (MgCl2) (Applied Biosystems) 2 
10 mMDeoxynucleoside triphosphate (dNTP) mix (Celtic Molecular Diagnostics, Cape Town, 
South Africa) 2 
Primer mix*  3 
AmpliTaq Gold®(Applied Biosystems) 0.3 
crude template DNA 1 
Total reaction volume 25 
 
 
 
 
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Primer mix * 
85 µl autoclaved TE buffer (Appendix A11) 
2.5 µl of 20 µM 16SrRNA-B 
2.5 µl of 20 µM 16SrRNA-r 
5.0 µl of 20 µM ctxA-f 
5.0 µl of 20 µM ctxA-r 
 
PCR conditions  
  
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.15 
35 Annealing 55 1.15 
Extension 72 1.15 
Final extension 72 7 1 
Hold 4 ∞ (Infinite hold) 1 
 
 
B2: Detection and analysis of the toxin co-regulated pilus (tcpA) of El Tor and classical 
variants 
 
 
 
 
 
 
 
 
 
 

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PCR primer sets  
 
Primer pair(s) Primer sequence 
 (5’to 3’) 
Target 
gene 
Expected size 
of  PCR 
product  
(~bp) 
PCR-positive control  
isolate(s) 
tcpA-Classic-F CACGATAAGAAAACCGGTCAAGAG tcpA-
Classical 
617 
V. cholerae O1 
ATCC9458 tcpA-Classic-R ACCAAATGCAACGCCGAATGGAGC 
tcpA-ElTor-F GAAGAAGTTTGTAAAAGAAGAACAC tcpA-
ElTor 
471 
V. cholerae O139 
VIBCH05 tcpA-ElTor-R GAAAGGACCTTCTTTCACGTTG 
 
 
PCR cocktail mix  
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water 15.0 
10X PCR Gold Buffer (Applied Biosystems) 2.5 
25 mM Magnesium chloride (MgCl2) (Applied Biosystems) 1.5 
10 mMdNTP mix (Celtic Molecular Diagnostics) 2 
Primer mix**  3 
AmpliTaq Gold®(Applied Biosystems) 0.3 
crude template DNA 1 
Total reaction volume 25 
 
Primer mix ** 
20 µl autoclaved TE buffer (Appendix A11) 
20 µl of 20 µM tcpA-Classic-F 
20 µl of 20 µM tcpA-Classic-R 
20 µl of 20 µM tcpA-ElTor-F 
20 µl of 20 µM tcpA-ElTor-R 
 

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
 
PCR conditions  
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1 
35 Annealing 60 1.15 
Extension 72 1.15 
Final extension 72 7 1 
Hold 4 ∞ 1 
 
B3: Detection and analysis of ESBL genes 
 
PCR primer sets  
 
Primer 
pair(s) 
Primer sequence 
(5’to 3’) 
Target 
gene 
Expected size 
of  PCR 
product (~bp) 
PCR-positive control 
isolate(s) 
TEM-F1 ATGAGTATTCAACATTTCCGTG 
blaTEM 840 
Klebsiella pneumoniae 
ATCC51503 TEM-R1 TTACCAATGCTTAATCAGTGAG 
SHV-F1 ATGCGTTATATTCGCCTGTG 
blaSHV 846 
Klebsiella pneumoniae 
ATCC700603 SHV-R1 GTTAGCGTTGCCAGTGCTCG 
CTXM-F1 CGATGTGCAGTACCAGTAA 
blaCTX-M 550 Klebsiella pneumoniae D-17 
CTXM-R1 TWRGTSACCAGAAYCAGCGG 
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PCR cocktail mix  
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water 18.2 
S-T Gold Buffer with 15 mM MgCl2 (Southern Cross Biotechnology, Cape Town, South Africa) 2.5 
10 mMdNTP mix (Celtic Molecular Diagnostics) 2 
20 µM Forward primer  0.5 
20 µM Reverse primer  0.5 
Super-Therm Gold (Southern Cross Biotechnology) 0.3 
crude template DNA 1 
Total reaction volume 25 
 
PCR conditions  
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 60 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 
 
 
 
 
 
 
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B4: Detection and analysis of class 1 and class 2 integrons 
 
PCR primer sets  
 
Primer 
pair(s) 
Primer sequence 
(5’to 3’) 
Target 
gene 
Expected size 
of  PCR 
product 
(~bp) 
PCR-positive control 
isolate(s) 
qacE∆1-F ATCGCAATAGTTGGCGAAGT  
3’-CS 800 
Escherichia coli 
803Rif:p3iANG sul1-B  GCAAGGCGGAAACCCGCGCC 
inDS-F CGGAATGGCCGAGCAGATC  
5’-CS 870 
Escherichia coli 
803Rif:p3iANG inDS-B  CAAGGTTCTGGACCAGTTGCG  
in-F  GGCATCCAAGCAGCAAGC Gene 
cassette 
variable 
Escherichia coli 
803Rif:p3iANG in-B AAGCAGACTTGACCTGAT  
INT-2U ATGTCTAACAGTCCATTTT 
intI2 450  
INT-2D AAATCTTTAACCCGCAAAC 
hep74 CGGGATCCCGGACGGCATGCACGATTTGTA Gene 
cassette 
variable  
hep51 GAT GCCATCGCAAGTACGAG 
 
PCR cocktail mix  
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water 18.2 
S-T Gold Buffer with 15 mM MgCl2 (Southern Cross Biotechnology) 2.5 
10 mMdNTP mix (Celtic Molecular Diagnostics) 2 
20 µM Forward primer  0.5 
20 µM Reverse primer  0.5 
Super-Therm Gold (Southern Cross Biotechnology) 0.3 
crude template DNA 1 
Total reaction volume 25 
 
 
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PCR conditions  
 
3’-CS and 5’-CS 
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 62 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 
 
 
intI2 
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 57 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 
 
 
 
 




B5: Detection and analysis of the tetracycline resistance determinant, SXT element-
integrase and SXT associated resistance genes 
 
PCR primer sets  
 
Primer 
pair(s) 
Primer sequence 
(5’to 3’) 
Target gene Expected size 
of  PCR 
product (~bp) 
PCR-positive control 
isolate(s) 
TetA-F  GTAATTCTGAGCACTGTCGC 
tetA 950 TCD273377 
TetA-R CTGCCTGGACAACATTGCTT  
int1-F  GCTGGATAGGTTAAGGGCGG  
SXTint 592 
Escherichia coli 
CAG18439:SXTMO10 Int1-B  CTCTATGGGCACTGTCCACATTG  
FLOR-F  TTATCTCCCTGTCGTTCCAGCG  
floR 526 Escherichia coli 
CAG18439:SXTMO10 FLOR-2  CCTATGAGCACACGGGGAGC  
SUL2-F  AGGGGGCAGATGTGATCGC 
sul2 625 
Escherichia coli 
CAG18439:SXTMO10 SUL2-B TGTGCGGATGAAGTCAGCTCC 
dfr1-F  CGAAGAATGGAGTTATCGGG 
dfrA1 372 TCD273377 
dfr1-B  TGCTGGGGATTTCAGGAAAG  
TMP-F TGGGTAAGACACTCGTCATGGG  
dfr18 389 Escherichia coli 
CAG18439:SXTMO10 TMP-B ACTGCCGTTTTCGATAATGTGG 
STRA-F  TTGATGTGGTGTCCCGCAATGC 
strA 383 
Escherichia coli 
CAG18439:SXTMO10 STRA-B  CCAATCGCAGATAGAAGGCAA 
strB-F GGCACCCATAAGCGTACGCC 
strB 470 
Escherichia coli 
CAG18439:SXTMO10 strB-R  TGCCGAGCACGGCGACTACC 
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PCR cocktail mix  
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water 18.2 
S-T Gold Buffer with 15 mM MgCl2 (Southern Cross Biotechnology) 2.5 
10 mMdNTP mix (Celtic Molecular Diagnostics) 2 
20 µM Forward primer  0.5 
20 µM Reverse primer  0.5 
Super-Therm Gold (Southern Cross Biotechnology) 0.3 
crude template DNA 1 
Total reaction volume 25 

PCR conditions  
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 60 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 

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B6: Detection and analysis of PMQR genes and the quinolone resistance determinant 
 
PCR primer sets  
 
Primer 
pair(s) 
Primer sequence 
(5’to 3’) 
Target gene Expected size 
of  PCR 
product (~bp) 
PCR-positive control 
isolate(s) 
QP1 GATAAAGTTTTTCAGCAAGAGG 
qnrA 657 
Escherichia coli 
pMG252 QP2 ATCCAGATCGGCAAAGGTTA 
FQ1 ATGACGCCATTACTGTATAA 
qnrB 566 
Escherichia coli 
pMG298 FQ2 GATCGCAATGTGTGAAGTTT 
qnrS-F TGGAAACCTACAATCATACATATCG 
qnrS 585 
Escherichia coli 
pMG306 qnrS-R TTAGTCAGGATAAACAACAATACC 
qnrC-F  GGGTTGTACATTTATTGAATCG  
qnrC 307 
Proteus  mirabils 06-
498 qnrC-R  CACCTACCCATTTATTTTCA  
qepA-F  AACTGCTTGAGCCCGTAGAT 
qepA 596 
Escherichia coli 
pAT851 qepA-R GTCTACGCCATGGACCTCAC  
qnrVC-F  AATTTTAAGCGCTCAAACCTCCG  
qnrVC3 521  
qnrVC-R TCCTGTTGCCACGAGCATATTTT 
 
 
PCR cocktail mix  
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water 18.2 
S-T Gold Buffer with 15 mM MgCl2 (Southern Cross Biotechnology) 2.5 
10 mMdNTP mix (Celtic Molecular Diagnostics) 2 
20 µM Forward primer  0.5 
20 µM Reverse primer  0.5 
Super-Therm Gold (Southern Cross Biotechnology) 0.3 
crude template DNA 1 
Total reaction volume 25 
 

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PCR conditions 
 
qnrA 
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 57 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 
 
qnrB and qnrS 
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 53 1.3 
Extension 72 1. 
Final extension 72 7 1 
Hold 4 ∞ 1 
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qnrC, qepA and qnrVC3 
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 60 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 
 
 
B7: Detection, nucleotide sequencing and analysis of the QRDR of DNA gyrase and 
topoisomerase IV  
 
PCR primer sets  
 
Primer 
pair(s) 
Primer sequence 
(5’to 3’) 
Target gene Expected size 
of  PCR 
product (~bp) 
PCR-positive control 
isolate(s) 
gyrA-F1  AATGTGCTGGGCAACGACTGG  
gyrA 239 TCD273377 
gyrA-R1 GTGCGCGATTTTCGACATACG  
gyrB-F1  GGAAATGACTCGCCGTAAAGG  
gyrB 309 TCD273377 
gyrB-R1  GTTGTGATAACGCAGTTTATCTGGG  
parC-F1  GTCTGAGTTGGGTCTCTCGGC 
parC 248 TCD273377 
parC-R1  AGAATCTCGGCAAACTTTGACAG  
parE-F1 ATGCGTGCCAGCAAGAAAGTG  
parE 268 TCD273377 
parE-R1 TTATCGCTGTCAGGGTCAATCC  
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PCR cocktail mix  
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water 18.2 
S-T Gold Buffer with 15 mM MgCl2 (Southern Cross Biotechnology) 2.5 
10 mMdNTP mix (Celtic Molecular Diagnostics) 2 
20 µM Forward primer  0.5 
20 µM Reverse primer  0.5 
Super-Therm Gold (Southern Cross Biotechnology) 0.3 
crude template DNA 1 
Total reaction volume 25 
 
PCR conditions  
 
gyrA 
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 60 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 
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gyrB and parE 
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 0.3 
3 Annealing 37 0.3 
Extension 72 1 
Denaturation 95 0.3 
30 Annealing 45 0.45 
Extension 72 1 
Final extension 72 7 1 
Hold 4 ∞ 1 
 
parC 
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 62 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 


 

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Appendix C:  Detection of PCR products using conventional agarose gel electrophoresis 
 
C1: 10X Tris : acetate: EDTA (TAE) 
48 g Tris (Merck) 
7.5 g EDTA (Sigma) 
Dissolve in 500 ml distilled water 
11 ml of glacial acetic acid (Merck) 
Adjust to a final volume of 1000 ml with distilled water 
Sterilize the mixture by autoclaving 
Store at room temperature 
 
C2: 1X TAE  
100 ml 10X TAE 
Dissolve in 900 ml distilled water 
Store in the fridge at + 2 ºC to + 8 ºC 
 
C3: Bromophenol blue (Loading buffer) 
250 mg bromophenol blue (Merck) 
40 g sucrose (Merck) 
Dissolve in 100 ml distilled water 
Store in the fridge at + 2 ºC to + 8 ºC 
 
C4: 1.5% Seakem LE agarose gel 
1.5 g Seakem LE agarose (Lonza) 
Dissolve in 100 ml of 1X TAE buffer 
Dissolve agarose by boiling in the microwave 
Add 6 µl of the ethidium bromide stock solution (Appendix A19) to the molten agarose 
  
 
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Appendix D: Nucleotide sequencing using the ABI Prism®BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems) 
 
PCR cocktail mix 
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water 7.5 
5X Sequencing v1.1, v3.1 Buffer 1.5 
ABI Prism®BigDye® Terminator v3.1 Ready Reaction mix 3 
5 µM Forward primer or 5 µM Reverse primer 1 
Purified template DNA 2 
Total reaction volume 15 
 
Cycle sequencing PCR conditions  
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 2 1 
Denaturation 95 0.5 
25 Annealing 50 0.5 
Extension 60 4 
Hold 4 ∞ 1 
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Appendix E: Isolation and preparation of plasmid DNA 
 
E1: Luria-Bertani (LB) agar plates  
10 g Bacto tryptone (Oxoid, Basingstoke, Hampshire, England) 
5 g Yeast extract (Oxoid) 
10 g NaCl (Merck) 
Dissolve in 500 ml distilled water 
Adjust to a final volume of 1000 ml with distilled water  
15 g Bacto agar (Becton, Dickinson and Company, Sparks, USA) 
Sterilize the mixture by autoclaving 
 
E2: Ceftriaxone (1 mg/ml) 
10 mg ceftriaxone (Sigma) 
Dissolve in 10 ml distilled water 
Solution filtered through a filtered tip syringe and passed through 0.22 µm Millex®-GS filter 
unit (Millipore S.A., Molsheim, France) 
Store in the freezer at minus (-) 10 ºC to - 20 ºC 
 
E3: LB broth 
10 g Bacto tryptone (Oxoid) 
5 g Yeast extract (Oxoid) 
10 g NaCl (Merck) 
Dissolve in 500 ml distilled water 
Adjust to a final volume of 1000 ml with distilled water 
Sterilize the mixture by autoclaving 
Store at room temperature 
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E4: 10X E-buffer (0.5 M Tris-HCl : 10 mM EDTA)  
6.05 g Tris (Merck) 
372 mg EDTA (Sigma) 
Dissolve in 50 ml distilled water 
Adjust to a final volume of 100 ml with distilled water 
Sterilize by autoclaving 
Store at room temperature  
 
E5: 1X E-buffer 
10 ml 10X E-buffer 
Dissolve in 90 ml distilled water 
Sterilize by autoclaving 
Store in the fridge at +2 °C to +8 °C 
 
E6: Lysis solution (3 % SDS in 50 mM Tris-HCl, pH 12.56)  
605 mg Tris (Merck) 
Dissolve in 50 ml distilled water 
Adjust to pH 12.56 with 32 % HCl (Merck) or NaOH pellets (Merck) 
Adjust to a final volume of 100 ml with distilled water 
3 g SDS 
Store at room temperature  
 
E7: Phenol : chloroform : isoamyl alcohol 
25 ml phenol(Sigma) 
24 ml chloroform(Merck) 
1 ml isoamyl alcohol (Merck) 
Prepare fresh 
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Appendix F: PCR Digoxigenin (DIG)-labelling and Southern blot hybridization 
 
F1: PCR cocktail mix for DIG-labeled hybridization target gene, blaTEM using the PCR 
DIG Probe Synthesis Kit (Roche) 

Reagent 
Final concentration Volume (µl) / 
reaction 
Autoclaved distilled water - 32.25 
PCR buffer with MgCl2 (10X concentration) (Roche) 1x104 5 
PCR DIG mix (10X concentration) (Roche) 200 µM 5 
20 µM TEM-F1  1 µM  2.5 
20 µM TEM-R1  1 µM 2.5 
Enzyme mix, Expand High, Fidelity (Roche) 2.6 units 0.75 
Purified template DNA ~ 10 ng 2 
Total reaction volume - 50 
 
  
 
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F2: PCR cocktail mix for unlabelled control, blaTEM using the PCR DIG Probe Synthesis 
Kit (Roche) 
 
Reagent 
Final concentration Volume (µl) / 
reaction 
Autoclaved distilled water - 32.25 
PCR buffer with MgCl2 (10X concentration) (Roche) 1x104 5 
dNTP stock solution (10X concentration) (Roche) 200 µM  5 
20 µM TEM-F1  1 µM 2.5 
20 µM TEM-R1  1 µM 2.5 
Enzyme mix, Expand High, Fidelity (Roche) 2.60units 0.75 
Purified template DNA ~ 10 ng 2 
Total reaction volume - 50 
 
F3: PCR conditions for labeled hybridization target genes and unlabeled controls using the 
PCR DIG Probe Synthesis Kit (Roche) 
 
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 2 1 
Denaturation 95 1 
30 Annealing 60 1 
Extension 72 1 
Final extension 72 7 1 
Hold 4 ∞ 1 
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F4: Denaturation solution (0.5 M NaOH : 1.5 M NaCl)  
20 g NaOH (Merck) 
87.66 g NaCl (Merck) 
Dissolve in 500 ml distilled water 
Adjust to a final volume of 1000 ml with distilled water 
Sterilize the mixture by autoclaving 
Store at room temperature 
 
F5: Neutralization solution (0.5 M Tris-HCl, pH 7.50 : 1.5 M NaCl) 
60.55 g Tris (Merck) 
Dissolve in 500 ml distilled water 
Adjust to pH 7.50 with 32 % HCl (Merck) or NaOH pellets (Merck) 
87.66 g NaCl (Merck) 
Adjust to a final volume of 1000 ml with distilled water 
Sterilize the mixture by autoclaving 
Store at room temperature 
 
F6: Sodium chloride, Sodium citrate buffer (SSC) 
20X SSC (Roche) 
 
F7: 2X SSC buffer 
10 ml 20X SSC (Roche) 
Dissolve in 90 ml distilled water 
Store at room temperature 
 
F8: 0.5X SSC buffer 
2.5 ml 20X SSC (Roche) 
Dissolve in 97.5 ml distilled water 
Store at room temperature 
 
 
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F9: Low stringency buffer (2X SSC buffer containing 0.1 % SDS) 
100 ml 2X SSC buffer 
1 ml 10 % SDS 
Prepare fresh and keep at room temperature 
 
F10: High stringency buffer (0.5X SSC buffer containing 0.1 % SDS) 
100 ml 0.5X SSC buffer 
1 ml 10 % SDS 
Prepare fresh and keep at + 65 °C 

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Appendix G: Involvement of efflux pumps 
 
G1: Mueller-Hinton agar plates 
1.52 g Mueller-Hinton agar(Oxoid) 
Dissolve in 40 ml distilled water 
Sterilize the mixture by autoclaving 
 
G2: Reserpine (1 mg/ml stock) 
10 mgresperpine (Sigma) 
Dissolve in 10 ml glacial acetic acid 
Solution filtered through a filtered tip syringe and passed through 0.22 µm Millex®-GS filter unit 
(Millipore S.A.) 
 
G3: Phenylalanyl arginine-β-naphthylamide (PAβN) (1 mg/ml stock) 
10 mgPAβN (Sigma) 
Dissolve in 10 ml distilled water 
Solution filtered through a filtered tip syringe and passed through 0.22 µm Millex®-GS filter unit 
(Millipore S.A.) 

G4: Nalidixic acid (1 mg/ml stock) 
10 mgnalidixic acid (Sigma) 
Dissolve in distilled water together with 0.1M NaOH 
Solution filtered through a filtered tip syringe and passed through 0.22 µm Millex®-GS filter unit 
(Millipore S.A.) 
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Appendix H: Tracking seventh pandemic variants 
 
H1: Detection, nucleotide sequencing and analysis of the cholera toxin, ctxAB gene 
 
PCR primer sets  
 
Primer pair(s) Primer sequence 
 (5’to 3’) 
Target 
gene 
Expected size 
of PCR 
product  
(~bp) 
PCR-positive control  
isolate(s) 
CTXA-comp-F  GGCTGTGGGTAGAAGTGAAACGG 
ctxAB 1350 
V.. cholerae O1 ATCC9458 
orV. cholerae O139 
VIBCH05 CTXB-comp-R CTAAGGATGTGGAATAAAAACATC 
CTX93-F GGCAGATTCTAGACCTCCT 
Internal sequencing primers 
V.. cholerae O1 
ATCC9458orV. cholerae 
O139 VIBCH05 CTX618-R TCGATGATCTTGGAGCATTC 
 
PCR cocktail mix  
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water 15 
10X PCR Gold Buffer (Applied Biosystems) 2.5 
25 mM Magnesium chloride (MgCl2) (Applied Biosystems) 1.5 
10 mMdNTP mix (Celtic Molecular Diagnostics) 2 
10 µM Forward primer  2 
10 µM Reverse primer  2 
AmpliTaq Gold®(Applied Biosystems) 0.3 
crude template DNA 1 
Total reaction volume 25 
 
PCR conditions  
 
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PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 92 0.4 
2 Annealing 60 0.4 
Extension 72 1.3 
Denaturation 92 0.4 
2 Annealing 58 0.4 
Extension 72 1.3 
Denaturation 95 0.4 
2 Annealing 56 0.4 
Extension 72 1.3 
Denaturation 95 0.4 
2 Annealing 54 0.4 
Extension 72 1.3 
Denaturation 95 0.4 
3 Annealing 52 0.4 
Extension 72 1.3 
Denaturation 95 0.4 
30 Annealing 50 0.4 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 
 
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H2: Detection, nucleotide sequencing and analysis of thetoxin co-regulated pilus, tcpA gene 
 
PCR primer sets 
 
Primer pair(s) Primer sequence  
(5’to 3’) 
Target gene Expected size 
of PCR 
product (~bp) 
PCR-positive control 
isolate(s) 
tcpH1 AGCCGCCTAGATAGTCTGTG 
tcpA 1 234 V. cholerae O1 ATCC9458 
tcpA4 TCGCCTCCAATAATCCGAC 

PCR cocktail mix  
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water 18.2 
S-T Gold Buffer with 15 mM MgCl2 (Southern Cross Biotechnology) 2.5 
10 mMdNTP mix (Celtic Molecular Diagnostics)P 2 
20 µM Forward primer  0.5 
20 µM Reverse primer  0.5 
Super-Therm Gold (Southern Cross Biotechnology) 0.3 
crude template DNA 1 
Total reaction volume 25 

 
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PCR conditions  
  
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 52 1.3 
Extension 72 2 
Final extension 72 7 1 
Hold 4 ∞ 1 

H3: Detectionand analysis of the Mobilome 
 
Primer sets for multiplex PCR 1 
 
Primer 
pair(s) 
Primer sequence  
(5’to 3’) 
Target gene Expected size of 
PCR product 
(~bp) 
VSPIIintF CCGACAAAGAATACACTCTCTCTGATGG 
VSP-II integrase 170 
VSPIIintR ACGTCTTTTCCTTGCCTCGGCAAGAG 
VSPIIcutF TTATCTACGACCACACCAGACAGC 
Prototypical VSP-II 245 
VSPIIcutR ATGGGCATAGCAAAGGCACTTACCCA 
ICEdetF TCAGTTAGCTGGCTCGATGCCAGG 
SXT/R391 ICEs integrase 505 
ICEdetR GCAGTACAGACACTAGGCGCTCTG 
SXTdetF ACTTGTCGAATACAACCGATCATGAGG 
SXT Hotspot IV 357 
SXTdetR CAGCATCGGAAAATTGAGCTTCAAACTCG 
Ind5detF TGCACATTGAGGCCCTGCAAGCAC 
ICEVchInd5 Hotspot IV 423 
Ind5detR GTGCATTCACCAGCTCTAACGTCG 
Moz10detF CGGAAGATGACGAAGACCGCCTAAGC 
ICEVchMoz10 Hotspot IV 712 
Moz10detR ATTTGCCTTCGAACAAAAGGGGCA 

 
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Primer sets for multiplex PCR 2 
 
Primer 
pair(s) 
Primer sequence  
(5’to 3’) 
Target gene Expected size of 
PCR product (~bp) 
TLCdetF AATCAACTCACGGGTGCAGACCTC 
TLC phage 449 
TLCdetR TCCGCCAAGAAGTGACGTTGTAGC 
KdetF CGTCCGTAACCTTAAAGATGGCAGC 
Kappa phage 230 
KdetR TCGTATGTCCGTGAACTTGCCACC 
GI12detF CTACGGTTGAGCCGCTCCATTTGTC 
GI 12 571 
GI12detR GTGCCTTCTAAATTGACCAAACGCGGCA 
GI14detF AGACGAGTATCTAGTAAACGCCAAACC 
GI 14 142 
GI14detR CTTTGCTTGCACTGGCAACCTCAG 
GI15detF CAGACCGCGAAGGAAAACGCTCTTTGC 
GI 15 348 
GI15detR AGCGTCTCAGATGATGTCCGGCTG 

 
PCR cocktail mix for multiplex PCR 1 and for multiplex PCR 2 
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water variable 
S-T Gold Buffer with 15 mM MgCl2 (Southern Cross Biotechnology) 2.5 
10 mMdNTP mix (Celtic Molecular Diagnostics) 2 
20 µM Forward primer (For each primer) 0.5 
20 µM Reverse primer (For each primer) 0.5 
Super-Therm Gold (Southern Cross Biotechnology) 0.3 
crude template DNA 1 
Total reaction volume 25 
 
 
 
 
 

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PCR conditions for multiplex PCR 1 
  
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 59 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 


PCR conditions for multiplex PCR 2 
  
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 64.5 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 

 
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Appendix I: Azithromycin susceptibility testing 
 
I1:Azithromycin (1 mg/ml stock) 
10 mgazithromycin(Sigma) 
Dissolve in 10 ml 95 % ethanol 
Solution filtered through a filtered tip syringe and passed through 0.22 µm Millex®-GS filter unit 
(Millipore S.A.) 
 
I2: Detection, nucleotide sequencing and analysis of macrolide resistance determinants 
 
Primer sets 
 
Primer pair(s) Primer sequence  
(5’to 3’) 
Target  Expected size of 
PCR product(~bp) 
mefF TGTGCATATTTCTATTACG 
mefA 
324 mefR CCAATTGGCATAGCAAG 
mefI GCTGTGCAATAATGGGGC Internal sequencing primer 
ereAF GCCGGTGCTCATGAACTTGAG 
ereA 
420 ereAR CGACTCTATTCGATCAGAGGC 
ereAI TCACTGGCTAGAGCTAGTCTT Internal sequencing primer 
ereBF GCCTTGAAGCTATGGCTCC 
ereB 
303 ereBR GGCCCATTGGTAGGCAAC 
ereBI TTGGAGATACCCGAGTTGTAG Internal sequencing primer 
ermBF GAAAAGGTACTCAACCAAATA 
ermB 
639 ermBR AGTAACGGTACTTAAATTGTTTAC 
ermBI AGCCATGCGTCTGACATCTAT Internal sequencing primer 
mphAF GTGAGGAGGAGCTTCGCGAG 
mphA 
403 mphAR TGCCGCAGGACTCGGAGGTC 
mphAI TGCCGCAGGACTCGGAGGTC Internal sequencing primer 
mphBF TTAAACAAGTAATCGAGATAGC 
mphB 
889 mphBR CCTTGTACTTCCAATGCTTG 
mphBI GCGTATGGATGCAGTAAGAGC Internal sequencing primer 
mphDF2 GCGGATCTCCTCCCAGAGTG 
mphD 
436 mphDR2 CTTCGGAAGCATTGGAGGCGC 
mphDI GCGGATCTCCTCCCAGAGTG Internal sequencing primer 
 

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Primer sets forinternal positive control DNA constructs 
 
Primer pair(s) Primer sequence  
(5’to 3’) 
Expected size of PCR 
product (~bp) 
mph(A)-eae-F GTGAGGAGGAGCTTCGCGAGTCAATGCAGTTCCGTTATCAGTT 
522 
mph(A)-eae-R TGCCGCAGGACTCGGAGGTCGTAAAGTCCGTTACCCCAACCTG 
mph(B)-eae-F TTAAACAAGTAATCGAGATAGCTCAATGCAGTTCCGTTATCAGTT 
524 
mph(B)-eae-R CCTTGTACTTCCAATGCTTGGTAAAGTCCGTTACCCCAACCTG 
ere(A)-eae-F GCCGGTGCTCATGAACTTGAGTCAATGCAGTTCCGTTATCAGTT 
524 
ere(A)-eae-R CGACTCTATTCGATCAGAGGCGTAAAGTCCGTTACCCCAACCTG 
ere(B)-eae-F GCCTTGAAGCTATGGCTCCTCAATGCAGTTCCGTTATCAGTT 
519 
ere(B)-eae-R GGCCCATTGGTAGGCAACGTAAAGTCCGTTACCCCAACCTG 
mph(D)-eae-F2 GCGGATCTCCTCCCAGAGTGTCAATGCAGTTCCGTTATCAGTT 
523 
mph(D)-eae-R2 CTTCGGAAGCATTGGAGGCGCGTAAAGTCCGTTACCCCAACCTG 
 
PCR cocktail mix  
 
Reagent Volume (µl) / reaction 
Autoclaved distilled water 17.2 
S-T Gold Buffer with 15 mM MgCl2 (Southern Cross Biotechnology) 2.5 
10 mMdNTP mix (Celtic Molecular Diagnostics) 2 
10 µM Forward primer  1 
10 µM Reverse primer  1 
Super-Therm Gold (Southern Cross Biotechnology) 0.3 
crude template DNA 1 
Total reaction volume 25 
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PCR conditions  
 
mefA and ermB 
  
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 60 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 

ereA, ereB, mphA, mphB and mphD 
  
PCR Cycle Temperature (°C) Time (minutes) # of cycles / reaction 
Initial denaturation 95 10 1 
Denaturation 95 1.3 
35 Annealing 58 1.3 
Extension 72 1.3 
Final extension 72 7 1 
Hold 4 ∞ 1 

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Appendix J: Plagiarism declaration with Turnitin report 
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